                               PARAMYOXOVIRUS AND METHODS OF USE
Abstract
The present invention is directed towards a novel virus, called Cedar Virus, and its methods of use.

                                           AUSTRALIA
                                          PatentsAct 1990
                            ORIGINAL COMPLETE SPECIFICATION
                                      STANDARD PATENT
Invention title:       PARAMYXOVIRUS AND METHODS OF USE
This application is a divisional of Australian Patent Application No 2013286866 which is the
Australian national phase entry of PCT/US2013/049069, which claims priority to US patent
application No 61/667,194 filed 2 July 2012. Each of these applications is herein incorporated
by reference in their entireties.
The following statement is a full description of this invention, including the best method of
performing it known to us:
                                                  1

                                  PARAMYXOVIRUS AND METHODS OF USE
                   Statement Regarding Federally Sponsored Research or Development
 [0001] Part of the work performed during development of this invention utilized U.S. Government
funds under National Institutes of Health Grant Nos. A1054715. The U.S. Government has certain rights
in this invention.
                                  Sequence Listing Submission via EFS-Web
 [0002] A computer readable text file, entitled "044508-5045-WO-SequenceListing.txt" created on or
about July 2, 2013 with a file size of about 70 kb contains the sequence listing for this application and is
hereby incorporated by reference in its entirety.
                                        Background of the Invention
Field of the Invention
 [0003] The present invention relates to a novel virus, called Cedar Virus, and its methods of use.
Background of the Invention
 [0004] Henipaviruses were first discovered in the 1990s in disease outbreaks in farm animals and
humans in Australia and Malaysia (1, 2). These viruses comprise the only known Biosafety Level 4 (BSL4)
agents in the family Paramyxoviridae (3),and mortality is between 40% to 100% in both humans and
animals (4, 5), depending upon the virus, animal species and geographic locations of outbreaks. The
genus Henipavirus in the subfamily Paramyxovirinae currently contains two members, Hendra virus
(HeV) and Nipah virus (NiV), with fruit bats, commonly known as flying foxes, as having been identified
as the main natural reservoir of both viruses. Serological evidence, however, also suggests that
henipaviruses may circulate in other types of bats (7-10).
 [0005] The discovery of henipaviruses has had a significant impact on our overall understanding of
paramyxoviruses. Indeed, Paramyxoviruses, such as measles virus and canine distemper virus, have a
narrow host range and are known to be genetically stable with a close to uniform genome size shared by
all members of Paramyxovirinae (3). Henipaviruses, however, shifted these paradigms as these viruses
have a much wider host range and a significantly larger genome (6).
                                                   la

[0006] Recently, research on henipavirus has successfully identified functional cellular receptors and has
driven the development of novel diagnostics, vaccine and therapeutics (15-25). There is, however, little
understanding of the pathogenesis of these highly lethal viruses, due in part to the requirement of a
high security BSL4 facility needed to conduct live infection studies and in part to the limited number of
research tools available used in the current animal models. Research into the mechanisms of
henipavirus pathogenesis is also hampered by the lack of related, non-pathogenic or less pathogenic
viruses that could be used in comparative pathogenetic studies.
[0007] Recent serological investigations in China and other regions indicated the presence of cross
reactive, but not necessarily cross-neutralizing, antibodies to henipaviruses in bats of different species
(8). Detection of henipavirus-like genomic sequences in African bats further support the results obtained
from the serological investigations (26).
[0008] The invention disclosed herein is directed to the isolation and characterization of a newly
discovered henipavirus.
                                        Summary of the Invention
[0009] There is provided a novel virus, named Cedar Virus ("CedPV"), and its methods of use.
[0010] There is also provided individual proteins, and fragments thereof, as well as the coding
sequences of the individual proteins that make up the CedPV.
[0011] Also provided are antibodies or fragments thereof that specifically bind to CedPV.
[0012] Vaccines and/or other therapeutic compositions comprising at least a portion of the CedPV are
also provided.
[0012a] It is to be noted that, throughout the description and claims of this specification, the word
'comprise' and variations of the word, such as 'comprising' and 'comprises', is not intended to exclude
other variants or additional components, integers or steps. Modifications and improvements to the
invention will be readily apparent to those skilled in the art. Such modifications and improvements are
intended to be within the scope of this invention.
                                                      2

[0012b] Any reference to or discussion of any document, act or item of knowledge in this specification is
included solely for the purpose of providing a context for the present invention. It is not suggested or
represented that any of these matters or any combination thereof formed at the priority date part of
the common general knowledge, or was known to be relevant to an attempt to solve any problem with
which this specification is concerned.
                                     Brief Description of the Drawings
[0013] FIGURE 1 depicts the genome sizes and organization of CedPV compared to those of the
prototype viruses of the five existing genera in the subfamily Paramyxovirinae. Each of the coding and
non-coding regions is drawn to scale. The six major genes present in all paramyxovirus genomes are
indicated as follows: shaded =RNA polymerase and nucleocapsid genes (N, P and L); slanted = envelope
                                                     2a

membrane protein genes (F and attachment protein); dotted = matrix protein (M). The small in the
genome of the mumps virus represents the gene (SH) not commonly shared among members of the
subfamily.
[0014] FIGURE 2 depicts a comparison of genomic features among different henipaviruses. (A)
Alignment of leader and trailer sequences (antigenome sequences shown). (B) Sequences of intergenic
regions (IGR) and transcriptional start and stop sties of CedPV in comparison with those of HeV and niV.
[0015] FIGURE 3 depicts a phylogenetic tree of selected paramyxoviruses. 2A: The tree is based on the
N protein sequences Virus name (abbreviation) and GenBank accession numbers are as follows: Avian
paramyxovirus 6 (APMV6) AY029299; Atlantic salmon paramyxovirus (AsaPV) EU156171; Beilong virus
(BeiPV) DQ100461; Bovine parainfluenza virus 3 (bPIV3) AF178654; Canine distemper virus (CDV)
AF014953; Cedar virus (CedPV) JQ001776; Fer-de-lance virus (FdIPV) AY141760; Hendra virus (HeV)
AF017149; Human parainfluenza virus 2 (hPIV2) AF533010; Human parainfluenza virus 3 (hPIV3) Z11575;
Human parainfluenza virus 4a (hPIV4a) AB543336; Human parainfluenza virus 4b (hPIV4b) EU627591; J
virus (JPV) AY900001; Menangle virus (MenPV) AF326114; Measles virus (MeV) AB016162; Mossman
virus (MosPV) AY286409; Mapeura virus (MprPV) EF095490; Mumps virus (MuV) AB000388; Newcastle
disease virus (NDV) AF077761; Nipah virus, Bangladesh strain (NiV-B) AY988601; Nipah virus, Malaysian
strain (NiV-M) AJ627196; Parainfluenza virus 5 (PIV5) AF052755; Peste-des-petits-ruminants (PPRV)
X74443; Porcine rubulavirus (PorPV) BK005918; Rinderpest virus (RPV) Z30697; Salem virus (SaIPV)
AF237881; Sendai virus (SeV) M19661; Simian virus 41 (SV41) X64275; Tioman virus (TioPV) AF298895;
Tupaia paramyxovirus (TupPV) AF079780. (B) The tree is based on whole genome sequence. (C) The
tree is based on a 550-nt region of the L-gene.
[0016] FIGURE 4 depicts the sequencing trace files for the editing site of P genes for HeV and NiV in
comparison to the editing site of the CedPV P gene. Trace files showing editing of the HeV and NiV P
gene (indicated by the * sign) and lack of editing in CedPV P gene mRNA in infected cells. Sequencing of
PCR products covering all potential editing sites in the P gene of CedPV did not reveal any RNA editing
activity. A representative potential editing site of the CedPV P gene is shown.
[0017] FIGURE 5 depicts the antigenic cross reactivity between CedPV and HeV. Vero cells infected
with CedPV and HeV, respectively, were stained with rabbit sera raised against recombinant N proteins
of each virus.
                                                       3

[0018] FIGURE 6 depicts antigenic cross reactivity of CedPV with other paramyxoviruses. An Indirect
Fluorescent Antibody (IFAT) assay conducted with anti-CedPV serum on Vero cells infected with J
paramyxovirus (JPV), Rinderpest virus (RPV), Sendai virus (SeV), Menangle virus (MenPV) and CedPV,
respectively. Mock infected cell monolayer was included as a negative control. The only panel showing
reactivity is the CedPV panel.
[0019] FIGURE 7 depicts the functional testing of ephrin-B2 and -B3 as an entry receptor for CedPV.
Infection of CedPV into HeLa-USU cells in the presence and absence of ephrin gene products is shown.
The susceptibility of infection, as an indirect measurement of receptor function, is demonstrated by the
formation of syncytial cytopathic effect (CPE).
[0020] FIGURE 8 depicts the immunohistochemical analysis of bronchial lymph node of CedPV-infected
ferrets. Bronchial lymph node of ferret #2, euthanized on day 6 pi, was stained with rabbit antiserum
against recombinant N protein of CedPV (B) and NiV (D), respectively. Bronchial lymph node of an
unrelated ferret (infected with influenza H5N1 from another experiment) was used as negative control
and stained with the same anti-CedPV (A) and anti-NiV (C) antisera under identical conditions.
[0021] FIGURE 9 depicts the results of CedPV glycoprotein mediated cell-cell fusion and heterotypic
mixing with HeV and NiV glycoproteins. Various target cell populations are shown in the legend.
[0022] FIGURE 10 depicts purified soluble ephrin-FC proteins alone or pre-mixed with CedPV-sG,
precipitated and analyzed by SDS-PAGE and coomassie. The separated sG is marked and the different
ephrin protein patterns are noted. CedPV-sG and ephrin-B2 run close together in lane 3.
[0023] FIGURE 11 depicts the results of Hela-USU target cell populations prepared by transfecting in
the indicated ephrin receptor constructs and then used in cell-cell fusion assay with effector cells
expressing either CedPV, HeV or NiV F and G glycoproteins, and a standard fusion-reporter gene assay
was carried out.
                                    Detailed Description of the Invention
[0024] The present invention is directed towards a novel virus, named Cedar Virus ("CedPV"), and its
methods of use. The present invention is also directed towards the individual proteins, and fragments
thereof, as well as the coding sequences of the individual proteins that make up the CedPV.
                                                      4

[0025] The inventors have isolated a novel paramyxovirus, in particular a Henipavirus. As is well
established, the Henipavirus genus belongs to the paramyxovirus family of viruses and includes both the
Hendrvirus (HeV) and Nipahvirus (NiV). In all likelihood, the newly isolated CedPV will belong to the
henipahvirus genus based on phylogentic studies, see Figure 3. Regardless of its classification, the
inventors establish herein that CedPV is a novel virus that shares antigenic properties, among other
properties, with Hendra virus. The newly discovered CedPV is an RNA virus containing a single strand of
RNA.
[0026] The genome of the virus is presented herein as SEQ ID NO:1.
           1  accagacaaa     ggaagtctag     tctccggatt      aaatcatatt    cgtatgatta      atcttaggat
          61  cccggtatct     agaatctgga     tctggattcg      gtttaattga    attgcgatcg      tttataaatt
         121  agaaaggaga     tttactactc     aaaatgtctg      acattttcaa    tgagactcaa      tcatttagaa
         181  actatcagtc     caacttaggc     agagatggca      gggccagtgc    agcaacgact      actttgacaa
         241  ctaaagtgag     gatctttgtt     ccagcgaata      ataatccaaa    cctcagatgg      cgtttaacac
         301  tattcttgat     ggatgtcgtg     aggtcacctg      cctccgcaga    gtctatgaaa      gtgggtgctg
         361  ggatatcctt     ggtatctatg     tatgctgaaa      aacccggggc    tcttgtgaga      gcattattga
         421  atgacccaga     tgttgaagcg     ataatcatag      atgtttatgg    ctttgatgaa      ggtattccta
         481  taatggaacg     aagaggtgat     aaagctacag      atgacatgga    ttccctaaga      aagattgtta
         541  aagctgcaca     tgatttcagc     agaggaagga      gtttatttgt    tgatcaaagg      gtccaggata
         601  ttgttatgtc     agatatgggg     tcatttgtga      atgctattac    ttccatagag      acgcagatat
         661  ggattttgat     cgcaaaggct     gtaactgccc      cagatacagc    agaagagagc      gaaggaagaa
         721  gatgggcaaa     atatgttcag     caaaagaggg      ttaatccttt    gttcttgatt      tctccacaat
         781  ggatcaatga     catgagatcc     ctgattgcgg      caagtctttc    gcttcgtaaa      ttcatggttg
         841  aactactgat     ggaagctaag     aaaggacggg      ggacaaaagg    aagaataatg      gagattgtat
         901  ccgatatcgg     aaattacgtt     gaagagacag      gaatggcagg    gttcttcgct      acaataaagt
         961  tcggtcttga     gaccaaattc     cctgctttgg      cacttaatga    gctccagagt      gacttgaaca
        1021  caatgaaaag     tctcatgata     ctgtacagaa      gcataggacc    aaaggccccc      tttatggtgt
        1081  tgttggaaga     ttcaattcag     accaaatttg      ctccaggaag    ctatccactt      ctttggagtt
        1141  ttgcgatggg     tgtaggcaca     actattgaca      gagctatggg    tgccttgaac      attaacagaa
        1201  gttatcttga     acctgtctat     tttaggctag      ggcaacaatc    agctaaacat      caagcaggaa
        1261  atgttgacaa     agaaatggca     gaaaagttag      gattgacaga    agaccagatc      gtgcacctat
        1321  cagctaatgt     gaaggatgca     agtcaaggta      gagatgacaa    tcaaatcaac      atccgagaag
        1381  ggaagttcac     aaatgttgtt     gatgacatcc      aggatcatgc    ccagagttcc      tctgaggatt
        1441  acaatcctag     taaaaagagt     ttctcaatat      tgacgagcat    cacatccacc      gtagatagtg
        1501  ctgacagtag     gtctgcaatg     aatgagtcaa      tgacaacaac    atccttgctg      aaattgagac
        1561  agaggctggc     agagaagaaa     ggagactcca      agaacagtca    agacacacct      ccaaaaccac
        1621  ccagagcaaa     agatcaaccc     actgatgagg      tctccttcat    ggattccaat      atatgatcag
        1681  aatgatggtt     aaaatcaacc     aactaagggc      gcgtagagta    ccttcagata      gaacactaca
        1741  ttaatcgggt     gaaacaatag     atttatgggt      ttggtgctta    atttttattt      aatcttactt
        1801  gcaaaacagg     cagctgctac     actcgtaacc      actcctcaca    gtaagggcaa      cacgggtcat
        1861  agaacttatg     cctatagatt     acctctatct      gtatatctag    ctatgattaa      aatgtatact
        1921  tctgctgacc     ggttttctag     caacagtcca      cattattact    ttatgggtat      tttttaatca
        1981  accttttata     atcaaatata     ttacaaaaaa      cttaggatcc    aagtggtcca      aacttttttt
       2041   gatcaagagt     catattggct     actttaggag      gacactttaa    acacaaattg      ttacaagagg
       2101   atattcatca     gatggacaaa     ctacaattga      ttgaagatgg    cctctctact      atcaatttta
       2161   tacaggaaaa     taaggaaaaa     ttacagcatt      cttacggaag    atcctccatc      agagagccac
       2221   ccacaagtgt     cagggttgaa     gagtgggaga      aatttattcg    aaagatcgct      tctggacctg
       2281   aacaagttca     agggggagga     tctgagactg      agatcacagg    cgataatgga      gatagaggca
       2341   attttaccaa     tcctgatcag     ggaggcggag      tcacaggaca    attcgaagaa      aggtatcaaa
                                                     5

2401 aatgggggtc acaagattca gaattacaac   tggacccaat ggttgtacac gatttcttct
2461 atgacgagag aagggagaat cccgacaatg   gaaaatatga ccgcagctct aaaaaacggg
2521 ataatatcag agaaggaaca cgacaggata   agtacaataa tcagtctact gatgaattac
2581 tgtcctgcct acaaccatct tctaagaacg   atgtcatcaa gaatgaaagt acatcagtgt
2641 caaatttgca tgttacagga aataaactga   atcctgacgc aaaacccttt gaacccacct
2701 cccagtcgaa agagcaccca accaccacac   agcacaacaa aaatgaccat cagaccgatg
2761 atgattataa gaatagaaga tccagtgaaa   acaatgtgat ctctgatcat gccaccacaa
2821 tggaagacaa caacaatttt atcccggcga   ccaaaagaaa gaatgcattg agcgaaccca
2881 tatacgtcca ggtattgccc tcaaacacag   agggtttctc gggaaaagat tatccactcc
2941 tcaaggacaa ctctgtcaag aagcgtgcag   agccagtcat cctagaaact gccaaccacc
3001 ctgcaggctc tgccgaccaa gacacaaatc   agattgaaga aaacatgcag ttcaaccttc
3061 caaaactgct cacagaagat acagacgatg   aaccagagga taacaatgat tccatgcctc
3121 ttgaggaaga cattagagag atcggttcca   tgctaaaaga tggaaccaaa gatatcaaga
3181 caaggatgaa tgagatagat gacgcaatca   agaagataaa taagaaatca aaaaatagaa
3241 gtctggatct agaatcagac ggtaaagatc   aggggagaag agatccatca gtagacctcg
3301 ggattaaaaa aagaaaggaa gggctaaagg   ccgcaatgca aaagacaaaa gagcaattgt
3361 ctataaaagt ggagagagag attggattga   acgacaggat atgtcaaaat tcgaagatga
3421 gtacagaaaa gaaattgata tatgctggga   tggaaatgga gtatggacaa acgagtactg
3481 ggtcaggagg tccacaagga tcaaaggatg   ggacttctga tgatgtccag gtagacgaag
3541 actacgatga aggggaagac tatgaggcta   tgccgtcaga taggttttat acaacattat
3601 caggtgaaca aaaggataga tttgatctag   atgctaacca aatgtctcag tatgacctcg
3661 aggcccaggt ggatgaatta accagaatga   atctcatact ctattctaga ttagaaacta
3721 ctaataagtt gcttattgac atattagatc   tagctaaaga aatgccaaag ttagttagaa
3781 aagtggataa tcttgagaga cagatgggta   acttgaatat gttaacctct acccttgagg
3841 gtcacctatc ttctgtaatg attatgatac   ccggtaagga taagagcgaa aaggaaatcc
3901 ctaaaaatcc ggacctgaga ccaatactgg   ggagaagcaa cacgtcgtta actgatgtta
3961 tcgacctaga ccattaccct gataaaggct   ccaaaggtat caaaccaagt ggatctggag
4021 acagacagta catcggctct ctagagagca   aattttctat aaatgatgag tacaattttg
4081 ctccataccc tatcagggac gaactcctat   tgccaggttt aagagatgac aaaaccaatg
4141 cttcatcgtt catcccagat gacacggaca   ggtctccaat ggtgctcaaa ataataattc
4201 gacagaacat ccatgatgaa gaagtgaagg   atgagctact gtccatacta gaacaacata
4261 acactgtgga ggaattgaat gaaatatgga   atactgtgaa tgattacctc gatggcaaca
4321 tctgattaac agatattgag attgatccta   ttctaaacaa gtaatctctg ataatgatag
4381 tatggaataa gaatactaat cacactattg   tactcttgta gaatcttaac gagtgtctaa
4441 tgtcagattt tagcaacaca tactaataac   ttgtaatcca tttctcctta ttccatttaa
4501 tctcacatta gaaaaaactt aggatcccag   atttgcaaag tcaaaacggg atctactatc
4561 aggtgttgga gctaacaata gcggagtctg   cataacaaat agcgttcaaa gaagtttgaa
4621 aaccatcata gaatatggat ccgtcagatt   tgaggaggat tataatggag gatgataaga
4681 gtctggtcaa caatgatgat agtacagaaa   ctgattttct cgagaaaact tggagagaag
4741 ggagtaagat tgacaagatc acaccagagg   ttgatgaaaa cgggaatatg gtccccaagt
4801 acgttgtctt caacccgggg aaaaatgaga   ggaaaacatc cggatatcaa tatatgattt
4861 gttatggttt cattgaggat ggacctatca   atggctcacc aagagtcaaa ggtaatatca
4921 gaaccaccgc ttcttttcct ttgggtgttg   gaaaaactta ctcgtctcca gaagagatct
4981 tacaagagct gacaacactc aagatcactg   tcagaaggac agccggatca aatgagaagt
5041 tggtgtatgg aataacaggg cctttaaatc   acctttaccc gtggtataaa gttttgacag
5101 gtggctccat ttttagtgcg gtgaaggtct   gtaggaatgt ggatcaaata ctattagaca
5161 gaccccaaat acttagagta ttctttctaa   gtataactaa attaacagat aaaggtgtgt
5221 atatgatacc caaaagtgtt ctcgacttca   gatcggataa ttcgatggcc ttcaatctgc
5281 ttgtgtatct caagatagac actgacatca   ccaaagcagg catcagaggg attgtcaaca
5341 aagaagggga gaggataacg tcattcatgt   tacacatcgg taactttaca agaagaggag
5401 gaaaacatta ctcagtggag tattgcaaaa   ggaaaattga caaaatgaag ctcacattcg
5461 ccttaggcac tataggcggt ctaagcttac   atatcaggat cgatggaagg ataagtaaaa
5521 ggctccaagc acaagttggc tttcagagaa   acatttgcta ctcactaatg gacacaaacc
5581 catggttgaa taaattaacg tggaacaata   gttgtgaaat acacaaagtc accgctgtca
5641 ttcagccatc tgtgccaaag gacttcatgt   tgtatgagga catcttaata gataatacag
5701 gcaagatctt aaaataaagt aggagagtca   gtcattaccc agtatattga atactaatga
5761 caactttatt aatccaattc tatctccagt   tactagaatt tctaaaacaa ttctactgct
                                      6

5821 cagcaacgca tctcaaacat tgtgatcttc aattatgatc gacgcattgt aatctatata
5881 gcttttagtt catgaaatac taaaaagggc ttaatcttgt aagttctcag caaatactcc
5941 aatgcaaaag agcgcctcaa catctcaagc agcaccaaaa taaaccacaa tcaatgtgca
6001 acaagagcaa tcgtctaaag tgtgaaaacc aaaatcacag atcagaaagg gcacatattt
6061 cagtcctgta aaaataccaa gtgggattaa taaaagagga tcaatcctta tcattttaag
6121 aaaaacttag gatcccagag atcctaaaga gccaattcct ttatattttg atcttgaagg
6181 gctagaagtc aggctgaaac acagaggtgg aggaacacag gaactaaaat tgatgaaatc
6241 aaccttagct caacatctaa tcaatcaagc ttaagtcatc ctaatactgt atacaaccag
6301 cagcgtagag agtggatttg atttcggcac ccttgcgaag tgaaggctat tactgcctgt
6361 cctttcaatc agaaaattac atttacccat aaagtaatct caacatgtct aacaagagga
6421 caacagtatt gatcataata agctatacgt tattttattt gaataatgca gcaattgtag
6481 ggtttgattt tgataaattg aataaaatag gtgtggtgca agggagagtc ctaaattata
6541 aaattaaagg agatccaatg acaaaagacc ttgtcttgaa atttatccct aacatagtga
6601 atatcactga atgtgtgaga gagcccttga gtaggtacaa tgagaccgtg aggagattgc
6661 ttttacctat acacaacatg cttgggttat acttgaataa cacaaatgct aaaatgactg
6721 ggttgatgat cgcgggtgtg atcatgggtg ggatagcaat aggtatagcc acagcagctc
6781 agatcacagc aggttttgct ctttatgagg caaaaaagaa cacagaaaat attcagaaat
6841 taacagacag catcatgaaa acacaggact cgattgataa acttactgac agtgtgggga
6901 caagcatact tatattgaat aagctacaga catacatcaa caatcaactg gtaccaaatc
6961 tagagcttct atcctgccga caaaacaaaa ttgagtttga tctaatgtta accaagtatt
7021 tggtggatct tatgactgtt attggtccta atatcaataa tcctgttaat aaagatatga
7081 ctattcaatc tttgtcactt ctttttgatg gcaattatga tataatgatg tcagaacttg
7141 gttatacacc tcaggatttc ttagatttga tagagagtaa gagtataaca gggcaaataa
7201 tttatgttga tatggaaaac ttgtacgttg tgatcaggac atatctacct accctaattg
7261 aagtacctga tgcccaaata tatgagttca acaaaataac tatgagtagc aatggaggag
7321 aatacttgtc aaccatacct aatttcatat taataagagg taattatatg tctaatatag
7381 atgttgcaac atgttatatg accaaagcaa gcgtaatttg taatcaagat tattcactcc
7441 cgatgagcca aaacttaaga agctgttatc aaggtgagac agaatactgt cctgttgagg
7501 cagtcatcgc gtcacactct ccaagatttg ctcttacaaa tggagttatt ttcgccaatt
7561 gtataaatac aatttgtagg tgtcaagaca atggtaagac tatcactcaa aacataaacc
7621 aattcgtaag catgatcgac aacagtactt gtaatgatgt catggtagat aagtttacta
7681 tcaaggtagg aaaatatatg gggagaaaag atatcaataa tattaatatc cagataggac
7741 cgcagatcat aattgataag gttgacttgt ctaatgaaat aaacaagatg aatcaatctt
7801 taaaagatag tattttctac ctgagagaag ccaagagaat tttagactca gtaaatatca
7861 gtcttatatc tccaagcgtt caattgtttc taataataat atcagtcctc tcatttatta
7921 tattattgat tatcatagta tacttgtact gtaaatcaaa acattcatat aaatataaca
7981 aatttataga tgatcctgat tattacaatg attacaaaag agaacgtatt aatggcaaag
8041 ccagtaagag taacaatata tattatgtag gtgattaaca atcgataatc taaaggatta
8101 cctcactatc actaccaagg taacttccat gtaagatcgg accttccccg aagacattaa
8161 ataaaactta ggatcccaga gtatccctct aagtgatcct tctagattgg ttactgatat
8221 atatacatat ttatcctctt tccgtcgttg tttattgatc attaataatg ctttctcagc
8281 tccaaaaaaa ttacttagac aactcaaacc aacaaggtga taaaatgaac aacccagata
8341 agaaattaag tgtcaacttc aaccctttag aattagataa aggtcaaaaa gatctcaata
8401 agtcttatta tgttaaaaac aagaattata acgtttcaaa tctattaaat gaaagtctgc
8461 acgatatcaa gttttgtatt tattgtatat tctcactgct aattatcatt acaataatca
8521 atataatcac aatatcaatt gttataactc gtctgaaagt acatgaagag aataatggca
8581 tggaatctcc taatttacaa tctattcaag atagtctctc atctcttact aacatgatca
8641 atacagagat aactcctaga atagggattt tagttacagc cacttctgtt actctctctt
8701 catctatcaa ttatgtcggg actaagacaa atcaactggt caatgaatta aaagattata
8761 taaccaaaag ttgtggcttt aaggtccctg aattaaagtt acatgaatgc aacataagtt
8821 gtgctgatcc aaaaattagc aaatctgcaa tgtacagcac caatgcctat gccgagcttg
8881 ctggtccacc taagatattt tgtaaaagtg tatccaaaga ccccgacttt agactgaagc
8941 agatagatta tgtaatacca gtgcagcaag atcggtctat ttgtatgaac aaccctttat
9001 tggatatttc tgatgggttt tttacctaca tacattatga aggaataaat agctgtaaaa
9061 aatcagattc atttaaagtg ctgctgtcac atggtgaaat agttgacagg ggtgattatc
9121 gaccatcatt atatctatta tcaagtcatt accatcctta ttcaatgcag gtaataaact
9181 gtgtacctgt gacttgtaac cagtcatcct ttgtattctg tcatatctcc aacaacacta
                                  7

 9241 aaacattgga caattcagat tactcgtcag   acgagtacta cataacatat ttcaatggca
 9301 tagatcgtcc caaaaccaag aagattccca   ttaacaatat gacagcagac aatcgttata
 9361 tccattttac attctcaggt gggggaggtg   tatgtttagg tgaagaattt attattcctg
 9421 ttaccacagt catcaatact gatgtattca   cgcatgatta ttgtgagagt ttcaactgtt
 9481 cagtccaaac cggtaaaagt ctaaaggaga   tatgctctga gtcattaaga tctccaacga
 9541 actcatcgcg atacaattta aacggaatca   tgattataag tcaaaacaac atgacagatt
 9601 ttaagattca gttgaatggt ataacttata   acaaactgtc attcggaagt cctggaagac
 9661 tgagcaagac actgggccag gtcctttatt   accaatcttc aatgagttgg gatacttatc
 9721 taaaggcagg atttgtcgag aaatggaaac   cctttacccc gaattggatg aacaatactg
 9781 tgatatccag acctaaccaa ggtaattgtc   caaggtatca taaatgcccc gagatatgtt
 9841 atggagggac atacaatgat attgctcctt   tagatctagg aaaagacatg tatgttagcg
 9901 ttattctaga ttcagatcag cttgcagaga   atccagagat tacagtattt aactctacta
 9961 ctatacttta taaggagaga gtatccaaag   atgaactaaa cacaagaagt actacaacga
10021 gctgttttct tttcctagat gaaccttggt   gtatatcagt attagaaaca aacagattta
10081 acggcaaatc tattaggccc gagatttatt   catacaaaat tcctaagtat tgttaatttg
10141 atgagcttat tcctcatact tcaatcaaat   ttaatataac taatatcaaa ttgttgcact
10201 cagctattat taaaactgga tcatcagaca   ataaagatgt atacaaagat atatcgaaga
10261 gggtattaaa gaaaacttag gatcccagat   ccttcaataa ggcagagcct tgattgtatc
10321 agcgtcattt acaattgaat ctcaattaac   aacactgatt aataacttaa gcagaatact
10381 cctattacag tgtttaattg acttaatttt   aattgaggat tttataatcc tataattgga
10441 gcagatctaa actctcaccg attcagttct   aatcctttat taactaaaga acaaattcta
10501 aataattgga tgacgtcaca ggagacaagc   tggaaacaat ttagttagaa ggaagaaacc
10561 ttttaccaga tatggaaagt gactttgata   tatctgttag cgacgtactg tacccagaat
10621 gtcatttgga cagtcctata gtcggcggta   agctcattac ttctcttgag tatgcgaatt
10681 tgactcataa ccaacctcat gaagatcaga   cattgctgac taatataaat gtcaataaaa
10741 agaagaagat aaaaagtcct ctaatatccc   aacaatcttt atttggaaat gaggttaata
10801 aggagatttt cgatcttaaa aattattacc   atgtccccta tccagaatgt aacagagatt
10861 tattcttaat ctctgatgac aaaatagcat   tcaaactcag taaaatcatg gataattcta
10921 ataaactgtt tgatggttta gagaggaaac   tgagtcgctt aatttcgaat gtagataatc
10981 aactattaaa tgcaacctct cttcataata   attctgagat ggatcggaag ggaaaagaac
11041 atccttgctt cccagaaaag agcacaattg   atgatgtaag acagcagaga cagacacgag
11101 attttccaaa gaattcaact agagagggaa   gatctccaaa acaccctgat gccggtccta
11161 cacctgaaaa cagtgccaaa aacgatttgc   atagagacaa cacagacaat atgccaacag
11221 gccatagttc gacatctatg aaaaaaccta   aaatatctgg agaagaatat cttagtatgt
11281 ggctagactc agaggatttg ggttctaaac   gaatttctgc acaattaggg aaggatgtat
11341 catgtaaagg ccatctgcac acgacagaag   acaaaccgat aatagttcct gacactcgat
11401 atatccaaaa tcatgaatct aataacgata   ttttccccaa aaaagagaaa aaattctgca
11461 aacttccacc gtcatcggat aatttaacca   aaatcatggt gaattcaaaa tggtacaatc
11521 ctttcctttt ttggtttact gtcaagactg   aacttagagc ctgccagaag gagaactaca
11581 aaaggaaaaa cagaaaattg ggaattatca   catcgattaa aggttcatgc tataagttga
11641 tactcaacca gaatctagta gcaatattcg   aggaagacag cagtggatac tcagatcata
11701 aaaaaagaaa aaaacgatgc tactatctaa   ctcccgaaat ggtccttatg ttctccgatg
11761 taactgaagg aagattgatg attgatgttg   caatgagatt tgacaaaaag tacaaaactc
11821 tagagaaaaa ggctttgaaa ttatggtttc   ttatagacga gttatttcct tctatgggaa
11881 atagagtgta taatattata tccatgcttg   agcctttgac tctcgcgata ttacaggtta
11941 aggatgagtc aaggttgttg agaggtgcat   tcatgcatca ttgtttaggt gacctcttcg
12001 aagaacttcg agagtccaag aactacccgg   aagatgagat caagagattt gccaacgacc
12061 taataaatgt catgacctgt cgggacattc   atttagtagc agaattcttc tcattcttta
12121 ggactttcgg acatccaata ttgaacgctc   aaactgcagc caggaaagtt agagagtaca
12181 tgttagcaga taaaatcctt gagtacgaac   ctatcatgaa aggtcatgcg attttctgtg
12241 ctataatcat aaatggattt agagatagac   atggaggagt ttggcctcct cttgatcttc
12301 caaaacattg ttcaaagaac ataatatctc   tcaaaaatac aggtgaaggg gtaacttatg
12361 aagtagcaat aaacaattgg agatcatttg   tcgggttaaa gttcaaatgt tttatgggtc
12421 tcaatttaga caatgatctc agcatgtaca   tgaaagataa agcattatca cctttaaggg
12481 atctttggga ttcaatctat tcacgtgaag   taatgtccta ccaaccacct agaaacaaaa
12541 aatcaagaag attggttgag gttttcgttg   atgatcagga ctttgatccc gttgatatga
12601 taaattatgt tctgaccgga gaatatctca   gagatgatga tttcaatgct tcttatagtt
                                       8

12661 taaaagagaa agagaccaaa caagttggca ggttgtttgc taagatgact tataaaatga
12721 gggcctgtca agttattgct gagaatttaa ttgcacatgg gattgggaga tatttccatg
12781 aaaacgggat ggttaaggat gagcatgagc tcagcaaatc actgtttcaa ttgtctatat
12841 caggaatacc aagagggaac aaaaacaaca aatcgacgaa cgacacaatc cacgaaagca
12901 agatcgagaa taaccattcc tttaaaaaca tccagaatcg atcatttcga aagacggata
12961 acccatacaa tagatttaac attgataacc caactttctt atccccaaac tgtaacccca
13021 agtataaccg taagaattca gagacaatag gtatattctc tcgtgcagaa accaaaagca
13081 tgattagaga acagaaaagt cacagagaag tcaaaataaa taagctagat atcggcagtg
13141 ataatgaaga gcaaggaaaa gagatagatg ccgccaagta caaaatcacg gacaacccaa
13201 atccacacat aaatcctcaa gatcaacccg gaatctgtca agaagacaaa ggcaaagaag
13261 gagcaaagtc agatctcaca gaaggcatga gttttctgga gatgcacaca ctctttaacc
13321 cgagtaagag cgatatcaga acaaatctcg aattggaaaa gagttcactt tcaaaccctg
13381 gatttatatc acaaaaagag aaaagaggca aaacttataa tgaatcccat tcactgggaa
13441 agttctctaa agaggatgaa gaaagatacg atgtcatcag tgcattcctg acaacagatt
13501 tacgaaaatt ctgcttaaat tggagacatg aatcaatcgg catttttgca agaaggatgg
13561 acgaaatcta tggtttgcct ggtttcttta attggatgca cagaagacta gagcgatctg
13621 tgttatatgt tgcggaccct cattgcccgc cgtctatcaa tgaacatatc gatctaaacg
13681 attcacccga aagagacata tttatacatc atccgaaagg gggtatagaa ggatacagcc
13741 aaaaactgtg gacaatagcg actatccctt ttctattcct cagtgctcat gagacaaaca
13801 cccggatagc ggcagttgta caaggtgaca atcaatcaat tgcaattaca cataaggtcc
13861 accctcattt gccttacaaa atgaagaaag aactctctgc aatgcaggca aaaaaatatt
13921 tttcaaggtt acggcacaac atgaaggcat tagggcatga attgaaggcg accgagacta
13981 tcattagtac tcatttcttc atttattcca agaaaatcca ctatgacggg gctgttttat
14041 cacaatctct gaaatcaatg gcaaggtgtg tattttggtc agaaaccctt gttgatgaaa
14101 ctagagcagc atgcagtaat atcagcacaa caattgcaaa ggctattgag aatggttata
14161 gcaggagatc tggctatctg ataaatgttc ttaaaaccat ccaacaaatt aatatatcat
14221 tgagttttaa tataaatgaa tgcatgacag atgacataat cagaccgttt agagataatc
14281 caaactggat caaacatgcc gcattaatcc ccgccagctt gggaggactc aactatatga
14341 acatgtctcg attgtatgtg aggaatatag gggatccagt cacagcatcg atagcagatg
14401 ttaagagaat gattctcggt ggtgtactac ccattggaat actccacaat atcatgttgc
14461 aagaacccgg tgatgccact tatttggact ggtgtagtga tccatactcc atcaacctaa
14521 agcagactca aagtatcaca aaagttataa agaacataac ggcaagagtg atactaagga
14581 attcggtcaa tccactgctc aaaggtctat ttcatgaagg tgcttatgag gaggacactg
14641 aattagcaac attcattttg gacaggagag tcatcttacc acgagtcggt cacgagatct
14701 taaacaactc catcacagga gcaagagaag agatctcggg cttactggat accacaaaag
14761 gattgataag aattggcata gcaaagggag gattaactca gagaacatta tctcgaattt
14821 ccaattatga ttatgaacaa tttttgaacc taatgaatat gttgaagaac aaagaacaaa
14881 acagtgtcat ttccctgtca gcttgctctg ttgactttgc tatagcttta agaagcagga
14941 tgtggaggaa attggcaaaa ggaagattaa tatatggttt agaagtccct gatccaatag
15001 aagcaatgat tggctttctc attcttggga gtgaaaattg tctactctgt gattcaggaa
15061 gcaaaaacta tacctggttt ttcataccaa aggatgtaca gttggataag attgataaag
15121 atcacgcatc aataagggta ccctatgtcg gatcaactac cgaagaaaga tcagagataa
15181 agttaggatc cgtgaaaaat ccaagcaaat ccctgaaatc tgctataaga ctcgcaactg
15241 tgtacacttg ggcatttggc acaagtgatg ctgaatggtg ggaggcttgg tacttgtcta
15301 atcaacgagc aaatataccc ttagatgttc tcaaaacgat aacacctata tctacttcaa
15361 cgaatattgc tcatagatta cgagaccgat caacacaggt taaatacgcc agtacatctc
15421 ttaacagagt atcgcggcat gtaacaatta gtaacgataa catgaatttt gaatttgacg
15481 gggttaaaat ggataccaac ttgatttatc aacaagtcat gctgttaggg ctttcatgct
15541 tggagagttt attccgaaat aggaaaatga caaatagtta caatatcgtg taccatttac
15601 acgttcaaga acattgttgt gtaaaggctc tgaatgattt accttataca ccgtcaacac
15661 atccagtgcc aaattataca gaagttagag ataataggtt aatttacgat cctcaaccta
15721 tattagaatt tgatgagcta agattagcaa ttcagcaaac aaagaaagta gatttggaat
15781 tttcattgtg ggatacaaaa gaacttcatg agaatttagc tcaaagttta gcgattacag
15841 taacggatat tatgacaaaa tctgataaag atcatattaa agaccaaaga agtatagatg
15901 ttgatgataa tattaagaca ctaataactg agtttttatt agtagaccct gaaatgtttg
15961 ccgtaaattt aggattgcat atatcaataa aatggtcatt tgatattcac tttaaaagac
16021 caagaggacg ctatagcatg atagaatact tgactgatct tttggataat acttcttctc
                                   9

      16081    atgtttatcg    aatccttact     aatgtattat     ctcatcccag    agttatgaga aaattcacta
      16141    atgccgggct    actagtaccg     aaatacggtc     cctaccttac    aagtcaagat ttcaaaaaga
      16201    tggcggtaga    tttcataata     acagcgtata     ccacattttt    gaccaattgg tgtaataata
      16261    acaagttttc    aattctaata     cctgaacaag     accctgatat    acttgaatta agaaaagaca
      16321    tcactcatgc    aaggcattta     tgtatgatct     cggatcttta    ctgctactct ttcaagcaac
      16381    cttggataaa    ggagcttaca     ccacaagaga     agatctgcgt    catggaggac ttcatagcca
      16441    attgtgttgc    taatgatcaa     acaagtgcgg     gctggaacat    aacgccctta agagtttaca
      16501    atctccctgc    atcgaccaca     tacatcagga     gagggataat    aaaacaatta agaatccgtc
      16561    aaagcaatga    gcctattgat     ctggaagata     ttaggattgg    tcagaacccc gattttgtga
      16621    ataaacctat    tgagttttgt     agcagtgaat     tcggtatcac    aatttataac cttgaagaaa
      16681    ttcttcaatc    aaatgtgcat     ctcagtgtaa     atatgaacat    tgactcctca acaagtaaca
      16741    atactgaaaa    tcatttattt     agaagggtag     gcttgaactc    tacttcatct tataaagcac
      16801    tatctttaac    acctgttatt     aaaagatatc     atcaacagaa    cactaatagg ctgtttatag
      16861    gagaaggatc    agggtctatg     atgtatcttt     accagaaaac    cttgggggag acaatatgct
      16921    tctttaattc    gggagttcag     tacaatgagg     atctgggtca    aagggaacaa tcattatacc
      16981    cgagtgaata    cagtatctgt     gaacaaggag     taaaaaaaga    aaaccctctc accgggcatg
      17041    ttataccact    attcaatgga     agaccagaaa     ccacatgggt    aggcaatgat gattctttca
      17101    agtatatatt    ggaacatact     ataaatagag     acatcgggct    tgttcactcc gatatggaaa
      17161    caggaatagg    gaaggataat     tatactatct     taaatgaaca    tgcacatctt atagcactga
      17221    gccttacagt    aatgattgat     gatggaatct     tggtgtctaa    ggtagcttat gcccctgggt
      17281    tttgcatctc    ttcattattg     aatatgtacc     ggacattttt    ttcattagtt ctatgtgcgt
      17341    ttccaccgta    tagcaatttt     gaatcaactg     aattttacct    gatttgcttg caaaaaagta
      17401    tacccggacc    tatcacacca     gctagagcca     tccaacaaac    gacgaagcaa tctagagaag
      17461    aggataatag    tataactaat     aatatcctca     aaatcaaaaa    tcttgttcag aaagaattta
      17521    tcaaaacagt    aaagaaaaaa     tacgaaatcc     atccttcgtt    taactgtcct atcaacttca
      17581    caaaggatga    taaatattta     atgagtgttg     ggtttcaagc    caatggtcct gatatgatac
      17641    gtaaagagac    gggctatgac     ataggtagca     atgtagagaa    tctccgagat gtcttaatca
      17701    agttgtttgc    agatgcagtc     accttctatg     atgatgtcac    aaataaaaag aactttttaa
      17761    atccttatcc    agtctacaca     agaactcagt     ataaaattct    gatggataaa atatgcaaga
      17821    aagtcacctt    atacacctta     atcatatcat     gtaaaggatc    caatcaatat tgctgggaaa
      17881    ttaaatccca    aataagaaag     cattgtctca     tacttgattt    gaaaagtaag gtttttacaa
      17941    aacttattcc    aaagggatta     agagaaaggg     gtgactcaaa    agggatgaag agcatatggt
      18001    tcactaaact    aaccagtcaa     gaggtgaaaa     gatggtggaa    gatgatatct tacatcgtga
      18061    taataagcaa    tccataacca     catccaactt     gtcagttaaa    cacttaaatc acaataaact
      18121    tgtcatcaga    ttaaagaaaa     cttataattc     ccttttttag    gt         (SEQ ID NO:1)
[0027] The present invention provides for nucleic acids related to the CedPV genome. In particular, the
present invention provides for nucleic acids with a polynucleotide sequence at least about 60%, 61%,
62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%,
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%
identical to the polynucleotide sequence of SEQ ID NO:1.
[0028] The present invention also provides for fragments of the polynucleotide of SEQ ID NO:1, for
example primers and probes.
[0029] The present invention also comprises vectors containing any of the nucleic acids disclosed
herein. As used herein, a "vector" may be any of a number of nucleic acids into which a desired
sequence may be inserted by restriction and ligation for transport between different genetic
environments or for expression in a host cell. Vectors are typically composed of DNA although RNA
                                                    10

vectors are also available. Vectors include, but are not limited to, plasmids and phagemids. A cloning
vector is one which is able to replicate in a host cell, and which is further characterized by one or more
endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a
desired DNA sequence may be ligated such that the new recombinant vector retains its ability to
replicate in the host cell. In the case of plasmids, replication of the desired: sequence may occur many
times as the plasmid increases in copy number within the host bacterium or just a single time per host
before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic
phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA
sequence may be inserted by restriction and ligation such that it is operably joined to regulatory
sequences and may be expressed as an RNA transcript. Vectors may further contain one or more
marker sequences suitable for use in the identification and selection of cells which have been
transformed or transfected with the vector. Markers include, for example, genes encoding proteins
which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes
which encode enzymes whose activities are detectable by standard assays known in the art (e.g., .beta.
galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or
transfected cells, hosts, colonies or plaques. Examples of vectors include but are not limited to those
capable of autonomous replication and expression of the structural gene products present in the DNA
segments to which they are operably joined.
[0030] The genomic sequence of SEQ ID NO:1 above codes for the nucleplasmid protein ("N-protein"),
the phosphoprotein ("P-protein"), the matrix protein ("M-protein"), the fusion protein ("F-protein"), the
glycoprotein protein or attachment protein ("G-protein") and the large protein ("L-protein") of CedPV.
In addition, the P gene also codes for the C-protein of CedPV. The terms "protein" and "polypeptide"
are under interchangeably herein and refer to a polymer of amino acids.
[0031] As used herein with respect to polypeptides, the term "substantially pure" means that the
polypeptides are essentially free of other substances with which they may be found in nature or in vivo
systems to an extent practical and appropriate for their intended use. In particular, the polypeptides are
sufficiently pure and are sufficiently free from other biological constituents of their host cells so as to be
useful in, for example, generating antibodies, sequencing, or producing pharmaceutical preparations.
By techniques well known in the art, substantially pure polypeptides may be produced in light of the
nucleic acid and amino acid sequences disclosed herein. Because a substantially purified polypeptide of
the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical
                                                       11

preparation, the polypeptide may comprise only a certain percentage by weight of the preparation. The
polypeptide is nonetheless substantially pure in that it has been substantially separated from the
substances with which it may be associated in living systems.
 [0032] As used herein with respect to nucleic acids and proteins, the term "isolated" means not found
in its native environment and includes but is not limited to such settings : (i) being amplified in vitro by,
for example, polymerase chain reaction (PCR); (ii) being recombinantly produced by cloning and/or
culturing; (iii) being purified, as by cleavage and gel separation; (iv) being part of a prepared plasmid or
expression vector, or (v) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one
which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide
sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase
chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid
sequence existing in its native state in its natural host is not. An isolated nucleic acid or protein may be
substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or
expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in
which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily
manipulable by standard techniques known to those of ordinary skill in the art.
 [0033] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the N
protein begins at position 144 and ends at 1676, resulting in a polypeptide of 510 amino acids long as
disclosed in SEQ ID NO:2. The present invention thus provides for nucleic acids that code for the amino
acid sequence of SEQ ID NO:2. In additon, the present invention also provides for nucleic acids with a
polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or100% identical to the polynucleotide
sequence of positions 144-1673 of SEQ ID NO:1.
 [0034] The invention also provides for polypeptides, derivatives and fragments of the CedPV N-protein.
Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%,
65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,
84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical
to the polypeptide of SEQ ID NO:2. As used herein, a "derivative" of a reference polypeptide is a
polypeptide that has less than 100% amino acid identity with the reference polypeptide. For example,
                                                       12

the invention provides for derivatives of the CedPV N-protein as described herein. The invention also
provides for polypeptides comrpsing or consisting of the amino acid sequence of SEQ ID NO:2.
[0035] The invention also provides for fragments of the polypeptide of SEQ ID NO:2. As used herein, a
fragment of the reference polypeptide is a polypeptide with a length that is less that that of the
reference polypeptide. The fragment may be within a larger molecule, such as a chimeric protein, such
that the total length of the molecule containing the fragment is larger than the reference protein. The
polypeptide fragments of SEQ ID NO:2 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50,
55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165,
170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270,
275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375,
380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480,
485, 490, 495, 500, 505, 506, 507, 508 or 509 amino acids in length. As used herein, the length of
fragments disclosed above are also used to indicate a polypeptide having a number of amino acids
within a certain range. For example, as used herein, a "polypeptide fragment of SEQ ID NO:2 can be
fragment of at least about 15, 20, 25, 30 ... amino cids in length" is used to mean that the fragments can
be between 15 and 20 amino acids in length, and that the fragments can be between 20 and 25 amino
acids in length, etc. One of skill in the art will recoginize that a polypeptide fragment of SEQ ID NO:2
that is, for example, "at least about ... 440, 445 ... amino acids in length" will include polypeptide
fragments that are between 440 and 445 amino acids in length.
MSDIFNETQS      FRNYQSNLGR      DGRASAATTT LTTKVRIFVP            ANNNPNLRWR    LTLFLMDVVR      SPASAESMKV
GAGISLVSMY      AEKPGALVRA      LLNDPDVEAI IIDVYGFDEG            IPIMERRGDK    ATDDMDSLRK      IVKAAHDFSR
GRSLFVDQRV      QDIVMSDMGS      FVNAITSIET QIWILIAKAV            TAPDTAEESE    GRRWAKYVQQ      KRVNPLFLIS
PQWINDMRSL       IAASLSLRKF     MVELLMEAKK GRGTKGRIME            IVSDIGNYVE    ETGMAGFFAT      IKFGLETKFP
ALALNELQSD      LNTMKSLMIL      YRSIGPKAPF MVLLEDSIQT            KFAPGSYPLL    WSFAMGVGTT      IDRAMGALNI
NRSYLEPVYF      RLGQQSAKHQ      AGNVDKEMAE KLGLTEDQIV            HLSANVKDAS    QGRDDNQINI      REGKFTNVVD
DIQDHAQSSS      EDYNPSKKSF      SILTSITSTV DSADSRSAMN            ESMTTTSLLK    LRQRLAEKKG      DSKNSQDTPP
KPPRAKDQPT      DEVSFMDSNI       (SEQ ID NO:2)
[0036] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the P
protein begins at position 2112 and ends at 4325, resulting in a polypeptide of 737amino acids long as
disclosed in SEQ ID NO:3. The present invention thus provides for nucleic acids that code for the amino
acid sequence of SEQ ID NO:3. In additon, the present invention also provides for nucleic acids with a
polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
                                                        13

89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or100% identical to the polynucleotide
sequence of positions 2112-4325 of SEQ ID NO:1.
[0037] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives
and fragments of the CedPV P-protein. Specifically, the present invention provides for polypeptides at
least a bout 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,
77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:3. The invention also provides
for polypeptides comrpsing or consisting of the amino acid sequence of SEQ ID NO:3.
[0038] The polypeptide fragments of SEQ ID NO:3 can be fragments of at least about 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155,
160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260,
265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365,
370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470,
475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575,
580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680,
685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 731, 732, 733, 734, 735 or 736 amino acids in length.
As used herein, the length of fragments disclosed above are also used to indicate a polypeptide having a
number of amino acids within a certain range. For example, as used herein, a "polypeptide fragment of
SEQ ID NO:3 can be fragment of at least about 15, 20, 25, 30 ... amino cids in length" is used to mean
that the fragments can be between 15 and 20 amino acids in length, and that the fragments can be
between 20 and 25 amino acids in length, etc. One of skill in the art will recoginize that a polypeptide
fragment of SEQ ID NO:3 that is, for example, "at least about ... 720, 725 ... amino acids in length" will
include polypeptide fragments that are between 720 and 725 amino acids in length.
MDKLQLIEDG      LSTINFIQEN      KEKLQHSYGR      SSIREPPTSV     RVEEWEKFIR KIASGPEQVQ         GGGSETEITG
DNGDRGNFTN      PDQGGGVTGQ      FEERYQKWGS      QDSELQLDPM     VVHDFFYDER RENPDNGKYD         RSSKKRDNIR
EGTRQDKYNN      QSTDELLSCL      QPSSKNDVIK      NESTSVSNLH     VTGNKLNPDA KPFEPTSQSK         EHPTTTQHNK
NDHQTDDDYK      NRRSSENNVI      SDHATTMEDN      NNFIPATKRK     NALSEPIYVQ VLPSNTEGFS         GKDYPLLKDN
SVKKRAEPVI      LETANHPAGS      ADQDTNQIEE      NMQFNLPKLL     TEDTDDEPED NNDSMPLEED         IREIGSMLKD
GTKDIKTRMN      EIDDAIKKIN      KKSKNRSLDL      ESDGKDQGRR     DPSVDLGIKK RKEGLKAAMQ         KTKEQLSIKV
EREIGLNDRI      CQNSKMSTEK      KLIYAGMEME      YGQTSTGSGG     PQGSKDGTSD DVQVDEDYDE         GEDYEAMPSD
RFYTTLSGEQ      KDRFDLDANQ      MSQYDLEAQV      DELTRMNLIL     YSRLETTNKL LIDILDLAKE         MPKLVRKVDN
LERQMGNLNM      LTSTLEGHLS      SVMIMIPGKD      KSEKEIPKNP     DLRPILGRSN TSLTDVIDLD         HYPDKGSKGI
KPSGSGDRQY      IGSLESKFSI      NDEYNFAPYP      IRDELLLPGL     RDDKTNASSF IPDDTDRSPM         VLKIIIRQNI
HDEEVKDELL      SILEQHNTVE      ELNEIWNTVN      DYLDGNI         (SEQ ID NO:3)
                                                       14

[0039] The coding sequence for the C-protein is within the P-protein coding sequence and begins at
position 2137 (of SEQ ID NO:1) and ends at position 2670, resulting in a polypeptide of 177 amino acids
long as disclosed in SEQ ID NO:4. The present invention thus provides for nucleic acids that code for the
amino acid sequence of SEQ ID NO:4. In additon, the present invention also provides for nucleic acids
with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%,
69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or100% identical to the polynucleotide
sequence of positions 2137-2670 of SEQ ID NO:1.
[0040] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives
and fragments of the CedPV C-protein. Specifically, the present invention provides for polypeptides at
least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,
77%,78%,79%,80%,81%,82%,83%,84%,85%,86%,87%,88%,89%,90%,91%,92%,93%,94%,95%,
96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:4. The invention also provides
for polypeptides comrpsing or consisting of the amino acid sequence of SEQ ID NO:4.
[0041] The polypeptide fragments of SEQ ID NO:4 can be fragments of at least about 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155,
160, 165, 166, 167m 168, 169, 170, 171, 172, 173, 174, 175 or 176 amino acids in length. As used
herein, the length of fragments disclosed above are also used to indicate a polypeptide having a number
of amino acids within a certain range. For example, as used herein, a "polypeptide fragment of SEQ ID
NO:4 can be fragment of at least about 15, 20, 25, 30 ... amino cids in length" is used to mean that the
fragments can be between 15 and 20 amino acids in length, and that the fragments can be between 20
and 25 amino acids in length, etc. One of skill in the art will recoginize that a polypeptide fragment of
SEQ ID NO:4 that is, for example, "at least about ... 140, 145 ... amino acids in length" will include
polypeptide fragments that are between 140 and 145 amino acids in length.
MASLLSILYR KIRKNYSILT EDPPSESHPQ VSGLKSGRNL FERSLLDLNK FKGEDLRLRS QAIMEIEAIL
PILIREAESQ DNSKKGIKNG GHKIQNYNWT QWLYTISSMT REGRIPTMEN MTAALKNGII SEKEHDRIST
IISLLMNYCP AYNHLLRTMS SRMKVHQCQI CMLQEIN                        (SEQ ID NO:4)
[0042] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the M
protein begins at position 4635 and ends at 5717, resulting in a polypeptide of 360 amino acids long as
disclosed in SEQ ID NO:5. The present invention thus provides for nucleic acids that code for the amino
                                                       15

acid sequence of SEQ ID NO:5. In additon, the present invention also provides for nucleic acids with a
polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or100% identical to the polynucleotide
sequence of positions 4635-5717 of SEQ ID NO:1.
[0043] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives
and fragments of the CedPV M-protein. Specifically, the present invention provides for polypeptides at
least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,
77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:5. The invention also provides
for polypeptides comrpsing or consisting of the amino acid sequence of SEQ ID NO:5.
[0044] The polypeptide fragments of SEQ ID NO:5 can be fragments of at least about 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155,
160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260,
265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 351, 352, 353,
354, 355, 356, 357, 358 or 359 amino acids in length. As used herein, the length of fragments disclosed
above are also used to indicate a polypeptide having a number of amino acids within a certain range.
For example, as used herein, a "polypeptide fragment of SEQ ID NO:5 can be fragment of at least about
15, 20, 25, 30 ... amino cids in length" is used to mean that the fragments can be between 15 and 20
amino acids in length, and that the fragments can be between 20 and 25 amino acids in length, etc. One
of skill in the art will recoginize that a polypeptide fragment of SEQ ID NO:5 that is, for example, "at least
about ... 280, 285 ... amino acids in length" will include polypeptide fragments that are between 280 and
285 amino acids in length.
MDPSDLRRII       MEDDKSLVNN DDSTETDFLE KTWREGSKID              KITPEVDENG     NMVPKYVVFN      PGKNERKTSG
YQYMICYGFI       EDGPINGSPR VKGNIRTTAS FPLGVGKTYS              SPEEILQELT     TLKITVRRTA      GSNEKLVYGI
TGPLNHLYPW       YKVLTGGSIF SAVKVCRNVD QILLDRPQIL              RVFFLSITKL     TDKGVYMIPK      SVLDFRSDNS
MAFNLLVYLK        IDTDITKAGI RGIVNKEGER ITSFMLHIGN             FTRRGGKHYS     VEYCKRKIDK      MKLTFALGTI
GGLSLHIRID       GRISKRLQAQ VGFQRNICYS LMDTNPWLNK              LTWNNSCEIH     KVTAVIQPSV      PKDFMLYEDI
LIDNTGKILK                     (SEQ ID NO:5)
[0045] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the F
protein begins at position 6405 and ends at 8078, resulting in a polypeptide of 557 amino acids long as
                                                        16

disclosed in SEQ ID NO:6. The present invention thus provides for nucleic acids that code for the amino
acid sequence of SEQ ID NO:6. In additon, the present invention also provides for nucleic acids with a
polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or100% identical to the polynucleotide
sequence of positions 6405-8078 of SEQ ID NO:1.
[0046] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives
and fragments of the CedPV F-protein. Specifically, the present invention provides for polypeptides at
least a bout 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,
77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:6. The invention also provides
for polypeptides comrpsing or consisting of the amino acid sequence of SEQ ID NO:6.
[0047] The polypeptide fragments of SEQ ID NO:6 can be fragments of at least about 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155,
160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260,
265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365,
370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470,
475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 546, 547, 548, 549, 550, 551,
552, 553, 554, 555 or 556 amino acids in length. As used herein, the length of fragments disclosed
above are also used to indicate a polypeptide having a number of amino acids within a certain range.
For example, as used herein, a "polypeptide fragment of SEQ ID NO:6 can be fragment of at least about
15, 20, 25, 30 ... amino cids in length" is used to mean that the fragments can be between 15 and 20
amino acids in length, and that the fragments can be between 20 and 25 amino acids in length, etc. One
of skill in the art will recoginize that a polypeptide fragment of SEQ ID NO:6 that is, for example, "at least
about ... 515, 520 ... amino acids in length" will include polypeptide fragments that are between 515 and
520 amino acids in length.
MSNKRTTVLI        IISYTLFYLN      NAAIVGFDFD     KLNKIGVVQG    RVLNYKIKGD     PMTKDLVLKF      IPNIVNITEC
VREPLSRYNE       TVRRLLLPIH       NMLGLYLNNT     NAKMTGLMIA    GVIMGGIAIG     IATAAQITAG      FALYEAKKNT
ENIQKLTDSI       MKTQDSIDKL       TDSVGTSILI     LNKLQTYINN    QLVPNLELLS     CRQNKIEFDL      MLTKYLVDLM
TVIGPNINNP       VNKDMTIQSL       SLLFDGNYDI     MMSELGYTPQ    DFLDLIESKS     ITGQIIYVDM      ENLYVVIRTY
LPTLIEVPDA       QIYEFNKITM       SSNGGEYLST     IPNFILIRGN    YMSNIDVATC     YMTKASVICN      QDYSLPMSQN
LRSCYQGETE       YCPVEAVIAS       HSPRFALTNG     VIFANCINTI    CRCQDNGKTI     TQNINQFVSM      IDNSTCNDVM
VDKFTIKVGK       YMGRKDINNI       NIQIGPQIII     DKVDLSNEIN    KMNQSLKDSI     FYLREAKRIL      DSVNISLISP
                                                        17

SVQLFLIIIS VLSFIILLII           IVYLYCKSKH SYKYNKFIDD PDYYNDYKRE RINGKASKSN NIYYVGD
 (SEQ ID NO:6)
[0048] One example of a fragment of an F protein is a soluble CedPV F glycoprotein comprising all or
part of the extracellular domain of F glycoprotein of CedPV. The soluble forms of F glycoprotein may be
produced by deleting all or part of the transmembrane and/or cytoplasmic tail domains of the F
glycoprotein. By way of example, a soluble Fglycoprotein may comprise the complete extracellular
region of a CePV F glycoprotein. In some embodiments, the soluble F glycoprotein may be truncated at
after K490 in SEQ ID NO:6 Also, by way of example, a soluble F glycoprotein may comprise all or part of
the extracellular region and part of the transmembrane domain of a CedPV F glycoprotein. By way of
further example, several versions of a soluble F (sF) glycoprotein can be constructed, primarily through
removing the cytoplasmic tail and/or transmembrane domain that anchor the protein. As used herein,
"soluble Fglycoprotein" or "soluble form of F glycoprotein" or "sF glycoprotein" refers to an amino acid
sequence for a fragment or portion of native F glycoprotein that contains the extracellular domain or a
portion thereof. The sF glycoprotein is structurally similar to the native viral F glycoprotein.
[0049] The sF glycoproteins of the invention are structurally similar to the native viral F glycoprotein.
By way of example, the sF glycoproteins of the invention may be recognized by polyclonal antibodies
directed to CedPV. By way of example, the sF glycoproteins of the invention may assemble in the
oligomeric form or forms (such as a trimer), comparable to native CedPV F glycoprotein.
[0050] The sF or sG glycoproteins of the present invention are suitable, for example, for vaccine
development and for acting as an antigen to generate anti-viral antibodies when used as a vaccine or in
the isolation of recombinant monoclonal antibodies. The sF or sG glycoproteins are suitable to generate
antibodies capable of recognizing native F or G glycoprotein. The sF or sG glycoproteins of the present
invention that assemble in monomeric or oligomeric forms, such as trimers, can be of further use, such
as, for example, for crystallization and structural determination to provide further information to aid
structural-based antiviral research. The oligomeric forms of sF or sG glycoprotein of the present
invention may also generate further antibodies capable of recognizing native F or G glycoprotein and its
native oligomeric forms. The term "soluble" has no bearing on the protein's ability to dissolve in an
aqueous or non-aqueous solvent.
                                                      18

[0051] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the G
protein begins at position 8268 and ends at 10136, resulting in a polypeptide of 622 amino acids long as
disclosed in SEQ ID NO:7. The present invention thus provides for nucleic acids that code for the amino
acid sequence of SEQ ID NO:7. In additon, the present invention also provides for nucleic acids with a
polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or100% identical to the polynucleotide
sequence of positions 8268-10136 of SEQ ID NO:1.
[0052] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives
and fragments of the CedPV G-protein. Specifically, the present invention provides for polypeptides at
least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,
77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:7. The invention also provides
for polypeptides comrpsing or consisting of the amino acid sequence of SEQ ID NO:7.
[0053] The polypeptide fragments of SEQ ID NO:7 can be fragments of at least about 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155,
160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260,
265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365,
370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470,
475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575,
580, 585, 590, 595, 600, 605, 610, 612, 613, 614, 615, 616, 617, 618, 619, 620 or 621 amino acids in
length. As used herein, the length of fragments disclosed above are also used to indicate a polypeptide
having a number of amino acids within a certain range. For example, as used herein, a "polypeptide
fragment of SEQ ID NO:7 can be fragment of at least about 15, 20, 25, 30 ... amino cids in length" is used
to mean that the fragments can be between 15 and 20 amino acids in length, and that the fragments
can be between 20 and 25 amino acids in length, etc. One of skill in the art will recoginize that a
polypeptide fragment of SEQ ID NO:7 that is, for example, "at least about ... 300, 305 ... amino acids in
length" will include polypeptide fragments that are between 300 and 305 amino acids in length.
MLSQLQKNYL      DNSNQQGDKM      NNPDKKLSVN      FNPLELDKGQ     KDLNKSYYVK     NKNYNVSNLL     NESLHDIKFC
IYCIFSLLII      ITIINIITIS      IVITRLKVHE      ENNGMESPNL     QSIQDSLSSL     TNMINTEITP     RIGILVTATS
VTLSSSINYV      GTKTNQLVNE      LKDYITKSCG      FKVPELKLHE     CNISCADPKI     SKSAMYSTNA     YAELAGPPKI
FCKSVSKDPD      FRLKQIDYVI      PVQQDRSICM      NNPLLDISDG     FFTYIHYEGI     NSCKKSDSFK     VLLSHGEIVD
                                                       19

RGDYRPSLYL LSSHYHPYSM           QVINCVPVTC     NQSSFVFCHI       SNNTKTLDNS      DYSSDEYYIT    YFNGIDRPKT
KKIPINNMTA DNRYIHFTFS           GGGGVCLGEE     FIIPVTTVIN       TDVFTHDYCE      SFNCSVQTGK    SLKEICSESL
RSPTNSSRYN LNGIMIISQN           NMTDFKIQLN     GITYNKLSFG       SPGRLSKTLG      QVLYYQSSMS    WDTYLKAGFV
EKWKPFTPNW MNNTVISRPN           QGNCPRYHKC      PEICYGGTYN      DIAPLDLGKD      MYVSVILDSD    QLAENPEITV
FNSTTILYKE RVSKDELNTR           STTTSCFLFL     DEPWCISVLE       TNRFNGKSIR      PEIYSYKIPK    YC
 (SEQ ID NO:7)
[0054] Examples of fragments of G proteins CedPV include soluble forms of CedPV G-protein that retain
characteristics of the native viral G glycoprotein allowing for rapid high throughput production of
vaccines, diagnostics and screening.
[0055] Soluble forms of CedPV G glycoproteins comprise at least a portion of the ectodomain (e.g.
extracellular) of the G glycoprotein. In select embodiments, CedPV are generally produced by deleting
all or part of the transmembrane domain of the G glycoprotein and all or part of the cytoplasmic tail of
the G glycoprotein. In one embodiment, the soluble G protein of CedPV does not comprise any portion
of the ctyoplasmic region of the full length G protein. In another embodiment, the soluble G protein of
CedPV does not comprise any portion of the transmembrane domain. In yet another embodiment, the
soluble G protein of CedPV comprises no portion of the transmembrane domain and the cytoplasmic
domain. As used herein, the term "soluble" simply means that the G protein is missing a portion or all of
its cytoplasmic tail or that the G protein is missing all or part of its transmembrane domain, or both. In
some embodiments, the soluble G glycoprotein is truncated after K87 in SEQ ID NO:7. The term
"soluble" has no bearing on the protein's ability to dissolve in an aqueous or non-aqueous solvent.
[0056] The soluble CedPV G glycoproteins of the invention, generally retain one or more characteristics
of the corresponding native viral glycoprotein, such as, ability to interact or bind the viral host cell
receptor, can be produced in monomeric and/or oligomeric form or forms, or the ability to elicit
antibodies (including, but not limited to, viral neutralizing antibodies) capable of recognizing native G
glycoprotein. Examples of additional characteristics include, but are not limited to, the ability to block
or prevent infection of a host cell. Conventional methodology may be utilized to evaluate soluble CedPV
G glycoproteins for one of more of the characteristics. Examples of methodology that may be used
include, but are not limited to, the assays described herein in the Examples.
[0057] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the L
protein begins at position 10572 and ends at 18077, resulting in a polypeptide of 2501 amino acids long
as disclosed in SEQ ID NO:8. The present invention thus provides for nucleic acids that code for the
                                                       20

amino acid sequence of SEQ ID NO:8. In additon, the present invention also provides for nucleic acids
with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%,
69%,70%,71%,72%,73%,74%,75%,76%,77%,78%,79%,80%,81%,82%,83%,84%,85%,86%,87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or1OO% identical to the polynucleotide
sequence of positions 10572-18077 of SEQ ID NO:1.
[0058] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives
and fragments of the CedPV L-protein. Specifically, the present invention provides for polypeptides at
least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%,
77%,78%,79%,80%,81%,82%,83%,84%,85%,86%,87%,88%,89%,90%,91%,92%,93%,94%,95%,
96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:8. The invention also provides
for polypeptides comrpsing or consisting of the amino acid sequence of SEQ ID NO:8.
[0059] The polypeptide fragments of SEQ ID NO:8 can be fragments of at least about 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155,
160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260,
265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365,
370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470,
475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575,
580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680,
685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785,
790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890,
895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995,
1000,1005,1010,1015,1020,1025,1030,1035,1040,1045,1050,1055,1060,1065,1070,1075,1080,
1085, 1090, 1095, 1100, 1105, 1110, 1115, 1120, 1125, 1130, 1135, 1140, 1145, 1150, 1155, 1160, 1165,
1170, 1175, 1180, 1185, 1190, 1195, 1200, 1205, 1210, 1215, 1220, 1225, 1230, 1235, 1240, 1245, 1250,
1255,1260,1265,1270,1275,1280,1285,1290,1295,1300,1305,1310,1315,1320,1325,1330,1335,
1340,1345,1350,1355,1360,1365,1370,1375,1380,1385,1390,1395,1400,1405,1410,1415,1420,
1425,1430,1435,1440,1445,1450,1455,1460,1465,1470,1475,1480,1485,1490,1495,1500,1505,
1510,1515,1520,1525,1530,1535,1540,1545,1550,1555,1560,1565,1570,1575,1580,1585,1590,
1595,1600,1605,1610,1615,1620,1625,1630,1635,1640,1645,1650,1655,1660,1665,1670,1675,
1680,1685,1690,1695,1700,1705,1710,1715,1720,1725,1730,1735,1740,1745,1750,1755,1760,
1765,1770,1775,1780,1785,1790,1795,1800,1805,1810,1815,1820,1825,1830,1835,1840,1845,
                                                       21

1850, 1855, 1860, 1865, 1870, 1875, 1880, 1885, 1890, 1895, 1900, 1905, 1910, 1915, 1920, 1925, 1930,
1935, 1940, 1945, 1950, 1955, 1960, 1965, 1970, 1975, 1980, 1985, 1990,1995,2000, 2005, 2010, 2015,
2020,2025,2030,2035,2040,2045,2050,2055,2060,2065,2070,2075,2080,2085,2090,2095,2100,
2105, 2110, 2115, 2120, 2125, 2130, 2135, 2140, 2145, 2150, 2155, 2160, 2165, 2170, 2175, 2180, 2185,
2190, 2195, 2200, 2205, 2210, 2215, 2220, 2225, 2230, 2235, 2240, 2245, 2250, 2255, 2260, 2265, 2270,
2275,2280,2285,2290,2295,2300,2305,2310,2315,2320,2325,2330,2335,2340,2345,2350,2355,
2360,2365,2370,2375,2380,2385,2390,2395,2400,2405,2410,2415,2420,2425,2430,2435,2440,
2445,2450,2455,2460,2465,2470,2475,2480,2485,2490,2491,2492,2593,2494,2495,2496,2497,
2498, 2499 or 2500 amino acids in length. As used herein, the length of fragments disclosed above are
also used to indicate a polypeptide having a number of amino acids within a certain range. For example,
as used herein, a "polypeptide fragment of SEQ ID NO:8 can be fragment of at least about 15, 20, 25, 30
... amino cids in length" is used to mean that the fragments can be between 15 and 20 amino acids in
length, and that the fragments can be between 20 and 25 amino acids in length, etc. One of skill in the
art will recoginize that a polypeptide fragment of SEQ ID NO:8 that is, for example, "at least about ...
2050, 2055 ... amino acids in length" will include polypeptide fragments that are between 2050 and 2055
amino acids in length.
MESDFDISVS      DVLYPECHLD       SPIVGGKLIT    SLEYANLTHN    QPHEDQTLLT     NINVNKKKKI     KSPLISQQSL
FGNEVNKEIF      DLKNYYHVPY       PECNRDLFLI    SDDKIAFKLS    KIMDNSNKLF     DGLERKLSRL      ISNVDNQLLN
ATSLHNNSEM      DRKGKEHPCF       PEKSTIDDVR    QQRQTRDFPK    NSTREGRSPK     HPDAGPTPEN      SAKNDLHRDN
TDNMPTGHSS      TSMKKPKISG      EEYLSMWLDS     EDLGSKRISA    QLGKDVSCKG     HLHTTEDKPI      IVPDTRYIQN
HESNNDIFPK      KEKKFCKLPP       SSDNLTKIMV    NSKWYNPFLF    WFTVKTELRA     CQKENYKRKN     RKLGIITSIK
GSCYKLILNQ      NLVAIFEEDS       SGYSDHKKRK    KRCYYLTPEM    VLMFSDVTEG     RLMIDVAMRF     DKKYKTLEKK
ALKLWFLIDE      LFPSMGNRVY      NIISMLEPLT     LAILQVKDES    RLLRGAFMHH     CLGDLFEELR     ESKNYPEDEI
KRFANDLINV      MTCRDIHLVA      EFFSFFRTFG     HPILNAQTAA    RKVREYMLAD     KILEYEPIMK     GHAIFCAIII
NGFRDRHGGV      WPPLDLPKHC       SKNIISLKNT    GEGVTYEVAI    NNWRSFVGLK     FKCFMGLNLD     NDLSMYMKDK
ALSPLRDLWD       SIYSREVMSY     QPPRNKKSRR     LVEVFVDDQD    FDPVDMINYV     LTGEYLRDDD     FNASYSLKEK
ETKQVGRLFA      KMTYKMRACQ      VIAENLIAHG     IGRYFHENGM    VKDEHELSKS     LFQLSISGIP     RGNKNNKSTN
DTIHESKIEN      NHSFKNIQNR       SFRKTDNPYN    RFNIDNPTFL    SPNCNPKYNR     KNSETIGIFS     RAETKSMIRE
QKSHREVKIN      KLDIGSDNEE      QGKEIDAAKY     KITDNPNPHI    NPQDQPGICQ     EDKGKEGAKS     DLTEGMSFLE
MHTLFNPSKS      DIRTNLELEK       SSLSNPGFIS    QKEKRGKTYN    ESHSLGKFSK     EDEERYDVIS     AFLTTDLRKF
CLNWRHESIG       IFARRMDEIY     GLPGFFNWMH     RRLERSVLYV    ADPHCPPSIN     EHIDLNDSPE     RDIFIHHPKG
GIEGYSQKLW      TIATIPFLFL       SAHETNTRIA    AVVQGDNQSI    AITHKVHPHL      PYKMKKELSA    MQAKKYFSRL
RHNMKALGHE      LKATETIIST      HFFIYSKKIH     YDGAVLSQSL    KSMARCVFWS     ETLVDETRAA     CSNISTTIAK
AIENGYSRRS      GYLINVLKTI      QQINISLSFN     INECMTDDII    RPFRDNPNWI     KHAALIPASL     GGLNYMNMSR
LYVRNIGDPV      TASIADVKRM       ILGGVLPIGI    LHNIMLQEPG    DATYLDWCSD      PYSINLKQTQ     SITKVIKNIT
ARVILRNSVN       PLLKGLFHEG     AYEEDTELAT     FILDRRVILP    RVGHEILNNS      ITGAREEISG    LLDTTKGLIR
IGIAKGGLTQ      RTLSRISNYD      YEQFLNLMNM     LKNKEQNSVI    SLSACSVDFA      IALRSRMWRK    LAKGRLIYGL
EVPDPIEAMI      GFLILGSENC      LLCDSGSKNY     TWFFIPKDVQ    LDKIDKDHAS      IRVPYVGSTT    EERSEIKLGS
VKNPSKSLKS      AIRLATVYTW      AFGTSDAEWW     EAWYLSNQRA    NIPLDVLKTI     TPISTSTNIA     HRLRDRSTQV
KYASTSLNRV       SRHVTISNDN     MNFEFDGVKM     DTNLIYQQVM    LLGLSCLESL     FRNRKMTNSY     NIVYHLHVQE
HCCVKALNDL       PYTPSTHPVP     NYTEVRDNRL     IYDPQPILEF    DELRLAIQQT     KKVDLEFSLW     DTKELHENLA
QSLAITVTDI      MTKSDKDHIK      DQRSIDVDDN     IKTLITEFLL    VDPEMFAVNL     GLHISIKWSF     DIHFKRPRGR
YSMIEYLTDL      LDNTSSHVYR       ILTNVLSHPR    VMRKFTNAGL    LVPKYGPYLT      SQDFKKMAVD    FIITAYTTFL
                                                      22

TNWCNNNKFS       ILIPEQDPDI      LELRKDITHA     RHLCMISDLY   CYSFKQPWIK      ELTPQEKICV MEDFIANCVA
NDQTSAGWNI       TPLRVYNLPA      STTYIRRGII     KQLRIRQSNE   PIDLEDIRIG      QNPDFVNKPI EFCSSEFGIT
 IYNLEEILQS      NVHLSVNMNI      DSSTSNNTEN     HLFRRVGLNS   TSSYKALSLT      PVIKRYHQQN TNRLFIGEGS
GSMMYLYQKT       LGETICFFNS      GVQYNEDLGQ     REQSLYPSEY   SICEQGVKKE      NPLTGHVIPL FNGRPETTWV
GNDDSFKYIL       EHTINRDIGL      VHSDMETGIG     KDNYTILNEH   AHLIALSLTV      MIDDGILVSK VAYAPGFCIS
 SLLNMYRTFF      SLVLCAFPPY      SNFESTEFYL     ICLQKSIPGP   ITPARAIQQT      TKQSREEDNS ITNNILKIKN
LVQKEFIKTV       KKKYEIHPSF      NCPINFTKDD     KYLMSVGFQA   NGPDMIRKET      GYDIGSNVEN LRDVLIKLFA
DAVTFYDDVT       NKKNFLNPYP      VYTRTQYKIL     MDKICKKVTL   YTLIISCKGS      NQYCWEIKSQ IRKHCLILDL
KSKVFTKLIP       KGLRERGDSK      GMKSIWFTKL     TSQEVKRWWK   MISYIVIISN      P        (SEQ ID NO:8)
 [0060]    A polypeptide having an amino acid sequence at least, for example, about 95% "identical" to a
reference an amino acid sequence, e.g., SEQ ID NO:7, is understood to mean that the amino acid
sequence of the polypeptide is identical to the reference sequence except that the amino acid sequence
may include up to about five modifications per each 100 amino acids of the reference amino acid
sequence. In other words, to obtain a peptide having an amino acid sequence at least about 95%
identical to a reference amino acid sequence, up to about 5% of the amino acid residues of the
reference sequence may be deleted or substituted with another amino acid or a number of amino acids
up to about 5% of the total amino acids in the reference sequence may be inserted into the reference
sequence. These modifications of the reference sequence may occur at the N- terminus or C-terminus
positions of the reference amino acid sequence or anywhere between those terminal positions,
interspersed either individually among amino acids in the reference sequence or in one or more
contiguous groups within the reference sequence.
 [0061]    As used herein, "identity" is a measure of the identity of nucleotide sequences or amino acid
sequences compared to a reference nucleotide or amino acid sequence. In general, the sequences are
aligned so that the highest order match is obtained. "Identity" per se has an art-recognized meaning
and can be calculated using published techniques. (See, e.g., Computational Molecular Biology, Lesk, A.
 M., ed., Oxford University Press, New York (1988); Biocomputing: Informatics And Genome Projects,
Smith, D. W., ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin,
A. M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); von Heinje, G., Sequence Analysis In
 Molecular Biology, Academic Press (1987); and Sequence Analysis Primer, Gribskov, M. and Devereux, J.,
eds., M Stockton Press, New York (1991)). While there are several methods to measure identity
 between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled
artisans (Carillo, H. & Lipton, D., Siam J Applied Math 48:1073 (1988)). Methods commonly employed to
determine identity or similarity between two sequences include, but are not limited to, those disclosed
in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego (1994) and Carillo, H. &
                                                      23

Lipton, D., Siam J Applied Math 48:1073 (1988). Computer programs may also contain methods and
algorithms that calculate identity and similarity. Examples of computer program methods to determine
identity and similarity between two sequences include, but are not limited to, GCG program package
(Devereux, J., et al., Nucleic Acids Research 12(i):387 (1984)), BLASTP, ExPASy, BLASTN, FASTA (Atschul,
S. F., et al., J Molec Biol 215:403 (1990)) and FASTDB. Examples of methods to determine identity and
similarity are discussed in Michaels, G. and Garian, R., Current Protocols in Protein Science, Vol 1, John
Wiley & Sons, Inc. (2000), which is incorporated by reference.
[0062]       In one embodiment of the present invention, the algorithm used to determine identity
between two or more polypeptides is BLASTP. In another embodiment of the present invention, the
algorithm used to determine identity between two or more polypeptides is FASTDB, which is based
upon the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990), incorporated by reference).
In a FASTDB sequence alignment, the query and reference sequences are amino sequences. The result
of sequence alignment is in percent identity. In one embodiment, parameters that may be used in a
FASTDB alignment of amino acid sequences to calculate percent identity include, but are not limited to:
Matrix=PAM, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0,
Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject
amino sequence, whichever is shorter.
[0063]       If the reference sequence is shorter or longer than the query sequence because of N-terminus
or C-terminus additions or deletions, but not because of internal additions or deletions, a manual
correction can be made, because the FASTDB program does not account for N-terminus and C-terminus
truncations or additions of the reference sequence when calculating percent identity. For query
sequences truncated at the N- or C- termini, relative to the reference sequence, the percent identity is
corrected by calculating the number of residues of the query sequence that are N-and C- terminus to the
reference sequence that are not matched/aligned, as a percent of the total bases of the query
sequence. The results of the FASTDB sequence alignment determine matching/alignment. The
alignment percentage is then subtracted from the percent identity, calculated by the above FASTDB
program using the specified parameters, to arrive at a final percent identity score. This corrected score
can be used for the purposes of determining how alignments "correspond" to each other, as well as
percentage identity. Residues of the reference sequence that extend past the N- or C-termini of the
query sequence may be considered for the purposes of manually adjusting the percent identity score.
                                                       24

That is, residues that are not matched/aligned with the N- or C-termini of the comparison sequence may
be counted when manually adjusting the percent identity score or alignment numbering.
[0064]     For example, a 90 amino acid residue query sequence is aligned with a 100 residue reference
sequence to determine percent identity. The deletion occurs at the N-terminus of the query sequence
and therefore, the FASTDB alignment does not show a match/alignment of the first 10 residues at the N
terminus. The 10 unpaired residues represent 10% of the reference sequence (number of residues at
the N- and C-termini not matched/total number of residues in the reference sequence) so 10% is
subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90
residues were perfectly matched (100% alignment) the final percent identity would be 90% (100%
alignment - 10% unmatched overhang). In another example, a 90 residue query sequence is compared
with a 100 reference sequence, except that the deletions are internal deletions. In this case the percent
identity calculated by FASTDB is not manually corrected, since there are no residues at the N- or C
termini of the subject sequence that are not matched/aligned with the query. In still another example, a
110 amino acid query sequence is aligned with a 100 residue reference sequence to determine percent
identity. The addition in the query occurs at the N-terminus of the query sequence and therefore, the
FASTDB alignment may not show a match/alignment of the first 10 residues at the N-terminus. If the
remaining 100 amino acid residues of the query sequence have 95% identity to the entire length of the
reference sequence, the N-terminal addition of the query would be ignored and the percent identity of
the query to the reference sequence would be 95%.
[0065] As used herein, the terms "correspond(s) to" and "corresponding to," as they relate to sequence
alignment, are intended to mean enumerated positions within the reference protein, e.g., CedPV G
protein, and those positions in the modified CedPV G protein that align with the positions on the
reference protein. Thus, when the amino acid sequence of a subject CedPV G protein is aligned with the
amino acid sequence of a reference CedPV G protein, e.g., SEQ ID NO:7, the amino acids in the subject
sequence that "correspond to" certain enumerated positions of the reference sequence are those that
align with these positions of the reference sequence, e.g., SEQ ID NO:7, but are not necessarily in these
exact numerical positions of the reference sequence. Methods for aligning sequences for determining
corresponding amino acids between sequences are described herein. Accordingly, the invention
provides novel peptides whose sequences correspond to the sequence of SEQ ID NO:7.
                                                    25

 [0066] Variants resulting from insertion of the polynucleotide encoding a protein disclosed herein into
an expression vector system are also contemplated. For example, variants (usually insertions) may arise
from when the amino terminus and/or the carboxy terminus of a modified protein is/are fused to
another polypeptide.
 [0067] In another aspect, the invention provides deletion variants wherein one or more amino acid
residues in the modified protein are removed. Deletions can be effected at one or both termini of the
modified protein, or with removal of one or more non-terminal amino acid residues of the modified
protein. Deletion variants, therefore, include all fragments of the modified protein.
 [0068] Within the confines of the disclosed percent identity, the invention also relates to substitution
variants of disclosed polypeptides of the invention. Substitution variants include those polypeptides
wherein one or more amino acid residues of a modified protein are removed and replaced with
alternative residues. In one aspect, the substitutions are conservative in nature; however, the invention
embraces substitutions that are also non-conservative. Conservative substitutions for this purpose may
 be defined as set out in the tables below. Amino acids can be classified according to physical properties
and contribution to secondary and tertiary protein structure. A conservative substitution is recognized
in the art as a substitution of one amino acid for another amino acid that has similar properties.
 Exemplary conservative substitutions are set out in below.
Table I - Conservative Substitutions
SIDE CHAIN CHARACTERISTIC                AMINO ACID
Aliphatic
         Non-polar                       G, A, P, I, L, V
         Polar - uncharged               C, S, T, M, N, Q
         Polar - charged                 D, E, K, R
Aromatic                                 H, F,W,Y
Other                                    N, Q, D, E
 [0069] Alternatively, conservative amino acids can be grouped as described in Lehninger,
 [Biochemsitry, Second Edition; Worth Publishers, Inc. NY, N.Y. (1975), pp. 7177] as set out below.
                                                         26

Table II - Conservative Substitutions
SIDE CHAIN CHARACTERISTIC             AMINO ACID
Non-polar (hydrophobic)
          A.    Aliphatic:            A, L, I, V, P
          B.    Aromatic:             F, W
          C.    Sulfur-containing:    M
          D.     Borderline:          G
Uncharged-polar
          A.     Hydroxyl:            S, T, Y
          B.    Amides:               N, Q
          C.    Sylfhydryl:           C
          D.     Borderline:          G
Positively Charged (Basic):           K, R, H
Negatively Charged (Acidic)           D, E
                                                    27

[0070] And still other alternative, exemplary conservative substitutions are set out below.
Table Ill - Conservative Substitutions
Original Residue                                 Exemplary Substitution
Ala (A)                                          Val, Leu, Ile
Arg (R)                                          Lys, GIn, Asn
Asn (N)                                          GIn, His, Lys, Arg
Asp (D)                                          Glu
Cys (C)                                          Ser
GIn (Q)                                          Asn
Glu (E)                                          Asp
His (H)                                          Asn, GIn, Lys, Arg
Ile (1)                                          Leu, Val, Met, Ala, Phe
Leu (L)                                          lie, Val, Met, Ala, Phe
Lys (K)                                          Arg, GIn, Asn
Met (M)                                          Leu, Phe, Ile
Phe (F)                                          Leu, Val, lie, Ala
Pro (P)                                          Gly
Ser (S)                                          Thr
Thr (T)                                          Ser
Trp (W)                                          Tyr
Tyr (Y)                                          Trp, Phe, Thr, Ser
Val (V)                                          lie, Leu, Met, Phe, Ala
                                                    28

[0071] It should be understood that the definition of peptides or polypeptides of the invention is
intended to include polypeptides bearing modifications other than insertion, deletion, or substitution of
amino acid residues. By way of example, the modifications may be covalent in nature, and include for
example, chemical bonding with polymers, lipids, other organic and inorganic moieties. Such derivatives
may be prepared to increase circulating half-life of a polypeptide, or may be designed to improve the
targeting capacity of the polypeptide for desired cells, tissues or organs. Similarly, the invention further
embraces modified peptides that have been covalently modified to include one or more water-soluble
polymer attachments such as polyethylene glycol, polyoxyethylene glycol or polypropylene glycol.
[0072] The present invention is also directed to antibodies or fragments thereof that specifically bind to
CedPV or fragments of any of the CedPV proteins disclosed herein.
[0073] In particular, the present invention provides antibodies or antibody fragments that bind to the
four hydrophobic pockets in the head of the G glycoprotein of the Cedar virus. The antibodies may be
monoclonal or polyclonal. Cedar virus likely begins the infection process by binding to the ephrin B2
transmembrane protein that is present on at least endothelial cells, among others. Specifically, the
ephrin B2 protein contains a "GH-loop region" that inserts into the 4 hydrophobic binding pockets on
the head of the G glycoprotein of Cedar virus, thus allowing the virus to bind specifically to the cell
surface protein and begin the infection process. The contact residues of Cedar virus that bind the ephrin
B2 are V507, F458 and 1401, with the letters referring to the standard one-letter abbreviation of
standard amino acids and the numbering referring to the amino acid numbering of SEQ ID NO:7
according to the sequences disclosed herein. As such, the present invention provides antibodies or
antibody fragments that bind the non-linear epitope of Cedar virus defined by V507/F458/1401,
provided the antibodies or antibody fragments, provided that the antibodies are not any of the
antibodies disclosed in PCT/US05/040050 and PCT/US12/35806 which are hereby incorporated by
reference in their entirety.
[0074] For example, antibodies encompassed by the present invention, include, but are not limited to,
antibodies specific for CedPV G glycoprotein, antibodies that cross react with Hendra Virus G
glycoprotein and/or Nipah Virus G Glycoprotein and neutralizing antibodies. By way of example a
characteristic of a neutralizing antibody includes, but is not limited to, the ability to block or prevent
                                                     29

infection of a host cell. The antibodies of the invention may be characterized using methods well known
in the art.
 [0075] The antibodies useful in the present invention can encompass monoclonal antibodies, polyclonal
antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, Fv, Fc, etc.), chimeric antibodies, bispecific
antibodies, heteroconjugate antibodies, single chain (ScFv), mutants thereof, fusion proteins comprising
an antibody portion, humanized antibodies, and any other modified configuration of the
immunoglobulin molecule that comprises an antigen recognition site of the required specificity,
including glycosylation variants of antibodies, amino acid sequence variants of antibodies, and
covalently modified antibodies. Examples of antibodies are derived from murine, rat, human, primate,
or any other origin (including chimeric or humanized antibodies).
 [0076] Methods of preparing monoclonal and polyclonal antibodies are well known in the art.
 Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an
immunizing agent and, if desired an adjuvant. Examples of adjuvants include, but are not limited to,
keyhole limpet, hemocyanin, serum albumin, bovine thryoglobulin, soybean trypsin inhibitor, Freund
complete adjuvant and MPL-TDM adjuvant. The immunization protocol can be determined by one of
skill in the art.
 [0077] The antibodies may alternatively be monoclonal antibodies. Monoclonal antibodies may be
produced using hybridoma methods (see, e.g., Kohler, B. and Milstein, C. (1975) Nature 256:495-497 or
as modified by Buck, D. W., et al., In Vitro, 18:377-381 (1982).
 [0078] If desired, the antibody of interest may be sequenced and the polynucleotide sequence may
then be cloned into a vector for expression or propagation. The sequence encoding the antibody of
interest may be maintained in vector in a host cell and the host cell can then be expanded and frozen for
future use. In an alternative, the polynucleotide sequence may be used for genetic manipulation to
"humanize" the antibody or to improve the affinity, or other characteristics of the antibody (e.g.,
genetically manipulate the antibody sequence to obtain greater affinity to the G glycoprotein and/or
greater efficacy in inhibiting the fusion of a Cedar Virus, Hendra or Nipah virus to the host cell receptor.).
 [0079] The antibodies may also be humanized by methods known in the art. See, for example, U.S. Pat.
 Nos. 4,816,567; 5,807,715; 5,866,692; 6,331,415; 5,530,101; 5,693,761; 5,693,762; 5,585,089; and
6,180,370, which are incorporated by reference. In yet another embodiment, fully human antibodies
                                                      30

may be obtained by using commercially available mice that have been engineered to express specific
human immunoglobulin proteins.
 [0080] In another embodiment, antibodies may be made recombinantly and expressed using any
method known in the art. By way of example, antibodies may be made recombinantly by phage display
technology. See, for example, U.S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,150; and
Winter et al., Annu. Rev. Immunol. 12:433-455 (1994). Alternatively, the phage display technology
(McCafferty et al., Nature 348:552-553 (1990)) can be used to produce human antibodies and antibody
fragments in vitro. Phage display can be performed in a variety of formats; for review see, e.g., Johnson,
 Kevin S, and Chiswell, David J., Current Opinion in Structural Biology 3:564-571 (1993). By way of
example, a soluble G glycoprotein as described herein may be used as an antigen for the purposes of
isolating recombinant antibodies by these techniques.
 [0081] Antibodies may be made recombinantly by first isolating the antibodies and antibody producing
cells from host animals, obtaining the gene sequence, and using the gene sequence to express the
antibody recombinantly in host cells (e.g., CHO cells). Another method which may be employed is to
express the antibody sequence in plants (e.g., tobacco) or transgenic milk. Methods for expressing
antibodies recombinantly in plants or milk have been disclosed. See, for example, Peeters, et al. Vaccine
 19:2756 (2001); Lonberg, N. and D. Huszar Int. Rev. Immunol 13:65 (1995); and Pollock, et al., J Immunol
 Methods 231:147 (1999), which are inccorporated by reference. Methods for making derivatives of
antibodies, e.g., humanized, single chain, etc. are known in the art.
 [0082] The antibodies of the invention can be bound to a carrier by conventional methods, for use in,
for example, isolating or purifying CedPV G glycoproteins or detecting Hendra or Nipah G glycoproteins
in a biological sample or specimen. Alternatively, by way of example, the neutralizing antibodies of the
invention may be administered as passive immunotherapy to a subject infected with or suspected of
 being infected with Hendra, Nipah and/or Cedar virus. The terms "subject" and "patient" are used
interchangeably and include but are not limited to humans, simians, farm animals, sport animals and
pets. Veterinary uses are also encompassed by the invention.
 [0083] Diagnostics
 [0084] The proteins, protein fragment and/or antibodies of the invention may be used in a variety of
immunoassays for Cedar virus. The recombinant expressed protein fragments of the invention can be
                                                      31

produced with high quality control and are suitable as a antigen for the purposes of detecting antibody
in biological samples. By way of example, and not limitation, a soluble CedPV G glycoprotein could be
used as an antigen in an ELISA assay to detect antibody in a biological sample from a subject.
 [0085] The nucleic acids, including primers and probes, of the invention are also be used in a variety of
assays for Cedar virus. The primers and probes of the invention are used to detect the presence of
ribonucleic acids enconding the Cedar virus in a subject. The present invention also includes a method
for detecting the presence of Cedar virus utilizing nucleic acid amplification techniques, for example
reverse transcriptase-PCR methods, utilizing repeated cycles of denaturations, primer annealing and
extension carried out with DNA polymerase, for example Taq polymerase, to lead to exponential
increases in derived nucleic acid, so as to facilitate detection of the presence of the virus.
 [0086] Vaccines
 [0087] This invention also relates to vaccines for Cedar virus. In one aspect the vaccines are DNA based
vaccines. One skilled in the art is familiar with administration of expression vectors to obtain expression
of an exogenous protein in vivo. See, e.g., U.S. Pat. Nos. 6,436,908; 6,413,942; and 6,376,471. Viral
 based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in
the art and non-limiting examples are described herein. In another aspect, the vaccines are protein
 based and comprise one or more fragments of the proteins thor protein fragment of the invnetion.
 Examples of protein fragments include but are not limited to ectodomains, transmembranes domains,
cytoplasmic domains and functional portions thereof, as well as portions that are specifically reactive to
neutralizing antibodies. Vaccines may also be antibody-based vaccines for more immediate treatment
as well as prophylaxis against infection.
 [0088] Administration of expression vectors includes but is not limited to local or systemic
administration, including injection, oral administration, particle gun or catheterized administration, and
topical administration. Targeted delivery of therapeutic compositions containing an expression vector,
or subgenomic polynucleotides can also be used. Receptor-mediated DNA delivery techniques are
described in, for example, Findeis et al., Trends Biotechnol. (1993) 11:202; Chiou et al., Gene
Therapeutics: Methods And Applications Of Direct Gene Transfer (J.A. Wolff, ed.) (1994); Wu et al., J.
 Biol. Chem. (1988) 263:621; Wu et al., J. Biol. Chem. (1994) 269:542; Zenke et al., Proc. NatI. Acad. Sci.
 USA (1990) 87:3655; Wu et al., J. Biol. Chem. (1991) 266:338.
                                                       32

[0089] Non-viral delivery vehicles and methods can also be employed, including, but not limited to,
polyeationic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, Hum. Gene
Ther. (1992) 3:147); ligand-linked DNA (see, e.g., Wu, J. Biol. Chem. (1989) 264:16985); eukaryotic cell
delivery vehicles cells (see, e.g., U.S. Pat. No. 5,814,482; PCT Publication Nos. WO 95/07994; WO
96/17072; WO 95/30763; and WO 97/42338) (all of which are incorporated by reference) and nucleic
charge neutralization or fusion with cell membranes. Naked DNA can also be employed. Exemplary
naked DNA introduction methods are described in PCT Publication No. WO 90/11092 and U.S. Pat. No.
5,580,859, which are incorporated by reference. Liposomes that can act as gene delivery vehicles are
described in U.S. Pat. No. 5,422,120; PCT Publication Nos. WO 95/13796; WO 94/23697; WO 91/14445;
and EP 0524968, which are incorporated by reference. Additional approaches are described in Philip,
Mol. Cell. Biol. (1994) 14:2411, and in Woffendin, Proc. NatI. Acad. Sci. (1994) 91:1581, which are
incorporated by reference.
[0090] For human administration, codons comprising a polynucleotide encoding a protein or fragment
thereof may be optimized for human use.
[0091] In another aspect of the invention, a soluble CedPV G glycoprotein is used as a subunit vaccine.
The soluble CedPV glycoprotein or combination thereof may be administered by itself or in combination
with an adjuvant. Examples of adjuvants include, but are not limited, aluminum salts, water-in-soil
emulsions, oil-in-water emulsions, saponin, QuilA and derivatives, iscoms, liposomes, cytokines including
gamma interferon or interleukin 12, DNA, microencapsulation in a solid or semi-solid particle, Freunds
complete and incomplete adjuvant or active ingredients thereof including muramyl dipeptide and
analogues, DEAE dextran/mineral oil, Alhydrogel, Auspharm adjuvant, and Algammulin.
[0092] The subunit vaccine comprising soluble CedPV G glycoprotein or combinations thereof can be
administered orally, intravenously, subcutaneously, intraarterially, intramuscularly, intracardially,
intraspinally, intrathoracically, intraperitoneally, intraventricularly, sublingually, and/or transdermally.
[0093] Dosage and schedule of administration can be determined by methods known in the art.
Efficacy of the soluble CedPV G glycoprotein or combinations thereof as a vaccine for Cedar, Hendra,
Nipah or related Henipavirus viruses may also be evaluated by methods known in the art.
Examples
[0094] Example 1
                                                        33

 [0095] Urine (approximately 0.5-1 ml) was collected off plastic sheets placed underneath a colony of
flying foxes (predominantly Pteropus alecto with some P. Poliocephalus in the mixed population) in
Cedar Grove, South East Queensland, Australia and pooled into 2 ml tubes containing 0.5 ml of viral
transport medium (SPGA: a mix of sucrose, phosphate, glutamate and albumin plus penicillin,
streptomycin and fungizone). The tubes were temporarily stored on ice after collection and transported
to a laboratory in Queensland, frozen at -80 0 C. The samples were thawed at 4 0C and centrifuged at
 16,000 x g for 1 min to pellet debris. Urine in the supernatant (approximately 0.5-1 ml) was diluted 1:10
in cell culture media.
 [0096] The diluted urine was centrifuged at 1,200 x g for 5 min and split evenly over Vero, PaKi, PaBr,
 PaSp and PaPI cell monolayers in 75-cm 2 tissue culture flasks. Cell lines used this study were Vero
(ATCC), HeLa-USU (22), and the P. alecto primary cell lines derived from kidney (PaKi), brain (PaBr),
(spleen) PaSp and placenta (PaPI). Cells were grown in Dulbecco's Modified Eagle's Medium Nutrient
 Mixture F-12 Ham supplemented with double strength antibiotic-antimycotic (Invitrogen), 10 pg/ml
ciprofloxacin (MP Biomedicals) and 10% fetal calf serum at 37 0C in the presence of 5% CO2 . The flasks
were rocked for 2 h at 37 0C, 14 ml of fresh cell culture media was added and then incubated for 7 days
at 370C. The flasks were observed daily for toxicity, contamination, or viral cytopathic effect (CPE).
 [0097] Syncytial CPE was observed in kidney cell (PaKi) monolayers 5 days post inoculation (dpi) with
two different urine samples. No CPE was observed in any of the four other cell lines. Supernatant
harvested 6 dpi was used to inoculate fresh PaKi cell monolayers. After two passages in PaKi cells, the
virus was able to infect and cause CPE in Vero cells. The CPE morphology of the virus, however, in Vero
cells was different from that of HeV infection. Further analysis using HeV-specific PCR primers indicated
that the new bat virus was not an isolate of HeV.
 [0098] Example 2
 [0099] Cells from Example 1 showing syncytial CPE were screened using published broadly reactive
primers (31) for all known paramyxoviruses and a subset of paramyxoviruses. PCR products were gel
extracted and cloned into pGEM T-Easy (Promega) to facilitate sequencing using M13 primers.
Sequences were obtained and aligned with known paramyxovirus sequences allowing for initial
classification.
                                                      34

[00100]The entire genomic sequence was analyzed using a combination of 454 sequencing (43) and
conventional Sanger sequencing. Virions from tissue culture supernatant were collected by
centrifugation at 30,000 x g for 60 min and resuspended in 140 Ip of PBS and mixed with 560 Ip of
freshly made AVL for RNA extraction using QlAamp Viral RNA mini kit (Qiagen). Synthesis of cDNA and
random amplification was conducted using a modification of a published procedure (44). Briefly, cDNA
synthesis was performed using a random octomer-linked to a 17-mer defined primer sequence:
(5'-GTTTCCCAGTAGGTCTCNNN NNNNN-3') and SuperScript Ill Reverse Transcriptase (Life Technologies).
8 I of ds-cDNA was amplified in 200 I PCR reactions with hot-start Taq polymerase enzyme (Promega)
and 5'-A*G*C*A*C TGTAGGTTTCCCAGTAGGTCTC-3' (where * denotes thiol modifications) as
amplification primers for 40 cycles of 95 0C/1 min, 48 0C/1 min, 72 0C/1 min after an initial denaturation
step of 5 min at 95 0C and followed by purification with the QlAquick PCR purification kit (Qiagen).
Sample preparation for Roche 454 sequencing (454 Life Sciences Branford, CT, USA) was performed
according to the manufacturer's suggested protocol (Rapid Library Preparation and emPCR Lib-L SV).
[00101]To obtain an accurate CedPV genome sequence, 454 generated data (after removing low
quality, ambiguous and adapter sequences) was analysed by both de novo assembly and read mapping
of raw reads onto the CedPV draft genome sequence derived from Sanger sequencing. For 454 read
mapping, SNPs and DIPs generated with the CLC software were manually assessed for accuracy by
visualising the mapped raw reads (random PCR errors are obvious compared to real SNPs and DIPs
especially when read coverage is deep). Consensus sequences for both 454 de novo and read mapping
assembly methods were then compared to the Sanger sequence with the latter used to resolve conflicts
within the low coverage regions as well as to resolve 454 homopolymer errors.
[00102] Sequences of genome termini were determined by 3'- and 5'-RACE using a previously published
protocol (45). Briefly, approximately 100 ng of RNA was ligated with adaptor DT88 (see reference for
sequence information) using T4 RNA ligase (Promega) followed by cDNA synthesis using the SuperScript
Ill RT kit (Life Technologies) and an adaptor-specific primer, DT89. PCR amplification was then carried
out using DT89 and one or more genome-specific primers. PCR products were sequenced directly using
either DT89 or genome specific primers by an in-house service group on the ABI Sequencer 3100.
[00103]The CLC Genomics Workbench v4.5.1 (CLC Inc, Aarhus, Denmark) was used to trim 454 adapter
and cDNA/PCR primer sequences, to remove low quality, ambiguous and small reads < 15 bp and to
perform de novo and read mapping assemblies all with default parameters. Clone Manager
                                                      35

Professional version 9.11 (Scientific and Educational Software, Cary, NC, USA) was used to join
overlapping contigs generated by de novo assembly. Phylogenetic trees were constructed using the
neighbor-joining algorithm with bootstrap values determined by 1,000 replicates in the MEGA4 software
package (46).
[00104] Considering the formation of syncytial CPE by this new virus and the previous success in isolating
paramyxoviruses from bat urine, paramyxovirus family-specific and genus-specific primers were used to
determine whether this new virus was a member of the family Paramyxoviridae. Positive PCR fragments
of the expected sizes were obtained from the Paramyxovirinae and
Respirovirus/Morbillivirus/Henipavirus primer sets developed by Tong et al (31).
[00105] Sequencing of the PCR products indicated that it was a new paramyxovirus most closely related
to HeV and NiV. Based on these preliminary data, the virus was named Cedar virus (CedPV) after the
location of the bat colony sampled.
[00106] As shown in Figure 1, the genome of CedPV is 18,162 nt in length and is most similar to that of
HeV in the family. The full genome sequence has been deposited to GenBank (Accession No. JQ001776).
The genome size is a multiple of 6, which is in perfect agreement with the Rule-of-Six observed for all
known members of the subfamily Paramyxovirinae (3). The genome of CedPV has a 3-nt intergenic
sequence of CTT absolutely conserved at all seven positions and highly conserved gene start and stop
signals similar to those present in HeV and NiV (Figure 2).
[00107] Also similar to the HeV genome is the presence of relatively large non-coding regions in the
CedPV genome (Figure 1 and Table 1). The overall protein-coding capacity of the CedPV genome is
87.41% which is higher than HeV at 82.12%. As the genome size of CedPV and HeV is very similar, the
increased coding capacity of CedPV is attributed to an increase in protein sizes for five of the six major
proteins, with the L protein being 257-aa larger (Table 1). At 2,501 aa, the CedPV L protein is the
largest, not only in the family Paramyxoviridae but also for all known viruses in the order
Mononegavirale.
                                                     36

Table 1 - Comparison of common genes among CedPV, HeV and NiV
   Gene       Virus               Open Reading Frame                    Length of Untranslated
                                                                              Regions (nt)
                         Length     % sequence       % sequence        5' UTR           3'UTR
                           (aa)      identity to      identity to
                                       CedPV             HeV
  N        CedPV           510                                            88             334
           HeV             532           58                               57             568
           NiV             532           59               92              57             586
  P        CedPV           737                                            98              192
           HeV             707           25                              105             469
           NiV             709           27               65             105             469
  C        CedPV           177
           HeV             166           26
           NiV             166           25               83
  M        CedPV           359                                           114             408
           HeV             352           60                              100             200
           NiV             352           60               89             100             200
  F        CedPV           557                                           276               88
           HeV             546           42                              272             418
           NiV             546           43               87             284             412
  G        CedPV           622                                            98              139
           HeV             604           29                              233             516
           NiV             602           30               78             233             504
  L        CedPV          2501                                           293               63
           HeV            2244           50                              153               67
           NiV            2244           50               86             153               67
[00108] Phylogenetic analysis based on the full length genome sequence and the deduced amino acid
sequences of each structural protein confirmed the initial observation that CedPV is most closely related
to henipaviruses in the family. A phylogenetic tree based on the deduced sequences of the
nucleocapsid protein (N) is presented in Figure 3A. A phylogenetic tree analysis based on whole genome
sequences gave similar results (Figure 3B). Indeed, CedPV is more closely related to HeV and NiV than
henipavirus-like sequences detected in African bats (26, 32) as shown in a phylogenetic tree based on
the only sequences available of a 550-nt L gene fragment (Figure 3C).
[00109] Example 3
                                                    37

[00110] First discovered for the parainfluenza virus 5 (PIV5, previously known as simian virus 5), almost
all members of Paramyxovirinae have a P gene which produces multiple proteins through an RNA
editing mechanism by addition of non-templated G residues leading to production of N-terminal co
linear proteins from different reading frames downstream from the editing site (3, 33). These multiple
gene products are known to play a key role in antagonizing the innate response of susceptible hosts (3).
[00111]The CedPV genome codes for P protein of 737-aa and a C protein of 177-aa. PCR analysis,
however, failed to find the highly conserved, cysteine-rich V protein ORF that is present in most other
paramyxoviruses. The absence of the V protein ORF is attributed to the RNA editing site, with a
sequence of AAAAGGG that is conserved in all other known HeV and NiV isolates discovered to date, is
missing from the CedPV P gene sequence.
[00112]To verify that there are no multiple mRNAs produced from the CedPV P gene, direct sequencing
of P gene transcripts was conducted from CedPV-infected Vero cells using multiple sets of primers
generating overlapping fragments covering the entire coding region of the P gene. Briefly, quantitative
PCR assays (qPCR) were established based on CedPV-specific sequences obtained from the high
throughput sequencing. A TaqMan assay on the P gene was developed and used for all subsequent
studies. The sequences of the primer/probe were as follows: forward primer,
5'-TGCAT TGAGC GAACC CATAT AC; reverse primer, 5'-GCACG CTTCT TGACA GAGTT GT;
probe, 5'-TCCCG AGAAA CCCTC TGTGT TTGA-MGB.
[00113] Each produced uniform trace files indicating a lack of RNA editing activities, which is very
different from the mixed peaks generated by HeV and NiV immediately after the editing site (Figure 4).
It appears that CedPV is the first-identified member of Paramyxovirinae that lacks both RNA editing and
any V-related coding sequence in its P gene.
[00114] Example 4
[00115]The striking similarity in genome size and organization and the presence of highly conserved
protein domains among the N, M and L proteins between CedPV and henipaviruses would indicate that
CedPV may be antigenically related to HeV and/or NiV. To prepare antibodies directed against CedPV,
the coding region for the CedPV N protein was amplified by PCR with a pair of primers flanked byAscl (5'
end) and Notl (3' end) sites for cloning into a previously described GST-fusion expression vector (47).
The expression and purification by gel elution was conducted as previously described (48). For antibody
                                                      38

production, purified protein was injected subcutaneously into 4 different sites of 2 adult (at a dose of
100 pg per animal) New Zealand white female rabbits at days 0 and 27. A previously published triple
adjuvant (49) was used for the immunization. Animals were checked for specific antibodies after days 5
and 42 and euthanized at day 69 for the final blood collection.
[00116] For immunofluorescence antibody test, Vero cell monolayers were prepared in 8-well chamber
slides by seeding at a concentration of 30,000 cells/well in 300 l of cell media and incubating over night
at 37*C. The cell monolayers were infected with an MOI of 0.01 of CedPV, HeV or NiV and fixed with
100% ice-cold methanol at 24 hours post-infection. The chamber slides were blocked with 100 pl/well
of 1%BSA in PBS for 30 min at 37*C before adding 50 al/well of rabbit sera against CedPV N or NiV N
diluted 1:1000. After incubation at 37*C for 30 min, the slides were washed three times in PBS-T and
incubated with 50 al/well of anti-rabbit 488 Alexafluore conjugate (Life Technologies) diluted 1:1000 at
37*C for 30 min. The slides were then washed three times in PBS-T and mounted in 50% glycerol/PBS
for observation under a fluorescence microscope.
[00117] For virus neutralization test, serial two-fold dilutions of sera were prepared in duplicate in a 96
well tissue culture plate in 50 l cell media (Minimal Essential Medium containing Earle's salts and
supplemented with 2 mM glutamine, antibiotic-antimycotic and 10% fetal calf serum). An equal volume
containing 200 TCID 50 of target virus was added and the virus-sera mix incubated for 30 min at 37*C in a
humidified 5% CO2 incubator. 100 pl of Vero cell suspension containing 2 x 105 cells/ml was added and
the plate incubated at 37*C in a humidified 5% CO2 incubator. After 4 days, the plate was examined for
viral CPE. The highest serum dilution generating complete inhibition of CPE was defined as the final
neutralizing titer.
[00118] Staining of CedPV- infected Vero cells using rabbit anti-henipavirus antibodies indicated the
presence of cross-reactivity. This cross-reactivity was further confirmed in reverse by staining of HeV
infected Vero cells using a rabbit serum raised against a recombinant CedPV N protein (Figure 5).
Analysis by virus neutralization test, however, found that henipavirus-neutralizing antibodies were
unable to neutralize CedPV and vice versa. See also Figure 6 which shows IFAT conducted with anti
CedPV serum on Vero cells infected with J paramyxovirus (JPV), Rinderpest virus (RPV), Sendai virus
(SeV), Menangle virus (MenPV) and CedPV, respectively. Mock infected cell monolayer was included as
a negative control
[00119] Example 5
                                                       39

[00120]To further investigate the relationship between CedPV and recognized henipaviruses, CedPV's
use of the ephrin-B2 and -B3 host cell proteins was examined. Typically, HeV and NiV use ephrin-B2
receptor as points of entry for infection for CedPV infection (22, 34). Human ephrin B2 and B3 genes
were cloned into pQCXIH (Clontech) and the resulting plasmids packaged into retrovirus particles in the
GP2-293 packaging cell line (Clontech) and pseudotyped with vesicular stomatitis virus G glycoprotein
(VSV-G) following the manufacturer's instructions. HeLa-USU cell line (22) was infected with the VSV-G
pseudotyped retrovirus particles in the presence of 1 pg/ml polybrene (Sigma). 8 hours post infection,
the medium was changed and the cells were allowed to recover for 24 hours, which allows time for
completion of the retroviral insert into the cellular genome and for expression of the hygromycin
resistance gene.
[00121] 24 hours post-infection, cells transformed by the retrovirus were selected for by the addition of
200 pg/ml hygromycin in the media. Stocks of cells that were resistant to hygromycin were prepared
and frozen. HeLa-USU cells and ephrin-expressing HeLa-USU cells were seeded in 6-well tissue culture
plates at a density of 250,000 cells/well overnight. The viruses (HeV and CedPV) were diluted to give an
MOI of 0.01 and inoculated into the wells. The cell monolayers were examined daily for syncytial CPE.
[00122] For CedPV, similar observations were made with respect to the ephrin-B2 receptor. As shown in
Figure 7, CedPV failed to infect HeLa-USU, but was able to infect and cause syncytial CPE when the
human ephrin-B2 gene was expressed. In contrast, when ephrin-B3 molecule was introduced, there was
no evidence of infection.
[00123] Example 6
[00124] Ferrets, guinea pigs, and mice exhibit differing responses to HeV and NiV infections, with ferrets
and guinea pigs, but not mice, developing severe disease characterized by systemic vasculitis (20, 35, 36,
37, 38). CedPV (2 x 106 TCID 5 o/ml), which was passaged twice in bat PaKi cells, was administered to 2
male ferrets (1 ml oronasally), 4 female guinea pigs (1 ml intraperitoneally) and 5 female Balb-C mice (50
Ip oronasally). Guinea pigs and mice were implanted with temperature sensing microchips (LifeChip Bio
thermo*, Destron Fearing) and weighed daily. Ferret rectal temperature and weight was recorded at
sampling times. Animals were observed daily for clinical signs of illness and were euthanized at 21 days
post-inoculation. Sera were collected on days 10, 15 and 21 to test for neutralizing antibody against
CedPV.
                                                      40

[00125] Based on the asymptomatic seroconversion to CedPV noted in the ferrets, 7 additional female
ferrets were exposed by the oronasal route to a lower dose of 3 x   103 TCID 50 . Two animals were
euthanized on each of days 6, 8 and 10 post-inoculation and one on day 20. Nasal washes, oral swabs,
and rectal swabs were collected on days 2, 4, 6, 8 and 10 and urine was sampled on the day of
euthanazia. Each collected specimen was assessed for the CedPV genome. A wide range of tissue
samples were collected at post mortem examination and assessed by routine histology,
immunohistochemistry (using rabbit antibodies raised against recombinant CedPV and NiV N proteins,
respectively), qPCR (see above) and virus isolation using reagents and procedures previously established
(16).
[00126] In contrast to the response from exposure to NiV and HeV, the ferrets and guinea pigs exposed
to CedPV remained clinically well, although neutralizing antibody was detected in serum between 10 to
21 days pi (Table 2). Balb-C mice exposed to CedPV also remained clinically well but did not develop
neutralizing antibody in serum by day 21 pi. In ferrets electively euthanized at earlier time-points, there
was reactive hyperplasia of tonsillar lymphoid tissue, retropharyngeal and bronchial lymph nodes,
accompanied by edema and erythrophagocytosis. CedPV antigen was detected in bronchial lymph node
of one animal euthanized on day 6 pi, consistent with viral replication in that tissue. Cross-reactive
immunostaining against anti-NiV N protein antibodies was also noted (Figure 8). No other significant
histological lesions were identified.
                                                    41

Table 2 - Antibody responses in CedPV-infected ferrets and guinea pigs
     Animal #       Days post      Neutralizing antibody
                   inoculation              titers
                                    CedPV          HeV
     Ferret 1            0             -ve         -ve
                        10           1:320         -ve
                        15           1:640         -ve
                        21          1:1280         -ve
     Ferret 2            0             -ve         -ve
                        10           1:320         -ve
                        15           1:640         -ve
                        21          1:1280         -ve
  Guinea pig 1           0             -ve         -ve
                        10             -ve         -ve
                        21            1:80         -ve
  Guinea pig 2           0             -ve         -ve
                        10             -ve         -ve
                        21             -ve         -ve
  Guinea pig 3           0             -ve         -ve
                        10             -ve         -ve
                        21             -ve         -ve
  Guinea pig 4           0             -ve         -ve
                        10             -ve         -ve
                        21           1:160         -ve
[00127] Viral RNA was detected in selected lymphoid tissues of 3 of 4 ferrets sampled day 6 to 8 pi,
including pharynx, spleen, and retropharyngeal and bronchial lymph nodes, as well as the
submandibular lymph node of the ferret euthanized on day 20 pi. This pattern of lymphoid involvement
suggests that there may be transient replication in the upper and lower respiratory tracts although
CedPV genome was not recovered from nasal washes, oral swabs, pharynx or lung tissue of affected
animals.
[00128] Example 7
[00129] Sera from 100 flying foxes collected during 2003-2005 from Queensland, Australia were
screened for neutralizing antibodies to CedPV. Virus neutralization test was conducted as described
                                                    42

above (antibody tests). All serum samples were tested at a dilution of 1:20. Due to the antigenic cross
reactivity observed between HeV and CedPV described above, virus neutralization tests were conducted
to obtain more accurate infection data for each virus. Overall, 23% of the sera were CedPV-positive and
37% HeV-positive. Co-infection was reflected in 8% of the sera tested.
[00130] Example 8
[00131]The CedPV-G and F glycoproteins also represent an important system to explore the mapping of
the henipavirus G and F functional domains. The CedPV-F is only 42% and 43% identical with HeV-F and
NiV-F respectively; and CedPV-G is 29% and 30% identical with HeV-G and NiV-G. CedPV functional
ephrin receptor usage was characterized along with heterotypic F and G coexpression and fusion assays
using combinations of CedPV, HeV and NiV. Codon optimized clones were prepared in a pCDNA vector
and tagged for detection with the S-peptide tag. Both constructs have been expressed, detected, and
found to be functional in our reporter gene cell-cell fusion assay. A pilot assay (Figure 9) indicates this
feasibility of this approach. Ephrin-B2 and -B3 negative HeLa-USU cells are negative CedPV cell-cell
fusion, as has the ephrin-B3 expressing cell line Hela-B3.
[00132] Fusion is observed with 293T target cells and ephrin-B2 expressing HeLa-B2 cell line.
Importantly, Ced PV-F has heterotypic function with both HeV-G and NiV-G, but further; CedPV-G has
heterotypic function only with HeV-F and not NiV-F (Figure 9) and also correlates with ephrin use.
[00133] Example 9
[00134] Significant detail is available for the binding between HeV and NiV-G and either ephrin-B2 or -B3
Mutations in G can render it non-functional in fusion promotion activity and virus infectivity, while
retaining ephrin receptor binding ability, at locations in the stalk or globular head. In a co-ip assay with
the 3 sG proteins (HeV, NiV and CedPV) along with a series of ephrin receptors it was observed that
CedPV-sG is able to bind multiple ephrin subtypes including: B1, B2, B3- weak, Al, A2, A4-weak, and A5
(Figure 10). This remarkably wide receptor binding profile is in sharp contrast to NiV and HeV-G which
bind only ephrin-B2 and -B3.
[00135] Example 10
                                                       43

[00136]A pilot cell-cell fusion experiment using a HeLa-USU target cell will the various ephrin receptor
constructs transfected and expressed is shown in Figure 11. Hela-USU target cell populations were
prepared by transfecting in the indicated ephrin receptor constructs and then used in cell-cell fusion
assay with effector cells expressing either CedPV, HeV or NiV F and G glycoproteins, and a standard
fusion-reporter gene assay was carried out. CedPV G and F mediated fusion was highly permissive when
either ephrin Al or A2; or ephrin BI or B2 was utilized; whereas we know that HeV and NiV make use of
only ephrin B2 and B3.
[00137] Further, the background endogenous levels of ephrin Al (based on gene array data) in the Hela
USU cells is the cause of the fusion signal in untransfected cells. The results of this experiment indicate
the ephrin receptor binding data with CedPV G glycoprotein (Figure 10) correlates well with CedPV
receptor binding and functional cell-cell fusion carried out in vitro. A summary of the ephrin receptor
binding and fusion data obtained so far is shown in Table 3 below.
        A24
  ..... A.
        . . . . .. ..   .. . . .. . .. . . . .. . . . . .. . .
           4 .....
               A ...........
                      A.....5....
                          ...                       ......
                              A44

[00138]The following references are referred to herein by number and are incorporated by reference in
their entirety.
[00139] 1. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, et al. (1995) A morbillivirus that caused fatal
disease in horses and humans. Science 268: 94-97.
[00140] 2. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, et al. (2000) Nipah virus: a recently
emergent deadly paramyxovirus. Science 288: 1432-1435.
[00141]3. Lamb RA, Parks GD (2007) Paramyxoviridae: The viruses and their replication. In: Knipe DM,
Griffin DE, Lamb RA, Straus SE, Howley PM et al., editors. Fields Virology. Philadelphia: Lippincott
Williams & Wilkins. pp. 1449-1496.
[00142]4. Eaton BT, Broder CC, Middleton D, Wang LF (2006) Hendra and Nipah viruses: different and
dangerous. Nat Rev Microbiol 4: 23-35.
[00143]5. Pallister J, Middleton D, Broder CC, Wang L-F (2011) Henipavirus vaccine development.
Journal of Bioterrorism and Biodefense: S1:005.
[00144]6. Eaton BT, Mackenzie JS, Wang L-F (2007) Henipaviruses. In: Knipe DM, Griffin DE, Lamb RA,
Straus SE, Howley PM et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins. pp.
1587-1600.
[00145]7. Yob JiM, Field H, Rashdi AM, Morrissy C, van der Heide B, et al. (2001) Nipah virus infection in
bats (order Chiroptera) in peninsular Malaysia. Emerg Infect Dis 7: 439-441.
[00146]8. Li Y, Wang J, Hickey AC, Zhang Y, Li Y, et al. (2008) Antibodies to Nipah or Nipah-like viruses in
bats, China. Emerg Infect Dis 14: 1974-1976.
[00147]9. Hayman DT, Suu-Ire R, Breed AC, McEachern JA, Wang L, et al. (2008) Evidence of henipavirus
infection in West African fruit bats. PLoS One 3: e2739.
[00148] 10. Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, et al. (2011) Pteropid Bats are
Confirmed as the Reservoir Hosts of Henipaviruses: A Comprehensive Experimental Study of Virus
Transmission. Am J Trop Med Hyg 85: 946-951.
                                                     45

[00149]11. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, et al. (2005) Fruit bats as
reservoirs of Ebola virus. Nature 438: 575-576.
[00150] 12. Towner JS, Pourrut X, Albarino CG, Nkogue CN, Bird BH, et al. (2007) Marburg virus infection
detected in a common African bat. PLoS ONE 2: e764.
[00151] 13. Li W, Shi Z, Yu M, Ren W, Smith C, et al. (2005) Bats are natural reservoirs of SARS-like
coronaviruses. Science 310: 676-679.
[00152]14. Chua KB, Crameri G, Hyatt A, Yu M, Tompang MR, et al. (2007) A previously unknown
reovirus of bat origin is associated with an acute respiratory disease in humans. Proc Natl Acad Sci U S A
104: 11424-11429.
[00153]15. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, et al. (2006) Recombinant
Nipah virus vaccines protect pigs against challenge. J Virol 80: 7929-7938.
[00154]16. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, et al. (2006) Feline model of acute
Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 80:
12293-12302.
[00155] 17. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, et al. (2008) A recombinant
subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine 26: 3842-3852.
[00156]18. Pallister J, Middleton D, Wang LF, Klein R, Haining J, et al. (2011) A recombinant Hendra virus
G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 29:
5623-5630.
[00157]19. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, et al. (2011) A neutralizing human
monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 3:
105ra103.
[00158] 20. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, et al. (2009) A neutralizing human
monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus
infection. PLoS Pathog 5: e1000642.
                                                     46

 [00159] 21. Bossart KN, McEachern JA, Hickey AC, Choudhry V, Dimitrov DS, et al. (2007) Neutralization
assays for differential henipavirus serology using Bio-Plex Protein Array Systems. J Virol Methods 142:
29-40.
 [00160]22. Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, et al. (2005) Ephrin-B2 ligand
is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A 102: 10652-10657.
 [00161]23. Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R,et al. (2005) EphrinB2
is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436: 401-405.
 [00162] 24. Negrete OA, Wolf MC, Aguilar HC, Enterlein S, Wang W, et al. (2006) Two key residues in
ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog 2: e7.
 [00163]25. Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, et al. (2004) Nipah virus:
vaccination and passive protection studies in a hamster model. J Virol 78: 834-840.
 [00164] 26. Drexler JF, Corman VM, Gloza-Rausch F, Seebens A, Annan A, et al. (2009) Henipavirus RNA
in African bats. PLoS ONE 4: e6367.
 [00165] 27. Crameri G, Todd S, Grimley S, McEachern JA, Marsh GA, et al. (2009) Establishment,
immortalisation and characterisation of pteropid bat cell lines. PLoS ONE 4: e8266.
 [00166] 28. Chua KB, Wang LF, Lam SK, Crameri G, Yu M, et al. (2001) Tioman virus, a novel
paramyxovirus isolated from fruit bats in malaysia. Virology 283: 215-229.
 [00167] 29. Chua KB, Lek Koh C, Hooi PS, Wee KF, Khong JH, et al. (2002) Isolation of Nipah virus from
 Malaysian Island flying-foxes. Microbes Infect 4: 145-151.
 [00168]30. Chua KB (2003) A novel approach for collecting samples from fruit bats for isolation of
infectious agents. Microbes Infect 5: 487-490.
 [00169]31. Tong S, Chern SW, Li Y, Pallansch MA, Anderson U (2008) Sensitive and broadly reactive
reverse transcription-PCR assays to detect novel paramyxoviruses. J Clin Microbiol 46: 2652-2658.
 [00170]32. Baker KS, Todd S, Marsh G, Fernandez-Loras A, Suu-Ire R, et al. (2012) Co-circulation of
diverse paramyxoviruses in an urban African fruit bat population. J Gen Virol 93: 850-856.
                                                       47

[00171]33. Thomas SM, Lamb RA, Paterson RG (1988) Two mRNAs that differ by two nontemplated
nucleotides encode the amino coterminal proteins P and V of the paramyxovirus SV5. Cell 54: 891-902.
[00172]34. Bossart KN, Tachedjian M, McEachern JA, Crameri G, Zhu Z, et al. (2008) Functional studies
of host-specific ephrin-B ligands as Henipavirus receptors. Virology 372: 357-371.
[00173]35. Pallister J, Middleton D, Crameri G, Yamada M, Klein R, et al. (2009) Chloroquine
administration does not prevent Nipah virus infection and disease in ferrets. J Virol 83: 11979-11982.
[00174]36. Williamson MM, Hooper PT, Selleck PW, Westbury HA, Slocombe RF (2000) Experimental
hendra virus infectionin pregnant guinea-pigs and fruit Bats (Pteropus poliocephalus). J Comp Pathol
122: 201-207.
[00175]37. Westbury HA, Hooper PT, Selleck PW, Murray PK (1995) Equine morbillivirus pneumonia:
susceptibility of laboratory animals to the virus. Aust Vet J 72: 278-279.
[00176]38. Wong KT, Grosjean I, Brisson C, Blanquier B, Fevre-Montange M, et al. (2003) A golden
hamster model for human acute Nipah virus infection. Am J Pathol 163: 2127-2137.
[00177]39. Negredo A (2011) Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathogens 7:
e1002304.
[00178]40. Lamb RA, Collins PL, Kolakofsky D, Melero JA, Nagai Y, et al. (2005) Family Paramyxoviridae. .
In: Fauquet CM, Mayo J, Maniloff J, Desselberger U, Ball LA, editors. Virus Taxonomy: 8 th Report of the
International Comittee on Taxonomy of Viruses. San Diego: Elsevier Academic Press. pp. 655-668.
[00179]41. Chambers R, Takimoto T (2009) Antagonism of innate immunity by paramyxovirus accessory
proteins. Viruses 1: 574-593.
[00180]42. Matsuoka Y, Curran J, Pelet T, Kolakofsky D, Ray R, et al. (1991) The P gene of human
parainfluenza virus type 1 encodes P and C proteins but not a cysteine-rich V protein. J Virol 65: 3406
3410.
[00181]43. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome sequencing in
microfabricated high-density picolitre reactors. Nature 437: 376-380.
                                                     48

[00182]44. Palacios G, Quan PL, Jabado OJ, Conlan S, Hirschberg DL, et al. (2007) Panmicrobial
oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis 13: 73-81.
[00183]45. Li Z, Yu M, Zhang H, Wang HY, Wang LF (2005) Improved rapid amplification of cDNA ends
(RACE) for mapping both the 5' and 3' terminal sequences of paramyxovirus genomes. J Virol Methods
130: 154-156.
[00184]46. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics
Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
[00185]47. Wang LF, Yu M, White JR, Eaton BT (1996) BTag: a novel six-residue epitope tag for
surveillance and purification of recombinant proteins. Gene 169: 53-58.
[00186]48. Wang LF, Gould AR, Selleck PW (1997) Expression of equine morbillivirus (EMV) matrix and
fusion proteins and their evaluation as diagnostic reagents. Arch Virol 142: 2269-2279.
[00187]49. Prowse S (2000) A new adjuvant. ANZCCART News 13: 7.
                                                     49

What is Claimed is:
1.     An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:1.
2.     An isolated polynucleotide sequence comprising a nucleotide sequence that is at least 50, 100,
        150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050,
        1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750,
        1,800, 1,850, 1,900, 1,950, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, 5,000, 5,500, 6,000, 6,500,
       7,000, 7,500, 8,000, 8,500, 9,000, 9,500, 10,000, 10,500, 11,000, 11,500, 12,000, 12, 500,
        13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500 or 18,000
       contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, or the complement thereof.
3.     The polynucleotide of claim 1 or 2, wherein the polynucleotide is RNA.
4.     The polynucleotide of claim 1 or 2, wherein the molecule is DNA.
5.     A vector comprising the nucleic acid molecule of claim 4.
6.     A host cell comprising the vector of claim 5.
7.     The host cell of claim 6, wherein the host cell is a prokaryotic cell.
8.     The host cell of claim 6, wherein the host cell is a eukaryotic cell.
9.     The host cell of claim 8, wherein the host cell is a mammalian cell.
10.    A method for producing a polypeptide, the method comprising culturing the host cell of claim 6
       in conditions that promote protein production and isolating the polypeptide from the culture.
11.    A composition comprising a nucleic acid molecule of claim 1 or 2, and a pharmaceutically
       acceptable carrier.
12.    An isolated polypeptide comprising an amino acid sequence selected from the group consisting
       of
       a. a polypeptide with an amino acid sequence at least 85% identical to the amino acid
            sequence of SEQ ID NO:2,
                                                     50

 b. a polypeptide comprising the amino acid sequence of SEQ ID NO:2,
c.  a polypeptide consisting of the amino acid sequence of SEQ ID NO:2,
d. a polypeptide with an amino acid sequence at least 85% identical to the amino acid
    sequence of SEQ ID NO:3,
e.  a polypeptide comprising the amino acid sequence of SEQ ID NO:3,
f.  a polypeptide consisting of the amino acid sequence of SEQ ID NO:3,
g. a polypeptide with an amino acid sequence at least 85% identical to the amino acid
    sequence of SEQ ID NO:4,
h. a polypeptide comprising the amino acid sequence of SEQ ID NO:4,
i.  a polypeptide consisting of the amino acid sequence of SEQ ID NO:4,
j.  a polypeptide with an amino acid sequence at least 85% identical to the amino acid
    sequence of SEQ ID NO:5,
k. a polypeptide comprising the amino acid sequence of SEQ ID NO:5,
I.  a polypeptide consisting of the amino acid sequence of SEQ ID NO:5,
m. a polypeptide with an amino acid sequence at least 85% identical to the amino acid
    sequence of SEQ ID NO:6,
n. a polypeptide comprising the amino acid sequence of SEQ ID NO:6,
o.  a polypeptide consisting of the amino acid sequence of SEQ ID NO:6,
p. a polypeptide with an amino acid sequence at least 85% identical to the amino acid
    sequence of SEQ ID NO:7,
q. a polypeptide comprising the amino acid sequence of SEQ ID NO:7,
r.  a polypeptide consisting of the amino acid sequence of SEQ ID NO:7,
                                           51

    s.  a polypeptide with an amino acid sequence at least 85% identical to the amino acid
        sequence of SEQ ID NO:8
    t.  a polypeptide comprising the amino acid sequence of SEQ ID NO:8, and
    u. a polypeptide consisting of the amino acid sequence of SEQ ID NO:8.
13. An isolated polynucleotide encoding the polypeptide of claim 12, or the complement thereof.
14. The polynucleotide of claim 13, wherein the polynucleotide is RNA.
15. The polynucleotide of claim 14, wherein the molecule is DNA.
16. A vector comprising the nucleic acid molecule of claim 15.
17. A host cell comprising the vector of claim 16.
18. The host cell of claim 17, wherein the host cell is a prokaryotic cell.
19. The host cell of claim 17, wherein the host cell is a eukaryotic cell.
20. The host cell of claim 19, wherein the host cell is a mammalian cell.
21. A method for producing a polypeptide, the method comprising culturing the host cell of claim 17
    in conditions that promote protein production and isolating the polypeptide from the culture.
22. An antibody or fragment thereof that specifically binds to the polypeptide of claim 12.
23. The antibody of claim 22, wherein the antibody is a monoclonal antibody or fragment thereof, a
    polyclonal antibody or a fragment thereof, a humanized antibody or a fragment thereof, a
    recombinantly produced antibody or a fragment thereof or a chimeric antibody or a fragment
    thereof.
24. A vaccine comprising the antibody or fragment of claim 22.
25. A method of treating or preventing an infection of Hendra virus, Nipah virus, Cedar virus, or
    other paramyxoviruses in a subject, the method comprising administering the vaccine of claim
    24 to a subject in need or treatment or prevention thereof.
                                                52

26. A method of detecting the presence of a first polynucleotide in a sample, wherein the first
    polynucleotide comprises a nucleotide sequence of at least 100 contiguous nucleotides of SEQ
    ID NO:1, the method comprising contacting the sample with a binding molecule that selectively
    binds to at least a portion of the first polynucleotide, or the complement thereof, and detecting
    the binding of the binding molecule to the first polynucleotide.
27. The method of claim 26 wherein the first polynucleotide comprises a nucleotide sequence that
    is at least 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000,
    8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 16000, 17000 or 18000 contiguous
    nucleotides of SEQ ID NO:1.
28. The method of claim 26 or 27 wherein the binding molecule is a second polynucleotide
    comprising at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900 or
    1000 nucleotides in length.
29. The method of claim 26 or 27 wherein the first polynucleotide is amplified using PCR or RT-PCR
    prior to detection.
30. A recombinant virus comprising the polynucleotide of any of claims 1 to 4.
31. The recombinant virus of claim 30 wherein the virus is an attenuated virus.
                                                  53

<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
                                       SEQUENCE LISTING
              <110>   WANG, Lin-Fa
                      MARSH, Glenn
                      FIELD, Hume
                      BRODER, Christopher
              <120>   PARAMYXOVIRUS AND METHODS OF USE
              <130>   044508-5045-WO
<removed-apn>
              <150>   US 61/667,194
              <151>   2012-07-02
              <160>   8
              <170>   PatentIn version 3.5
              <210>   1
              <211>   18162
              <212>   DNA
              <213>   Cedar virus
              <400> 1
              accagacaaa ggaagtctag tctccggatt aaatcatatt cgtatgatta atcttaggat   60
              cccggtatct agaatctgga tctggattcg gtttaattga attgcgatcg tttataaatt   120
              agaaaggaga tttactactc aaaatgtctg acattttcaa tgagactcaa tcatttagaa   180
              actatcagtc caacttaggc agagatggca gggccagtgc agcaacgact actttgacaa   240
              ctaaagtgag gatctttgtt ccagcgaata ataatccaaa cctcagatgg cgtttaacac   300
              tattcttgat ggatgtcgtg aggtcacctg cctccgcaga gtctatgaaa gtgggtgctg   360
              ggatatcctt ggtatctatg tatgctgaaa aacccggggc tcttgtgaga gcattattga   420
              atgacccaga tgttgaagcg ataatcatag atgtttatgg ctttgatgaa ggtattccta   480
              taatggaacg aagaggtgat aaagctacag atgacatgga ttccctaaga aagattgtta   540
              aagctgcaca tgatttcagc agaggaagga gtttatttgt tgatcaaagg gtccaggata   600
              ttgttatgtc agatatgggg tcatttgtga atgctattac ttccatagag acgcagatat   660
              ggattttgat cgcaaaggct gtaactgccc cagatacagc agaagagagc gaaggaagaa   720
              gatgggcaaa atatgttcag caaaagaggg ttaatccttt gttcttgatt tctccacaat   780
              ggatcaatga catgagatcc ctgattgcgg caagtctttc gcttcgtaaa ttcatggttg   840
                                                    Page 1

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              aactactgat ggaagctaag aaaggacggg ggacaaaagg aagaataatg gagattgtat   900
              ccgatatcgg aaattacgtt gaagagacag gaatggcagg gttcttcgct acaataaagt   960
              tcggtcttga gaccaaattc cctgctttgg cacttaatga gctccagagt gacttgaaca   1020
              caatgaaaag tctcatgata ctgtacagaa gcataggacc aaaggccccc tttatggtgt   1080
              tgttggaaga ttcaattcag accaaatttg ctccaggaag ctatccactt ctttggagtt   1140
<removed-apn>
              ttgcgatggg tgtaggcaca actattgaca gagctatggg tgccttgaac attaacagaa   1200
              gttatcttga acctgtctat tttaggctag ggcaacaatc agctaaacat caagcaggaa   1260
              atgttgacaa agaaatggca gaaaagttag gattgacaga agaccagatc gtgcacctat   1320
              cagctaatgt gaaggatgca agtcaaggta gagatgacaa tcaaatcaac atccgagaag   1380
              ggaagttcac aaatgttgtt gatgacatcc aggatcatgc ccagagttcc tctgaggatt   1440
              acaatcctag taaaaagagt ttctcaatat tgacgagcat cacatccacc gtagatagtg   1500
              ctgacagtag gtctgcaatg aatgagtcaa tgacaacaac atccttgctg aaattgagac   1560
              agaggctggc agagaagaaa ggagactcca agaacagtca agacacacct ccaaaaccac   1620
              ccagagcaaa agatcaaccc actgatgagg tctccttcat ggattccaat atatgatcag   1680
              aatgatggtt aaaatcaacc aactaagggc gcgtagagta ccttcagata gaacactaca   1740
              ttaatcgggt gaaacaatag atttatgggt ttggtgctta atttttattt aatcttactt   1800
              gcaaaacagg cagctgctac actcgtaacc actcctcaca gtaagggcaa cacgggtcat   1860
              agaacttatg cctatagatt acctctatct gtatatctag ctatgattaa aatgtatact   1920
              tctgctgacc ggttttctag caacagtcca cattattact ttatgggtat tttttaatca   1980
              accttttata atcaaatata ttacaaaaaa cttaggatcc aagtggtcca aacttttttt   2040
              gatcaagagt catattggct actttaggag gacactttaa acacaaattg ttacaagagg   2100
              atattcatca gatggacaaa ctacaattga ttgaagatgg cctctctact atcaatttta   2160
              tacaggaaaa taaggaaaaa ttacagcatt cttacggaag atcctccatc agagagccac   2220
              ccacaagtgt cagggttgaa gagtgggaga aatttattcg aaagatcgct tctggacctg   2280
              aacaagttca agggggagga tctgagactg agatcacagg cgataatgga gatagaggca   2340
              attttaccaa tcctgatcag ggaggcggag tcacaggaca attcgaagaa aggtatcaaa   2400
                                                   Page 2

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              aatgggggtc acaagattca gaattacaac tggacccaat ggttgtacac gatttcttct   2460
              atgacgagag aagggagaat cccgacaatg gaaaatatga ccgcagctct aaaaaacggg   2520
              ataatatcag agaaggaaca cgacaggata agtacaataa tcagtctact gatgaattac   2580
              tgtcctgcct acaaccatct tctaagaacg atgtcatcaa gaatgaaagt acatcagtgt   2640
              caaatttgca tgttacagga aataaactga atcctgacgc aaaacccttt gaacccacct   2700
<removed-apn>
              cccagtcgaa agagcaccca accaccacac agcacaacaa aaatgaccat cagaccgatg   2760
              atgattataa gaatagaaga tccagtgaaa acaatgtgat ctctgatcat gccaccacaa   2820
              tggaagacaa caacaatttt atcccggcga ccaaaagaaa gaatgcattg agcgaaccca   2880
              tatacgtcca ggtattgccc tcaaacacag agggtttctc gggaaaagat tatccactcc   2940
              tcaaggacaa ctctgtcaag aagcgtgcag agccagtcat cctagaaact gccaaccacc   3000
              ctgcaggctc tgccgaccaa gacacaaatc agattgaaga aaacatgcag ttcaaccttc   3060
              caaaactgct cacagaagat acagacgatg aaccagagga taacaatgat tccatgcctc   3120
              ttgaggaaga cattagagag atcggttcca tgctaaaaga tggaaccaaa gatatcaaga   3180
              caaggatgaa tgagatagat gacgcaatca agaagataaa taagaaatca aaaaatagaa   3240
              gtctggatct agaatcagac ggtaaagatc aggggagaag agatccatca gtagacctcg   3300
              ggattaaaaa aagaaaggaa gggctaaagg ccgcaatgca aaagacaaaa gagcaattgt   3360
              ctataaaagt ggagagagag attggattga acgacaggat atgtcaaaat tcgaagatga   3420
              gtacagaaaa gaaattgata tatgctggga tggaaatgga gtatggacaa acgagtactg   3480
              ggtcaggagg tccacaagga tcaaaggatg ggacttctga tgatgtccag gtagacgaag   3540
              actacgatga aggggaagac tatgaggcta tgccgtcaga taggttttat acaacattat   3600
              caggtgaaca aaaggataga tttgatctag atgctaacca aatgtctcag tatgacctcg   3660
              aggcccaggt ggatgaatta accagaatga atctcatact ctattctaga ttagaaacta   3720
              ctaataagtt gcttattgac atattagatc tagctaaaga aatgccaaag ttagttagaa   3780
              aagtggataa tcttgagaga cagatgggta acttgaatat gttaacctct acccttgagg   3840
              gtcacctatc ttctgtaatg attatgatac ccggtaagga taagagcgaa aaggaaatcc   3900
              ctaaaaatcc ggacctgaga ccaatactgg ggagaagcaa cacgtcgtta actgatgtta   3960
                                                   Page 3

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              tcgacctaga ccattaccct gataaaggct ccaaaggtat caaaccaagt ggatctggag   4020
              acagacagta catcggctct ctagagagca aattttctat aaatgatgag tacaattttg   4080
              ctccataccc tatcagggac gaactcctat tgccaggttt aagagatgac aaaaccaatg   4140
              cttcatcgtt catcccagat gacacggaca ggtctccaat ggtgctcaaa ataataattc   4200
              gacagaacat ccatgatgaa gaagtgaagg atgagctact gtccatacta gaacaacata   4260
<removed-apn>
              acactgtgga ggaattgaat gaaatatgga atactgtgaa tgattacctc gatggcaaca   4320
              tctgattaac agatattgag attgatccta ttctaaacaa gtaatctctg ataatgatag   4380
              tatggaataa gaatactaat cacactattg tactcttgta gaatcttaac gagtgtctaa   4440
              tgtcagattt tagcaacaca tactaataac ttgtaatcca tttctcctta ttccatttaa   4500
              tctcacatta gaaaaaactt aggatcccag atttgcaaag tcaaaacggg atctactatc   4560
              aggtgttgga gctaacaata gcggagtctg cataacaaat agcgttcaaa gaagtttgaa   4620
              aaccatcata gaatatggat ccgtcagatt tgaggaggat tataatggag gatgataaga   4680
              gtctggtcaa caatgatgat agtacagaaa ctgattttct cgagaaaact tggagagaag   4740
              ggagtaagat tgacaagatc acaccagagg ttgatgaaaa cgggaatatg gtccccaagt   4800
              acgttgtctt caacccgggg aaaaatgaga ggaaaacatc cggatatcaa tatatgattt   4860
              gttatggttt cattgaggat ggacctatca atggctcacc aagagtcaaa ggtaatatca   4920
              gaaccaccgc ttcttttcct ttgggtgttg gaaaaactta ctcgtctcca gaagagatct   4980
              tacaagagct gacaacactc aagatcactg tcagaaggac agccggatca aatgagaagt   5040
              tggtgtatgg aataacaggg cctttaaatc acctttaccc gtggtataaa gttttgacag   5100
              gtggctccat ttttagtgcg gtgaaggtct gtaggaatgt ggatcaaata ctattagaca   5160
              gaccccaaat acttagagta ttctttctaa gtataactaa attaacagat aaaggtgtgt   5220
              atatgatacc caaaagtgtt ctcgacttca gatcggataa ttcgatggcc ttcaatctgc   5280
              ttgtgtatct caagatagac actgacatca ccaaagcagg catcagaggg attgtcaaca   5340
              aagaagggga gaggataacg tcattcatgt tacacatcgg taactttaca agaagaggag   5400
              gaaaacatta ctcagtggag tattgcaaaa ggaaaattga caaaatgaag ctcacattcg   5460
              ccttaggcac tataggcggt ctaagcttac atatcaggat cgatggaagg ataagtaaaa   5520
                                                   Page 4

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              ggctccaagc acaagttggc tttcagagaa acatttgcta ctcactaatg gacacaaacc   5580
              catggttgaa taaattaacg tggaacaata gttgtgaaat acacaaagtc accgctgtca   5640
              ttcagccatc tgtgccaaag gacttcatgt tgtatgagga catcttaata gataatacag   5700
              gcaagatctt aaaataaagt aggagagtca gtcattaccc agtatattga atactaatga   5760
              caactttatt aatccaattc tatctccagt tactagaatt tctaaaacaa ttctactgct   5820
<removed-apn>
              cagcaacgca tctcaaacat tgtgatcttc aattatgatc gacgcattgt aatctatata   5880
              gcttttagtt catgaaatac taaaaagggc ttaatcttgt aagttctcag caaatactcc   5940
              aatgcaaaag agcgcctcaa catctcaagc agcaccaaaa taaaccacaa tcaatgtgca   6000
              acaagagcaa tcgtctaaag tgtgaaaacc aaaatcacag atcagaaagg gcacatattt   6060
              cagtcctgta aaaataccaa gtgggattaa taaaagagga tcaatcctta tcattttaag   6120
              aaaaacttag gatcccagag atcctaaaga gccaattcct ttatattttg atcttgaagg   6180
              gctagaagtc aggctgaaac acagaggtgg aggaacacag gaactaaaat tgatgaaatc   6240
              aaccttagct caacatctaa tcaatcaagc ttaagtcatc ctaatactgt atacaaccag   6300
              cagcgtagag agtggatttg atttcggcac ccttgcgaag tgaaggctat tactgcctgt   6360
              cctttcaatc agaaaattac atttacccat aaagtaatct caacatgtct aacaagagga   6420
              caacagtatt gatcataata agctatacgt tattttattt gaataatgca gcaattgtag   6480
              ggtttgattt tgataaattg aataaaatag gtgtggtgca agggagagtc ctaaattata   6540
              aaattaaagg agatccaatg acaaaagacc ttgtcttgaa atttatccct aacatagtga   6600
              atatcactga atgtgtgaga gagcccttga gtaggtacaa tgagaccgtg aggagattgc   6660
              ttttacctat acacaacatg cttgggttat acttgaataa cacaaatgct aaaatgactg   6720
              ggttgatgat cgcgggtgtg atcatgggtg ggatagcaat aggtatagcc acagcagctc   6780
              agatcacagc aggttttgct ctttatgagg caaaaaagaa cacagaaaat attcagaaat   6840
              taacagacag catcatgaaa acacaggact cgattgataa acttactgac agtgtgggga   6900
              caagcatact tatattgaat aagctacaga catacatcaa caatcaactg gtaccaaatc   6960
              tagagcttct atcctgccga caaaacaaaa ttgagtttga tctaatgtta accaagtatt   7020
              tggtggatct tatgactgtt attggtccta atatcaataa tcctgttaat aaagatatga   7080
                                                   Page 5

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              ctattcaatc tttgtcactt ctttttgatg gcaattatga tataatgatg tcagaacttg   7140
              gttatacacc tcaggatttc ttagatttga tagagagtaa gagtataaca gggcaaataa   7200
              tttatgttga tatggaaaac ttgtacgttg tgatcaggac atatctacct accctaattg   7260
              aagtacctga tgcccaaata tatgagttca acaaaataac tatgagtagc aatggaggag   7320
              aatacttgtc aaccatacct aatttcatat taataagagg taattatatg tctaatatag   7380
<removed-apn>
              atgttgcaac atgttatatg accaaagcaa gcgtaatttg taatcaagat tattcactcc   7440
              cgatgagcca aaacttaaga agctgttatc aaggtgagac agaatactgt cctgttgagg   7500
              cagtcatcgc gtcacactct ccaagatttg ctcttacaaa tggagttatt ttcgccaatt   7560
              gtataaatac aatttgtagg tgtcaagaca atggtaagac tatcactcaa aacataaacc   7620
              aattcgtaag catgatcgac aacagtactt gtaatgatgt catggtagat aagtttacta   7680
              tcaaggtagg aaaatatatg gggagaaaag atatcaataa tattaatatc cagataggac   7740
              cgcagatcat aattgataag gttgacttgt ctaatgaaat aaacaagatg aatcaatctt   7800
              taaaagatag tattttctac ctgagagaag ccaagagaat tttagactca gtaaatatca   7860
              gtcttatatc tccaagcgtt caattgtttc taataataat atcagtcctc tcatttatta   7920
              tattattgat tatcatagta tacttgtact gtaaatcaaa acattcatat aaatataaca   7980
              aatttataga tgatcctgat tattacaatg attacaaaag agaacgtatt aatggcaaag   8040
              ccagtaagag taacaatata tattatgtag gtgattaaca atcgataatc taaaggatta   8100
              cctcactatc actaccaagg taacttccat gtaagatcgg accttccccg aagacattaa   8160
              ataaaactta ggatcccaga gtatccctct aagtgatcct tctagattgg ttactgatat   8220
              atatacatat ttatcctctt tccgtcgttg tttattgatc attaataatg ctttctcagc   8280
              tccaaaaaaa ttacttagac aactcaaacc aacaaggtga taaaatgaac aacccagata   8340
              agaaattaag tgtcaacttc aaccctttag aattagataa aggtcaaaaa gatctcaata   8400
              agtcttatta tgttaaaaac aagaattata acgtttcaaa tctattaaat gaaagtctgc   8460
              acgatatcaa gttttgtatt tattgtatat tctcactgct aattatcatt acaataatca   8520
              atataatcac aatatcaatt gttataactc gtctgaaagt acatgaagag aataatggca   8580
              tggaatctcc taatttacaa tctattcaag atagtctctc atctcttact aacatgatca   8640
                                                   Page 6

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              atacagagat aactcctaga atagggattt tagttacagc cacttctgtt actctctctt   8700
              catctatcaa ttatgtcggg actaagacaa atcaactggt caatgaatta aaagattata   8760
              taaccaaaag ttgtggcttt aaggtccctg aattaaagtt acatgaatgc aacataagtt   8820
              gtgctgatcc aaaaattagc aaatctgcaa tgtacagcac caatgcctat gccgagcttg   8880
              ctggtccacc taagatattt tgtaaaagtg tatccaaaga ccccgacttt agactgaagc   8940
<removed-apn>
              agatagatta tgtaatacca gtgcagcaag atcggtctat ttgtatgaac aaccctttat   9000
              tggatatttc tgatgggttt tttacctaca tacattatga aggaataaat agctgtaaaa   9060
              aatcagattc atttaaagtg ctgctgtcac atggtgaaat agttgacagg ggtgattatc   9120
              gaccatcatt atatctatta tcaagtcatt accatcctta ttcaatgcag gtaataaact   9180
              gtgtacctgt gacttgtaac cagtcatcct ttgtattctg tcatatctcc aacaacacta   9240
              aaacattgga caattcagat tactcgtcag acgagtacta cataacatat ttcaatggca   9300
              tagatcgtcc caaaaccaag aagattccca ttaacaatat gacagcagac aatcgttata   9360
              tccattttac attctcaggt gggggaggtg tatgtttagg tgaagaattt attattcctg   9420
              ttaccacagt catcaatact gatgtattca cgcatgatta ttgtgagagt ttcaactgtt   9480
              cagtccaaac cggtaaaagt ctaaaggaga tatgctctga gtcattaaga tctccaacga   9540
              actcatcgcg atacaattta aacggaatca tgattataag tcaaaacaac atgacagatt   9600
              ttaagattca gttgaatggt ataacttata acaaactgtc attcggaagt cctggaagac   9660
              tgagcaagac actgggccag gtcctttatt accaatcttc aatgagttgg gatacttatc   9720
              taaaggcagg atttgtcgag aaatggaaac cctttacccc gaattggatg aacaatactg   9780
              tgatatccag acctaaccaa ggtaattgtc caaggtatca taaatgcccc gagatatgtt   9840
              atggagggac atacaatgat attgctcctt tagatctagg aaaagacatg tatgttagcg   9900
              ttattctaga ttcagatcag cttgcagaga atccagagat tacagtattt aactctacta   9960
              ctatacttta taaggagaga gtatccaaag atgaactaaa cacaagaagt actacaacga   10020
              gctgttttct tttcctagat gaaccttggt gtatatcagt attagaaaca aacagattta   10080
              acggcaaatc tattaggccc gagatttatt catacaaaat tcctaagtat tgttaatttg   10140
              atgagcttat tcctcatact tcaatcaaat ttaatataac taatatcaaa ttgttgcact   10200
                                                   Page 7

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              cagctattat taaaactgga tcatcagaca ataaagatgt atacaaagat atatcgaaga   10260
              gggtattaaa gaaaacttag gatcccagat ccttcaataa ggcagagcct tgattgtatc   10320
              agcgtcattt acaattgaat ctcaattaac aacactgatt aataacttaa gcagaatact   10380
              cctattacag tgtttaattg acttaatttt aattgaggat tttataatcc tataattgga   10440
              gcagatctaa actctcaccg attcagttct aatcctttat taactaaaga acaaattcta   10500
<removed-apn>
              aataattgga tgacgtcaca ggagacaagc tggaaacaat ttagttagaa ggaagaaacc   10560
              ttttaccaga tatggaaagt gactttgata tatctgttag cgacgtactg tacccagaat   10620
              gtcatttgga cagtcctata gtcggcggta agctcattac ttctcttgag tatgcgaatt   10680
              tgactcataa ccaacctcat gaagatcaga cattgctgac taatataaat gtcaataaaa   10740
              agaagaagat aaaaagtcct ctaatatccc aacaatcttt atttggaaat gaggttaata   10800
              aggagatttt cgatcttaaa aattattacc atgtccccta tccagaatgt aacagagatt   10860
              tattcttaat ctctgatgac aaaatagcat tcaaactcag taaaatcatg gataattcta   10920
              ataaactgtt tgatggttta gagaggaaac tgagtcgctt aatttcgaat gtagataatc   10980
              aactattaaa tgcaacctct cttcataata attctgagat ggatcggaag ggaaaagaac   11040
              atccttgctt cccagaaaag agcacaattg atgatgtaag acagcagaga cagacacgag   11100
              attttccaaa gaattcaact agagagggaa gatctccaaa acaccctgat gccggtccta   11160
              cacctgaaaa cagtgccaaa aacgatttgc atagagacaa cacagacaat atgccaacag   11220
              gccatagttc gacatctatg aaaaaaccta aaatatctgg agaagaatat cttagtatgt   11280
              ggctagactc agaggatttg ggttctaaac gaatttctgc acaattaggg aaggatgtat   11340
              catgtaaagg ccatctgcac acgacagaag acaaaccgat aatagttcct gacactcgat   11400
              atatccaaaa tcatgaatct aataacgata ttttccccaa aaaagagaaa aaattctgca   11460
              aacttccacc gtcatcggat aatttaacca aaatcatggt gaattcaaaa tggtacaatc   11520
              ctttcctttt ttggtttact gtcaagactg aacttagagc ctgccagaag gagaactaca   11580
              aaaggaaaaa cagaaaattg ggaattatca catcgattaa aggttcatgc tataagttga   11640
              tactcaacca gaatctagta gcaatattcg aggaagacag cagtggatac tcagatcata   11700
              aaaaaagaaa aaaacgatgc tactatctaa ctcccgaaat ggtccttatg ttctccgatg   11760
                                                   Page 8

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              taactgaagg aagattgatg attgatgttg caatgagatt tgacaaaaag tacaaaactc   11820
              tagagaaaaa ggctttgaaa ttatggtttc ttatagacga gttatttcct tctatgggaa   11880
              atagagtgta taatattata tccatgcttg agcctttgac tctcgcgata ttacaggtta   11940
              aggatgagtc aaggttgttg agaggtgcat tcatgcatca ttgtttaggt gacctcttcg   12000
              aagaacttcg agagtccaag aactacccgg aagatgagat caagagattt gccaacgacc   12060
<removed-apn>
              taataaatgt catgacctgt cgggacattc atttagtagc agaattcttc tcattcttta   12120
              ggactttcgg acatccaata ttgaacgctc aaactgcagc caggaaagtt agagagtaca   12180
              tgttagcaga taaaatcctt gagtacgaac ctatcatgaa aggtcatgcg attttctgtg   12240
              ctataatcat aaatggattt agagatagac atggaggagt ttggcctcct cttgatcttc   12300
              caaaacattg ttcaaagaac ataatatctc tcaaaaatac aggtgaaggg gtaacttatg   12360
              aagtagcaat aaacaattgg agatcatttg tcgggttaaa gttcaaatgt tttatgggtc   12420
              tcaatttaga caatgatctc agcatgtaca tgaaagataa agcattatca cctttaaggg   12480
              atctttggga ttcaatctat tcacgtgaag taatgtccta ccaaccacct agaaacaaaa   12540
              aatcaagaag attggttgag gttttcgttg atgatcagga ctttgatccc gttgatatga   12600
              taaattatgt tctgaccgga gaatatctca gagatgatga tttcaatgct tcttatagtt   12660
              taaaagagaa agagaccaaa caagttggca ggttgtttgc taagatgact tataaaatga   12720
              gggcctgtca agttattgct gagaatttaa ttgcacatgg gattgggaga tatttccatg   12780
              aaaacgggat ggttaaggat gagcatgagc tcagcaaatc actgtttcaa ttgtctatat   12840
              caggaatacc aagagggaac aaaaacaaca aatcgacgaa cgacacaatc cacgaaagca   12900
              agatcgagaa taaccattcc tttaaaaaca tccagaatcg atcatttcga aagacggata   12960
              acccatacaa tagatttaac attgataacc caactttctt atccccaaac tgtaacccca   13020
              agtataaccg taagaattca gagacaatag gtatattctc tcgtgcagaa accaaaagca   13080
              tgattagaga acagaaaagt cacagagaag tcaaaataaa taagctagat atcggcagtg   13140
              ataatgaaga gcaaggaaaa gagatagatg ccgccaagta caaaatcacg gacaacccaa   13200
              atccacacat aaatcctcaa gatcaacccg gaatctgtca agaagacaaa ggcaaagaag   13260
              gagcaaagtc agatctcaca gaaggcatga gttttctgga gatgcacaca ctctttaacc   13320
                                                   Page 9

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              cgagtaagag cgatatcaga acaaatctcg aattggaaaa gagttcactt tcaaaccctg   13380
              gatttatatc acaaaaagag aaaagaggca aaacttataa tgaatcccat tcactgggaa   13440
              agttctctaa agaggatgaa gaaagatacg atgtcatcag tgcattcctg acaacagatt   13500
              tacgaaaatt ctgcttaaat tggagacatg aatcaatcgg catttttgca agaaggatgg   13560
              acgaaatcta tggtttgcct ggtttcttta attggatgca cagaagacta gagcgatctg   13620
<removed-apn>
              tgttatatgt tgcggaccct cattgcccgc cgtctatcaa tgaacatatc gatctaaacg   13680
              attcacccga aagagacata tttatacatc atccgaaagg gggtatagaa ggatacagcc   13740
              aaaaactgtg gacaatagcg actatccctt ttctattcct cagtgctcat gagacaaaca   13800
              cccggatagc ggcagttgta caaggtgaca atcaatcaat tgcaattaca cataaggtcc   13860
              accctcattt gccttacaaa atgaagaaag aactctctgc aatgcaggca aaaaaatatt   13920
              tttcaaggtt acggcacaac atgaaggcat tagggcatga attgaaggcg accgagacta   13980
              tcattagtac tcatttcttc atttattcca agaaaatcca ctatgacggg gctgttttat   14040
              cacaatctct gaaatcaatg gcaaggtgtg tattttggtc agaaaccctt gttgatgaaa   14100
              ctagagcagc atgcagtaat atcagcacaa caattgcaaa ggctattgag aatggttata   14160
              gcaggagatc tggctatctg ataaatgttc ttaaaaccat ccaacaaatt aatatatcat   14220
              tgagttttaa tataaatgaa tgcatgacag atgacataat cagaccgttt agagataatc   14280
              caaactggat caaacatgcc gcattaatcc ccgccagctt gggaggactc aactatatga   14340
              acatgtctcg attgtatgtg aggaatatag gggatccagt cacagcatcg atagcagatg   14400
              ttaagagaat gattctcggt ggtgtactac ccattggaat actccacaat atcatgttgc   14460
              aagaacccgg tgatgccact tatttggact ggtgtagtga tccatactcc atcaacctaa   14520
              agcagactca aagtatcaca aaagttataa agaacataac ggcaagagtg atactaagga   14580
              attcggtcaa tccactgctc aaaggtctat ttcatgaagg tgcttatgag gaggacactg   14640
              aattagcaac attcattttg gacaggagag tcatcttacc acgagtcggt cacgagatct   14700
              taaacaactc catcacagga gcaagagaag agatctcggg cttactggat accacaaaag   14760
              gattgataag aattggcata gcaaagggag gattaactca gagaacatta tctcgaattt   14820
              ccaattatga ttatgaacaa tttttgaacc taatgaatat gttgaagaac aaagaacaaa   14880
                                                  Page 10

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              acagtgtcat ttccctgtca gcttgctctg ttgactttgc tatagcttta agaagcagga   14940
              tgtggaggaa attggcaaaa ggaagattaa tatatggttt agaagtccct gatccaatag   15000
              aagcaatgat tggctttctc attcttggga gtgaaaattg tctactctgt gattcaggaa   15060
              gcaaaaacta tacctggttt ttcataccaa aggatgtaca gttggataag attgataaag   15120
              atcacgcatc aataagggta ccctatgtcg gatcaactac cgaagaaaga tcagagataa   15180
<removed-apn>
              agttaggatc cgtgaaaaat ccaagcaaat ccctgaaatc tgctataaga ctcgcaactg   15240
              tgtacacttg ggcatttggc acaagtgatg ctgaatggtg ggaggcttgg tacttgtcta   15300
              atcaacgagc aaatataccc ttagatgttc tcaaaacgat aacacctata tctacttcaa   15360
              cgaatattgc tcatagatta cgagaccgat caacacaggt taaatacgcc agtacatctc   15420
              ttaacagagt atcgcggcat gtaacaatta gtaacgataa catgaatttt gaatttgacg   15480
              gggttaaaat ggataccaac ttgatttatc aacaagtcat gctgttaggg ctttcatgct   15540
              tggagagttt attccgaaat aggaaaatga caaatagtta caatatcgtg taccatttac   15600
              acgttcaaga acattgttgt gtaaaggctc tgaatgattt accttataca ccgtcaacac   15660
              atccagtgcc aaattataca gaagttagag ataataggtt aatttacgat cctcaaccta   15720
              tattagaatt tgatgagcta agattagcaa ttcagcaaac aaagaaagta gatttggaat   15780
              tttcattgtg ggatacaaaa gaacttcatg agaatttagc tcaaagttta gcgattacag   15840
              taacggatat tatgacaaaa tctgataaag atcatattaa agaccaaaga agtatagatg   15900
              ttgatgataa tattaagaca ctaataactg agtttttatt agtagaccct gaaatgtttg   15960
              ccgtaaattt aggattgcat atatcaataa aatggtcatt tgatattcac tttaaaagac   16020
              caagaggacg ctatagcatg atagaatact tgactgatct tttggataat acttcttctc   16080
              atgtttatcg aatccttact aatgtattat ctcatcccag agttatgaga aaattcacta   16140
              atgccgggct actagtaccg aaatacggtc cctaccttac aagtcaagat ttcaaaaaga   16200
              tggcggtaga tttcataata acagcgtata ccacattttt gaccaattgg tgtaataata   16260
              acaagttttc aattctaata cctgaacaag accctgatat acttgaatta agaaaagaca   16320
              tcactcatgc aaggcattta tgtatgatct cggatcttta ctgctactct ttcaagcaac   16380
              cttggataaa ggagcttaca ccacaagaga agatctgcgt catggaggac ttcatagcca   16440
                                                  Page 11

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              attgtgttgc taatgatcaa acaagtgcgg gctggaacat aacgccctta agagtttaca   16500
              atctccctgc atcgaccaca tacatcagga gagggataat aaaacaatta agaatccgtc   16560
              aaagcaatga gcctattgat ctggaagata ttaggattgg tcagaacccc gattttgtga   16620
              ataaacctat tgagttttgt agcagtgaat tcggtatcac aatttataac cttgaagaaa   16680
              ttcttcaatc aaatgtgcat ctcagtgtaa atatgaacat tgactcctca acaagtaaca   16740
<removed-apn>
              atactgaaaa tcatttattt agaagggtag gcttgaactc tacttcatct tataaagcac   16800
              tatctttaac acctgttatt aaaagatatc atcaacagaa cactaatagg ctgtttatag   16860
              gagaaggatc agggtctatg atgtatcttt accagaaaac cttgggggag acaatatgct   16920
              tctttaattc gggagttcag tacaatgagg atctgggtca aagggaacaa tcattatacc   16980
              cgagtgaata cagtatctgt gaacaaggag taaaaaaaga aaaccctctc accgggcatg   17040
              ttataccact attcaatgga agaccagaaa ccacatgggt aggcaatgat gattctttca   17100
              agtatatatt ggaacatact ataaatagag acatcgggct tgttcactcc gatatggaaa   17160
              caggaatagg gaaggataat tatactatct taaatgaaca tgcacatctt atagcactga   17220
              gccttacagt aatgattgat gatggaatct tggtgtctaa ggtagcttat gcccctgggt   17280
              tttgcatctc ttcattattg aatatgtacc ggacattttt ttcattagtt ctatgtgcgt   17340
              ttccaccgta tagcaatttt gaatcaactg aattttacct gatttgcttg caaaaaagta   17400
              tacccggacc tatcacacca gctagagcca tccaacaaac gacgaagcaa tctagagaag   17460
              aggataatag tataactaat aatatcctca aaatcaaaaa tcttgttcag aaagaattta   17520
              tcaaaacagt aaagaaaaaa tacgaaatcc atccttcgtt taactgtcct atcaacttca   17580
              caaaggatga taaatattta atgagtgttg ggtttcaagc caatggtcct gatatgatac   17640
              gtaaagagac gggctatgac ataggtagca atgtagagaa tctccgagat gtcttaatca   17700
              agttgtttgc agatgcagtc accttctatg atgatgtcac aaataaaaag aactttttaa   17760
              atccttatcc agtctacaca agaactcagt ataaaattct gatggataaa atatgcaaga   17820
              aagtcacctt atacacctta atcatatcat gtaaaggatc caatcaatat tgctgggaaa   17880
              ttaaatccca aataagaaag cattgtctca tacttgattt gaaaagtaag gtttttacaa   17940
              aacttattcc aaagggatta agagaaaggg gtgactcaaa agggatgaag agcatatggt   18000
                                                  Page 12

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              tcactaaact aaccagtcaa gaggtgaaaa gatggtggaa gatgatatct tacatcgtga   18060
              taataagcaa tccataacca catccaactt gtcagttaaa cacttaaatc acaataaact   18120
              tgtcatcaga ttaaagaaaa cttataattc ccttttttag gt                      18162
              <210>   2
              <211>   510
              <212>   PRT
<removed-apn>
              <213>   Cedar virus
              <400>   2
              Met Ser Asp Ile Phe Asn Glu Thr Gln Ser Phe Arg Asn Tyr Gln Ser
              1               5                   10                  15
              Asn Leu Gly Arg Asp Gly Arg Ala Ser Ala Ala Thr Thr Thr Leu Thr
                          20                  25                  30
              Thr Lys Val Arg Ile Phe Val Pro Ala Asn Asn Asn Pro Asn Leu Arg
                      35                  40                  45
              Trp Arg Leu Thr Leu Phe Leu Met Asp Val Val Arg Ser Pro Ala Ser
                  50                  55                  60
              Ala Glu Ser Met Lys Val Gly Ala Gly Ile Ser Leu Val Ser Met Tyr
              65                  70                  75                  80
              Ala Glu Lys Pro Gly Ala Leu Val Arg Ala Leu Leu Asn Asp Pro Asp
                              85                  90                  95
              Val Glu Ala Ile Ile Ile Asp Val Tyr Gly Phe Asp Glu Gly Ile Pro
                          100                 105                 110
              Ile Met Glu Arg Arg Gly Asp Lys Ala Thr Asp Asp Met Asp Ser Leu
                      115                 120                 125
              Arg Lys Ile Val Lys Ala Ala His Asp Phe Ser Arg Gly Arg Ser Leu
                  130                 135                 140
              Phe Val Asp Gln Arg Val Gln Asp Ile Val Met Ser Asp Met Gly Ser
              145                 150                 155                 160
                                                  Page 13

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Phe Val Asn Ala Ile Thr Ser Ile Glu Thr Gln Ile Trp Ile Leu Ile
                              165                 170                 175
              Ala Lys Ala Val Thr Ala Pro Asp Thr Ala Glu Glu Ser Glu Gly Arg
                          180                 185                 190
<removed-apn>
              Arg Trp Ala Lys Tyr Val Gln Gln Lys Arg Val Asn Pro Leu Phe Leu
                      195                 200                 205
              Ile Ser Pro Gln Trp Ile Asn Asp Met Arg Ser Leu Ile Ala Ala Ser
                  210                 215                 220
              Leu Ser Leu Arg Lys Phe Met Val Glu Leu Leu Met Glu Ala Lys Lys
              225                 230                 235                 240
              Gly Arg Gly Thr Lys Gly Arg Ile Met Glu Ile Val Ser Asp Ile Gly
                              245                 250                 255
              Asn Tyr Val Glu Glu Thr Gly Met Ala Gly Phe Phe Ala Thr Ile Lys
                          260                 265                 270
              Phe Gly Leu Glu Thr Lys Phe Pro Ala Leu Ala Leu Asn Glu Leu Gln
                      275                 280                 285
              Ser Asp Leu Asn Thr Met Lys Ser Leu Met Ile Leu Tyr Arg Ser Ile
                  290                 295                 300
              Gly Pro Lys Ala Pro Phe Met Val Leu Leu Glu Asp Ser Ile Gln Thr
              305                 310                 315                 320
              Lys Phe Ala Pro Gly Ser Tyr Pro Leu Leu Trp Ser Phe Ala Met Gly
                              325                 330                 335
              Val Gly Thr Thr Ile Asp Arg Ala Met Gly Ala Leu Asn Ile Asn Arg
                          340                 345                 350
              Ser Tyr Leu Glu Pro Val Tyr Phe Arg Leu Gly Gln Gln Ser Ala Lys
                      355                 360                 365
                                                  Page 14

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              His Gln Ala Gly Asn Val Asp Lys Glu Met Ala Glu Lys Leu Gly Leu
                  370                 375                 380
              Thr Glu Asp Gln Ile Val His Leu Ser Ala Asn Val Lys Asp Ala Ser
              385                 390                 395                 400
<removed-apn>
              Gln Gly Arg Asp Asp Asn Gln Ile Asn Ile Arg Glu Gly Lys Phe Thr
                              405                 410                 415
              Asn Val Val Asp Asp Ile Gln Asp His Ala Gln Ser Ser Ser Glu Asp
                          420                 425                 430
              Tyr Asn Pro Ser Lys Lys Ser Phe Ser Ile Leu Thr Ser Ile Thr Ser
                      435                 440                 445
              Thr Val Asp Ser Ala Asp Ser Arg Ser Ala Met Asn Glu Ser Met Thr
                  450                 455                 460
              Thr Thr Ser Leu Leu Lys Leu Arg Gln Arg Leu Ala Glu Lys Lys Gly
              465                 470                 475                 480
              Asp Ser Lys Asn Ser Gln Asp Thr Pro Pro Lys Pro Pro Arg Ala Lys
                              485                 490                 495
              Asp Gln Pro Thr Asp Glu Val Ser Phe Met Asp Ser Asn Ile
                          500                 505                 510
              <210>   3
              <211>   737
              <212>   PRT
              <213>   Cedar virus
              <400>   3
              Met Asp Lys Leu Gln Leu Ile Glu Asp Gly Leu Ser Thr Ile Asn Phe
              1               5                   10                  15
              Ile Gln Glu Asn Lys Glu Lys Leu Gln His Ser Tyr Gly Arg Ser Ser
                          20                  25                  30
                                                  Page 15

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Ile Arg Glu Pro Pro Thr Ser Val Arg Val Glu Glu Trp Glu Lys Phe
                      35                  40                  45
              Ile Arg Lys Ile Ala Ser Gly Pro Glu Gln Val Gln Gly Gly Gly Ser
                  50                  55                  60
              Glu Thr Glu Ile Thr Gly Asp Asn Gly Asp Arg Gly Asn Phe Thr Asn
<removed-apn>
              65                  70                  75                  80
              Pro Asp Gln Gly Gly Gly Val Thr Gly Gln Phe Glu Glu Arg Tyr Gln
                              85                  90                  95
              Lys Trp Gly Ser Gln Asp Ser Glu Leu Gln Leu Asp Pro Met Val Val
                          100                 105                 110
              His Asp Phe Phe Tyr Asp Glu Arg Arg Glu Asn Pro Asp Asn Gly Lys
                      115                 120                 125
              Tyr Asp Arg Ser Ser Lys Lys Arg Asp Asn Ile Arg Glu Gly Thr Arg
                  130                 135                 140
              Gln Asp Lys Tyr Asn Asn Gln Ser Thr Asp Glu Leu Leu Ser Cys Leu
              145                 150                 155                 160
              Gln Pro Ser Ser Lys Asn Asp Val Ile Lys Asn Glu Ser Thr Ser Val
                              165                 170                 175
              Ser Asn Leu His Val Thr Gly Asn Lys Leu Asn Pro Asp Ala Lys Pro
                          180                 185                 190
              Phe Glu Pro Thr Ser Gln Ser Lys Glu His Pro Thr Thr Thr Gln His
                      195                 200                 205
              Asn Lys Asn Asp His Gln Thr Asp Asp Asp Tyr Lys Asn Arg Arg Ser
                  210                 215                 220
              Ser Glu Asn Asn Val Ile Ser Asp His Ala Thr Thr Met Glu Asp Asn
              225                 230                 235                 240
                                                  Page 16

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Asn Asn Phe Ile Pro Ala Thr Lys Arg Lys Asn Ala Leu Ser Glu Pro
                              245                 250                 255
              Ile Tyr Val Gln Val Leu Pro Ser Asn Thr Glu Gly Phe Ser Gly Lys
                          260                 265                 270
              Asp Tyr Pro Leu Leu Lys Asp Asn Ser Val Lys Lys Arg Ala Glu Pro
<removed-apn>
                      275                 280                 285
              Val Ile Leu Glu Thr Ala Asn His Pro Ala Gly Ser Ala Asp Gln Asp
                  290                 295                 300
              Thr Asn Gln Ile Glu Glu Asn Met Gln Phe Asn Leu Pro Lys Leu Leu
              305                 310                 315                 320
              Thr Glu Asp Thr Asp Asp Glu Pro Glu Asp Asn Asn Asp Ser Met Pro
                              325                 330                 335
              Leu Glu Glu Asp Ile Arg Glu Ile Gly Ser Met Leu Lys Asp Gly Thr
                          340                 345                 350
              Lys Asp Ile Lys Thr Arg Met Asn Glu Ile Asp Asp Ala Ile Lys Lys
                      355                 360                 365
              Ile Asn Lys Lys Ser Lys Asn Arg Ser Leu Asp Leu Glu Ser Asp Gly
                  370                 375                 380
              Lys Asp Gln Gly Arg Arg Asp Pro Ser Val Asp Leu Gly Ile Lys Lys
              385                 390                 395                 400
              Arg Lys Glu Gly Leu Lys Ala Ala Met Gln Lys Thr Lys Glu Gln Leu
                              405                 410                 415
              Ser Ile Lys Val Glu Arg Glu Ile Gly Leu Asn Asp Arg Ile Cys Gln
                          420                 425                 430
              Asn Ser Lys Met Ser Thr Glu Lys Lys Leu Ile Tyr Ala Gly Met Glu
                      435                 440                 445
                                                  Page 17

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Met Glu Tyr Gly Gln Thr Ser Thr Gly Ser Gly Gly Pro Gln Gly Ser
                  450                 455                 460
              Lys Asp Gly Thr Ser Asp Asp Val Gln Val Asp Glu Asp Tyr Asp Glu
              465                 470                 475                 480
              Gly Glu Asp Tyr Glu Ala Met Pro Ser Asp Arg Phe Tyr Thr Thr Leu
<removed-apn>
                              485                 490                 495
              Ser Gly Glu Gln Lys Asp Arg Phe Asp Leu Asp Ala Asn Gln Met Ser
                          500                 505                 510
              Gln Tyr Asp Leu Glu Ala Gln Val Asp Glu Leu Thr Arg Met Asn Leu
                      515                 520                 525
              Ile Leu Tyr Ser Arg Leu Glu Thr Thr Asn Lys Leu Leu Ile Asp Ile
                  530                 535                 540
              Leu Asp Leu Ala Lys Glu Met Pro Lys Leu Val Arg Lys Val Asp Asn
              545                 550                 555                 560
              Leu Glu Arg Gln Met Gly Asn Leu Asn Met Leu Thr Ser Thr Leu Glu
                              565                 570                 575
              Gly His Leu Ser Ser Val Met Ile Met Ile Pro Gly Lys Asp Lys Ser
                          580                 585                 590
              Glu Lys Glu Ile Pro Lys Asn Pro Asp Leu Arg Pro Ile Leu Gly Arg
                      595                 600                 605
              Ser Asn Thr Ser Leu Thr Asp Val Ile Asp Leu Asp His Tyr Pro Asp
                  610                 615                 620
              Lys Gly Ser Lys Gly Ile Lys Pro Ser Gly Ser Gly Asp Arg Gln Tyr
              625                 630                 635                 640
              Ile Gly Ser Leu Glu Ser Lys Phe Ser Ile Asn Asp Glu Tyr Asn Phe
                              645                 650                 655
                                                  Page 18

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Ala Pro Tyr Pro Ile Arg Asp Glu Leu Leu Leu Pro Gly Leu Arg Asp
                          660                 665                 670
              Asp Lys Thr Asn Ala Ser Ser Phe Ile Pro Asp Asp Thr Asp Arg Ser
                      675                 680                 685
              Pro Met Val Leu Lys Ile Ile Ile Arg Gln Asn Ile His Asp Glu Glu
<removed-apn>
                  690                 695                 700
              Val Lys Asp Glu Leu Leu Ser Ile Leu Glu Gln His Asn Thr Val Glu
              705                 710                 715                 720
              Glu Leu Asn Glu Ile Trp Asn Thr Val Asn Asp Tyr Leu Asp Gly Asn
                              725                 730                 735
              Ile
              <210>   4
              <211>   177
              <212>   PRT
              <213>   Cedar virus
              <400>   4
              Met Ala Ser Leu Leu Ser Ile Leu Tyr Arg Lys Ile Arg Lys Asn Tyr
              1               5                   10                  15
              Ser Ile Leu Thr Glu Asp Pro Pro Ser Glu Ser His Pro Gln Val Ser
                          20                  25                  30
              Gly Leu Lys Ser Gly Arg Asn Leu Phe Glu Arg Ser Leu Leu Asp Leu
                      35                  40                  45
              Asn Lys Phe Lys Gly Glu Asp Leu Arg Leu Arg Ser Gln Ala Ile Met
                  50                  55                  60
              Glu Ile Glu Ala Ile Leu Pro Ile Leu Ile Arg Glu Ala Glu Ser Gln
              65                  70                  75                  80
                                                  Page 19

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Asp Asn Ser Lys Lys Gly Ile Lys Asn Gly Gly His Lys Ile Gln Asn
                              85                  90                  95
              Tyr Asn Trp Thr Gln Trp Leu Tyr Thr Ile Ser Ser Met Thr Arg Glu
                          100                 105                 110
              Gly Arg Ile Pro Thr Met Glu Asn Met Thr Ala Ala Leu Lys Asn Gly
                      115                 120                 125
<removed-apn>
              Ile Ile Ser Glu Lys Glu His Asp Arg Ile Ser Thr Ile Ile Ser Leu
                  130                 135                 140
              Leu Met Asn Tyr Cys Pro Ala Tyr Asn His Leu Leu Arg Thr Met Ser
              145                 150                 155                 160
              Ser Arg Met Lys Val His Gln Cys Gln Ile Cys Met Leu Gln Glu Ile
                              165                 170                 175
              Asn
              <210>   5
              <211>   360
              <212>   PRT
              <213>   Cedar virus
              <400>   5
              Met Asp Pro Ser Asp Leu Arg Arg Ile Ile Met Glu Asp Asp Lys Ser
              1               5                   10                  15
              Leu Val Asn Asn Asp Asp Ser Thr Glu Thr Asp Phe Leu Glu Lys Thr
                          20                  25                  30
              Trp Arg Glu Gly Ser Lys Ile Asp Lys Ile Thr Pro Glu Val Asp Glu
                      35                  40                  45
              Asn Gly Asn Met Val Pro Lys Tyr Val Val Phe Asn Pro Gly Lys Asn
                  50                  55                  60
              Glu Arg Lys Thr Ser Gly Tyr Gln Tyr Met Ile Cys Tyr Gly Phe Ile
                                                  Page 20

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              65                 70                  75                  80
              Glu Asp Gly Pro Ile Asn Gly Ser Pro Arg Val Lys Gly Asn Ile Arg
                              85                  90                  95
              Thr Thr Ala Ser Phe Pro Leu Gly Val Gly Lys Thr Tyr Ser Ser Pro
                          100                 105                 110
<removed-apn>
              Glu Glu Ile Leu Gln Glu Leu Thr Thr Leu Lys Ile Thr Val Arg Arg
                      115                 120                 125
              Thr Ala Gly Ser Asn Glu Lys Leu Val Tyr Gly Ile Thr Gly Pro Leu
                  130                 135                 140
              Asn His Leu Tyr Pro Trp Tyr Lys Val Leu Thr Gly Gly Ser Ile Phe
              145                 150                 155                 160
              Ser Ala Val Lys Val Cys Arg Asn Val Asp Gln Ile Leu Leu Asp Arg
                              165                 170                 175
              Pro Gln Ile Leu Arg Val Phe Phe Leu Ser Ile Thr Lys Leu Thr Asp
                          180                 185                 190
              Lys Gly Val Tyr Met Ile Pro Lys Ser Val Leu Asp Phe Arg Ser Asp
                      195                 200                 205
              Asn Ser Met Ala Phe Asn Leu Leu Val Tyr Leu Lys Ile Asp Thr Asp
                  210                 215                 220
              Ile Thr Lys Ala Gly Ile Arg Gly Ile Val Asn Lys Glu Gly Glu Arg
              225                 230                 235                 240
              Ile Thr Ser Phe Met Leu His Ile Gly Asn Phe Thr Arg Arg Gly Gly
                              245                 250                 255
              Lys His Tyr Ser Val Glu Tyr Cys Lys Arg Lys Ile Asp Lys Met Lys
                          260                 265                 270
              Leu Thr Phe Ala Leu Gly Thr Ile Gly Gly Leu Ser Leu His Ile Arg
                                                  Page 21

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
                      275                 280                 285
              Ile Asp Gly Arg Ile Ser Lys Arg Leu Gln Ala Gln Val Gly Phe Gln
                  290                 295                 300
              Arg Asn Ile Cys Tyr Ser Leu Met Asp Thr Asn Pro Trp Leu Asn Lys
              305                 310                 315                 320
<removed-apn>
              Leu Thr Trp Asn Asn Ser Cys Glu Ile His Lys Val Thr Ala Val Ile
                              325                 330                 335
              Gln Pro Ser Val Pro Lys Asp Phe Met Leu Tyr Glu Asp Ile Leu Ile
                          340                 345                 350
              Asp Asn Thr Gly Lys Ile Leu Lys
                      355                 360
              <210>   6
              <211>   557
              <212>   PRT
              <213>   Cedar virus
              <400>   6
              Met Ser Asn Lys Arg Thr Thr Val Leu Ile Ile Ile Ser Tyr Thr Leu
              1               5                   10                  15
              Phe Tyr Leu Asn Asn Ala Ala Ile Val Gly Phe Asp Phe Asp Lys Leu
                          20                  25                  30
              Asn Lys Ile Gly Val Val Gln Gly Arg Val Leu Asn Tyr Lys Ile Lys
                      35                  40                  45
              Gly Asp Pro Met Thr Lys Asp Leu Val Leu Lys Phe Ile Pro Asn Ile
                  50                  55                  60
              Val Asn Ile Thr Glu Cys Val Arg Glu Pro Leu Ser Arg Tyr Asn Glu
              65                  70                  75                  80
              Thr Val Arg Arg Leu Leu Leu Pro Ile His Asn Met Leu Gly Leu Tyr
                              85                  90                  95
                                                  Page 22

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Leu Asn Asn Thr Asn Ala Lys Met Thr Gly Leu Met Ile Ala Gly Val
                          100                 105                 110
              Ile Met Gly Gly Ile Ala Ile Gly Ile Ala Thr Ala Ala Gln Ile Thr
                      115                 120                 125
<removed-apn>
              Ala Gly Phe Ala Leu Tyr Glu Ala Lys Lys Asn Thr Glu Asn Ile Gln
                  130                 135                 140
              Lys Leu Thr Asp Ser Ile Met Lys Thr Gln Asp Ser Ile Asp Lys Leu
              145                 150                 155                 160
              Thr Asp Ser Val Gly Thr Ser Ile Leu Ile Leu Asn Lys Leu Gln Thr
                              165                 170                 175
              Tyr Ile Asn Asn Gln Leu Val Pro Asn Leu Glu Leu Leu Ser Cys Arg
                          180                 185                 190
              Gln Asn Lys Ile Glu Phe Asp Leu Met Leu Thr Lys Tyr Leu Val Asp
                      195                 200                 205
              Leu Met Thr Val Ile Gly Pro Asn Ile Asn Asn Pro Val Asn Lys Asp
                  210                 215                 220
              Met Thr Ile Gln Ser Leu Ser Leu Leu Phe Asp Gly Asn Tyr Asp Ile
              225                 230                 235                 240
              Met Met Ser Glu Leu Gly Tyr Thr Pro Gln Asp Phe Leu Asp Leu Ile
                              245                 250                 255
              Glu Ser Lys Ser Ile Thr Gly Gln Ile Ile Tyr Val Asp Met Glu Asn
                          260                 265                 270
              Leu Tyr Val Val Ile Arg Thr Tyr Leu Pro Thr Leu Ile Glu Val Pro
                      275                 280                 285
              Asp Ala Gln Ile Tyr Glu Phe Asn Lys Ile Thr Met Ser Ser Asn Gly
                  290                 295                 300
                                                  Page 23

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Gly Glu Tyr Leu Ser Thr Ile Pro Asn Phe Ile Leu Ile Arg Gly Asn
              305                 310                 315                 320
              Tyr Met Ser Asn Ile Asp Val Ala Thr Cys Tyr Met Thr Lys Ala Ser
                              325                 330                 335
<removed-apn>
              Val Ile Cys Asn Gln Asp Tyr Ser Leu Pro Met Ser Gln Asn Leu Arg
                          340                 345                 350
              Ser Cys Tyr Gln Gly Glu Thr Glu Tyr Cys Pro Val Glu Ala Val Ile
                      355                 360                 365
              Ala Ser His Ser Pro Arg Phe Ala Leu Thr Asn Gly Val Ile Phe Ala
                  370                 375                 380
              Asn Cys Ile Asn Thr Ile Cys Arg Cys Gln Asp Asn Gly Lys Thr Ile
              385                 390                 395                 400
              Thr Gln Asn Ile Asn Gln Phe Val Ser Met Ile Asp Asn Ser Thr Cys
                              405                 410                 415
              Asn Asp Val Met Val Asp Lys Phe Thr Ile Lys Val Gly Lys Tyr Met
                          420                 425                 430
              Gly Arg Lys Asp Ile Asn Asn Ile Asn Ile Gln Ile Gly Pro Gln Ile
                      435                 440                 445
              Ile Ile Asp Lys Val Asp Leu Ser Asn Glu Ile Asn Lys Met Asn Gln
                  450                 455                 460
              Ser Leu Lys Asp Ser Ile Phe Tyr Leu Arg Glu Ala Lys Arg Ile Leu
              465                 470                 475                 480
              Asp Ser Val Asn Ile Ser Leu Ile Ser Pro Ser Val Gln Leu Phe Leu
                              485                 490                 495
              Ile Ile Ile Ser Val Leu Ser Phe Ile Ile Leu Leu Ile Ile Ile Val
                          500                 505                 510
                                                  Page 24

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Tyr Leu Tyr Cys Lys Ser Lys His Ser Tyr Lys Tyr Asn Lys Phe Ile
                      515                 520                 525
              Asp Asp Pro Asp Tyr Tyr Asn Asp Tyr Lys Arg Glu Arg Ile Asn Gly
                  530                 535                 540
<removed-apn>
              Lys Ala Ser Lys Ser Asn Asn Ile Tyr Tyr Val Gly Asp
              545                 550                 555
              <210>   7
              <211>   622
              <212>   PRT
              <213>   Cedar virus
              <400>   7
              Met Leu Ser Gln Leu Gln Lys Asn Tyr Leu Asp Asn Ser Asn Gln Gln
              1               5                   10                  15
              Gly Asp Lys Met Asn Asn Pro Asp Lys Lys Leu Ser Val Asn Phe Asn
                          20                  25                  30
              Pro Leu Glu Leu Asp Lys Gly Gln Lys Asp Leu Asn Lys Ser Tyr Tyr
                      35                  40                  45
              Val Lys Asn Lys Asn Tyr Asn Val Ser Asn Leu Leu Asn Glu Ser Leu
                  50                  55                  60
              His Asp Ile Lys Phe Cys Ile Tyr Cys Ile Phe Ser Leu Leu Ile Ile
              65                  70                  75                  80
              Ile Thr Ile Ile Asn Ile Ile Thr Ile Ser Ile Val Ile Thr Arg Leu
                              85                  90                  95
              Lys Val His Glu Glu Asn Asn Gly Met Glu Ser Pro Asn Leu Gln Ser
                          100                 105                 110
              Ile Gln Asp Ser Leu Ser Ser Leu Thr Asn Met Ile Asn Thr Glu Ile
                      115                 120                 125
                                                  Page 25

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Thr Pro Arg Ile Gly Ile Leu Val Thr Ala Thr Ser Val Thr Leu Ser
                  130                 135                 140
              Ser Ser Ile Asn Tyr Val Gly Thr Lys Thr Asn Gln Leu Val Asn Glu
              145                 150                 155                 160
              Leu Lys Asp Tyr Ile Thr Lys Ser Cys Gly Phe Lys Val Pro Glu Leu
<removed-apn>
                              165                 170                 175
              Lys Leu His Glu Cys Asn Ile Ser Cys Ala Asp Pro Lys Ile Ser Lys
                          180                 185                 190
              Ser Ala Met Tyr Ser Thr Asn Ala Tyr Ala Glu Leu Ala Gly Pro Pro
                      195                 200                 205
              Lys Ile Phe Cys Lys Ser Val Ser Lys Asp Pro Asp Phe Arg Leu Lys
                  210                 215                 220
              Gln Ile Asp Tyr Val Ile Pro Val Gln Gln Asp Arg Ser Ile Cys Met
              225                 230                 235                 240
              Asn Asn Pro Leu Leu Asp Ile Ser Asp Gly Phe Phe Thr Tyr Ile His
                              245                 250                 255
              Tyr Glu Gly Ile Asn Ser Cys Lys Lys Ser Asp Ser Phe Lys Val Leu
                          260                 265                 270
              Leu Ser His Gly Glu Ile Val Asp Arg Gly Asp Tyr Arg Pro Ser Leu
                      275                 280                 285
              Tyr Leu Leu Ser Ser His Tyr His Pro Tyr Ser Met Gln Val Ile Asn
                  290                 295                 300
              Cys Val Pro Val Thr Cys Asn Gln Ser Ser Phe Val Phe Cys His Ile
              305                 310                 315                 320
              Ser Asn Asn Thr Lys Thr Leu Asp Asn Ser Asp Tyr Ser Ser Asp Glu
                              325                 330                 335
                                                  Page 26

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Tyr Tyr Ile Thr Tyr Phe Asn Gly Ile Asp Arg Pro Lys Thr Lys Lys
                          340                 345                 350
              Ile Pro Ile Asn Asn Met Thr Ala Asp Asn Arg Tyr Ile His Phe Thr
                      355                 360                 365
              Phe Ser Gly Gly Gly Gly Val Cys Leu Gly Glu Glu Phe Ile Ile Pro
<removed-apn>
                  370                 375                 380
              Val Thr Thr Val Ile Asn Thr Asp Val Phe Thr His Asp Tyr Cys Glu
              385                 390                 395                 400
              Ser Phe Asn Cys Ser Val Gln Thr Gly Lys Ser Leu Lys Glu Ile Cys
                              405                 410                 415
              Ser Glu Ser Leu Arg Ser Pro Thr Asn Ser Ser Arg Tyr Asn Leu Asn
                          420                 425                 430
              Gly Ile Met Ile Ile Ser Gln Asn Asn Met Thr Asp Phe Lys Ile Gln
                      435                 440                 445
              Leu Asn Gly Ile Thr Tyr Asn Lys Leu Ser Phe Gly Ser Pro Gly Arg
                  450                 455                 460
              Leu Ser Lys Thr Leu Gly Gln Val Leu Tyr Tyr Gln Ser Ser Met Ser
              465                 470                 475                 480
              Trp Asp Thr Tyr Leu Lys Ala Gly Phe Val Glu Lys Trp Lys Pro Phe
                              485                 490                 495
              Thr Pro Asn Trp Met Asn Asn Thr Val Ile Ser Arg Pro Asn Gln Gly
                          500                 505                 510
              Asn Cys Pro Arg Tyr His Lys Cys Pro Glu Ile Cys Tyr Gly Gly Thr
                      515                 520                 525
              Tyr Asn Asp Ile Ala Pro Leu Asp Leu Gly Lys Asp Met Tyr Val Ser
                  530                 535                 540
                                                  Page 27

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Val Ile Leu Asp Ser Asp Gln Leu Ala Glu Asn Pro Glu Ile Thr Val
              545                 550                 555                 560
              Phe Asn Ser Thr Thr Ile Leu Tyr Lys Glu Arg Val Ser Lys Asp Glu
                              565                 570                 575
              Leu Asn Thr Arg Ser Thr Thr Thr Ser Cys Phe Leu Phe Leu Asp Glu
<removed-apn>
                          580                 585                 590
              Pro Trp Cys Ile Ser Val Leu Glu Thr Asn Arg Phe Asn Gly Lys Ser
                      595                 600                 605
              Ile Arg Pro Glu Ile Tyr Ser Tyr Lys Ile Pro Lys Tyr Cys
                  610                 615                 620
              <210>   8
              <211>   2501
              <212>   PRT
              <213>   Cedar virus
              <400>   8
              Met Glu Ser Asp Phe Asp Ile Ser Val Ser Asp Val Leu Tyr Pro Glu
              1               5                   10                  15
              Cys His Leu Asp Ser Pro Ile Val Gly Gly Lys Leu Ile Thr Ser Leu
                          20                  25                  30
              Glu Tyr Ala Asn Leu Thr His Asn Gln Pro His Glu Asp Gln Thr Leu
                      35                  40                  45
              Leu Thr Asn Ile Asn Val Asn Lys Lys Lys Lys Ile Lys Ser Pro Leu
                  50                  55                  60
              Ile Ser Gln Gln Ser Leu Phe Gly Asn Glu Val Asn Lys Glu Ile Phe
              65                  70                  75                  80
              Asp Leu Lys Asn Tyr Tyr His Val Pro Tyr Pro Glu Cys Asn Arg Asp
                              85                  90                  95
                                                  Page 28

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Leu Phe Leu Ile Ser Asp Asp Lys Ile Ala Phe Lys Leu Ser Lys Ile
                          100                 105                 110
              Met Asp Asn Ser Asn Lys Leu Phe Asp Gly Leu Glu Arg Lys Leu Ser
                      115                 120                 125
              Arg Leu Ile Ser Asn Val Asp Asn Gln Leu Leu Asn Ala Thr Ser Leu
                  130                 135                 140
<removed-apn>
              His Asn Asn Ser Glu Met Asp Arg Lys Gly Lys Glu His Pro Cys Phe
              145                 150                 155                 160
              Pro Glu Lys Ser Thr Ile Asp Asp Val Arg Gln Gln Arg Gln Thr Arg
                              165                 170                 175
              Asp Phe Pro Lys Asn Ser Thr Arg Glu Gly Arg Ser Pro Lys His Pro
                          180                 185                 190
              Asp Ala Gly Pro Thr Pro Glu Asn Ser Ala Lys Asn Asp Leu His Arg
                      195                 200                 205
              Asp Asn Thr Asp Asn Met Pro Thr Gly His Ser Ser Thr Ser Met Lys
                  210                 215                 220
              Lys Pro Lys Ile Ser Gly Glu Glu Tyr Leu Ser Met Trp Leu Asp Ser
              225                 230                 235                 240
              Glu Asp Leu Gly Ser Lys Arg Ile Ser Ala Gln Leu Gly Lys Asp Val
                              245                 250                 255
              Ser Cys Lys Gly His Leu His Thr Thr Glu Asp Lys Pro Ile Ile Val
                          260                 265                 270
              Pro Asp Thr Arg Tyr Ile Gln Asn His Glu Ser Asn Asn Asp Ile Phe
                      275                 280                 285
              Pro Lys Lys Glu Lys Lys Phe Cys Lys Leu Pro Pro Ser Ser Asp Asn
                  290                 295                 300
                                                  Page 29

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Leu Thr Lys Ile Met Val Asn Ser Lys Trp Tyr Asn Pro Phe Leu Phe
              305                 310                 315                 320
              Trp Phe Thr Val Lys Thr Glu Leu Arg Ala Cys Gln Lys Glu Asn Tyr
                              325                 330                 335
              Lys Arg Lys Asn Arg Lys Leu Gly Ile Ile Thr Ser Ile Lys Gly Ser
                          340                 345                 350
<removed-apn>
              Cys Tyr Lys Leu Ile Leu Asn Gln Asn Leu Val Ala Ile Phe Glu Glu
                      355                 360                 365
              Asp Ser Ser Gly Tyr Ser Asp His Lys Lys Arg Lys Lys Arg Cys Tyr
                  370                 375                 380
              Tyr Leu Thr Pro Glu Met Val Leu Met Phe Ser Asp Val Thr Glu Gly
              385                 390                 395                 400
              Arg Leu Met Ile Asp Val Ala Met Arg Phe Asp Lys Lys Tyr Lys Thr
                              405                 410                 415
              Leu Glu Lys Lys Ala Leu Lys Leu Trp Phe Leu Ile Asp Glu Leu Phe
                          420                 425                 430
              Pro Ser Met Gly Asn Arg Val Tyr Asn Ile Ile Ser Met Leu Glu Pro
                      435                 440                 445
              Leu Thr Leu Ala Ile Leu Gln Val Lys Asp Glu Ser Arg Leu Leu Arg
                  450                 455                 460
              Gly Ala Phe Met His His Cys Leu Gly Asp Leu Phe Glu Glu Leu Arg
              465                 470                 475                 480
              Glu Ser Lys Asn Tyr Pro Glu Asp Glu Ile Lys Arg Phe Ala Asn Asp
                              485                 490                 495
              Leu Ile Asn Val Met Thr Cys Arg Asp Ile His Leu Val Ala Glu Phe
                          500                 505                 510
                                                  Page 30

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Phe Ser Phe Phe Arg Thr Phe Gly His Pro Ile Leu Asn Ala Gln Thr
                      515                 520                 525
              Ala Ala Arg Lys Val Arg Glu Tyr Met Leu Ala Asp Lys Ile Leu Glu
                  530                 535                 540
              Tyr Glu Pro Ile Met Lys Gly His Ala Ile Phe Cys Ala Ile Ile Ile
              545                 550                 555                 560
<removed-apn>
              Asn Gly Phe Arg Asp Arg His Gly Gly Val Trp Pro Pro Leu Asp Leu
                              565                 570                 575
              Pro Lys His Cys Ser Lys Asn Ile Ile Ser Leu Lys Asn Thr Gly Glu
                          580                 585                 590
              Gly Val Thr Tyr Glu Val Ala Ile Asn Asn Trp Arg Ser Phe Val Gly
                      595                 600                 605
              Leu Lys Phe Lys Cys Phe Met Gly Leu Asn Leu Asp Asn Asp Leu Ser
                  610                 615                 620
              Met Tyr Met Lys Asp Lys Ala Leu Ser Pro Leu Arg Asp Leu Trp Asp
              625                 630                 635                 640
              Ser Ile Tyr Ser Arg Glu Val Met Ser Tyr Gln Pro Pro Arg Asn Lys
                              645                 650                 655
              Lys Ser Arg Arg Leu Val Glu Val Phe Val Asp Asp Gln Asp Phe Asp
                          660                 665                 670
              Pro Val Asp Met Ile Asn Tyr Val Leu Thr Gly Glu Tyr Leu Arg Asp
                      675                 680                 685
              Asp Asp Phe Asn Ala Ser Tyr Ser Leu Lys Glu Lys Glu Thr Lys Gln
                  690                 695                 700
              Val Gly Arg Leu Phe Ala Lys Met Thr Tyr Lys Met Arg Ala Cys Gln
              705                 710                 715                 720
                                                  Page 31

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Val Ile Ala Glu Asn Leu Ile Ala His Gly Ile Gly Arg Tyr Phe His
                              725                 730                 735
              Glu Asn Gly Met Val Lys Asp Glu His Glu Leu Ser Lys Ser Leu Phe
                          740                 745                 750
              Gln Leu Ser Ile Ser Gly Ile Pro Arg Gly Asn Lys Asn Asn Lys Ser
                      755                 760                 765
<removed-apn>
              Thr Asn Asp Thr Ile His Glu Ser Lys Ile Glu Asn Asn His Ser Phe
                  770                 775                 780
              Lys Asn Ile Gln Asn Arg Ser Phe Arg Lys Thr Asp Asn Pro Tyr Asn
              785                 790                 795                 800
              Arg Phe Asn Ile Asp Asn Pro Thr Phe Leu Ser Pro Asn Cys Asn Pro
                              805                 810                 815
              Lys Tyr Asn Arg Lys Asn Ser Glu Thr Ile Gly Ile Phe Ser Arg Ala
                          820                 825                 830
              Glu Thr Lys Ser Met Ile Arg Glu Gln Lys Ser His Arg Glu Val Lys
                      835                 840                 845
              Ile Asn Lys Leu Asp Ile Gly Ser Asp Asn Glu Glu Gln Gly Lys Glu
                  850                 855                 860
              Ile Asp Ala Ala Lys Tyr Lys Ile Thr Asp Asn Pro Asn Pro His Ile
              865                 870                 875                 880
              Asn Pro Gln Asp Gln Pro Gly Ile Cys Gln Glu Asp Lys Gly Lys Glu
                              885                 890                 895
              Gly Ala Lys Ser Asp Leu Thr Glu Gly Met Ser Phe Leu Glu Met His
                          900                 905                 910
              Thr Leu Phe Asn Pro Ser Lys Ser Asp Ile Arg Thr Asn Leu Glu Leu
                      915                 920                 925
                                                  Page 32

                              (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Glu Lys Ser Ser Leu Ser Asn Pro Gly Phe Ile Ser Gln Lys Glu Lys
                  930                 935                 940
              Arg Gly Lys Thr Tyr Asn Glu Ser His Ser Leu Gly Lys Phe Ser Lys
              945                 950                 955                 960
              Glu Asp Glu Glu Arg Tyr Asp Val Ile Ser Ala Phe Leu Thr Thr Asp
                              965                 970                 975
<removed-apn>
              Leu Arg Lys Phe Cys Leu Asn Trp Arg His Glu Ser Ile Gly Ile Phe
                          980                 985                 990
              Ala Arg Arg Met Asp Glu Ile Tyr Gly Leu Pro Gly Phe Phe Asn Trp
                      995                 1000                1005
              Met His Arg Arg Leu Glu Arg Ser Val Leu Tyr Val Ala Asp Pro
                  1010                1015                1020
              His Cys Pro Pro Ser Ile Asn Glu His Ile Asp Leu Asn Asp Ser
                  1025                1030                1035
              Pro Glu Arg Asp Ile Phe Ile His His Pro Lys Gly Gly Ile Glu
                  1040                1045                1050
              Gly Tyr Ser Gln Lys Leu Trp Thr Ile Ala Thr Ile Pro Phe Leu
                  1055                1060                1065
              Phe Leu Ser Ala His Glu Thr Asn Thr Arg Ile Ala Ala Val Val
                  1070                1075                1080
              Gln Gly Asp Asn Gln Ser Ile Ala Ile Thr His Lys Val His Pro
                  1085                1090                1095
              His Leu Pro Tyr Lys Met Lys Lys Glu Leu Ser Ala Met Gln Ala
                  1100                1105                1110
              Lys Lys Tyr Phe Ser Arg Leu Arg His Asn Met Lys Ala Leu Gly
                  1115                1120                1125
                                                  Page 33

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              His Glu Leu Lys Ala Thr Glu Thr Ile Ile Ser Thr His Phe Phe
                  1130                1135                 1140
              Ile Tyr Ser Lys Lys Ile His Tyr Asp Gly Ala Val Leu Ser Gln
                  1145                1150                1155
              Ser Leu Lys Ser Met Ala Arg Cys Val Phe Trp Ser Glu Thr Leu
                  1160                1165                1170
<removed-apn>
              Val Asp Glu Thr Arg Ala Ala Cys Ser Asn Ile Ser Thr Thr Ile
                  1175                1180                1185
              Ala Lys Ala Ile Glu Asn Gly Tyr Ser Arg Arg Ser Gly Tyr Leu
                  1190                1195                1200
              Ile Asn Val Leu Lys Thr Ile Gln Gln Ile Asn Ile Ser Leu Ser
                  1205                1210                1215
              Phe Asn Ile Asn Glu Cys Met Thr Asp Asp Ile Ile Arg Pro Phe
                  1220                1225                1230
              Arg Asp Asn Pro Asn Trp Ile Lys His Ala Ala Leu Ile Pro Ala
                  1235                1240                1245
              Ser Leu Gly Gly Leu Asn Tyr Met Asn Met Ser Arg Leu Tyr Val
                  1250                1255                1260
              Arg Asn Ile Gly Asp Pro Val Thr Ala Ser Ile Ala Asp Val Lys
                  1265                1270                1275
              Arg Met Ile Leu Gly Gly Val Leu Pro Ile Gly Ile Leu His Asn
                  1280                1285                1290
              Ile Met Leu Gln Glu Pro Gly Asp Ala Thr Tyr Leu Asp Trp Cys
                  1295                1300                1305
              Ser Asp Pro Tyr Ser Ile Asn Leu Lys Gln Thr Gln Ser Ile Thr
                  1310                1315                1320
                                                  Page 34

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Lys Val Ile Lys Asn Ile Thr Ala Arg Val Ile Leu Arg Asn Ser
                  1325                1330                 1335
              Val Asn Pro Leu Leu Lys Gly Leu Phe His Glu Gly Ala Tyr Glu
                  1340                1345                1350
              Glu Asp Thr Glu Leu Ala Thr Phe Ile Leu Asp Arg Arg Val Ile
                  1355                1360                1365
<removed-apn>
              Leu Pro Arg Val Gly His Glu Ile Leu Asn Asn Ser Ile Thr Gly
                  1370                1375                1380
              Ala Arg Glu Glu Ile Ser Gly Leu Leu Asp Thr Thr Lys Gly Leu
                  1385                1390                1395
              Ile Arg Ile Gly Ile Ala Lys Gly Gly Leu Thr Gln Arg Thr Leu
                  1400                1405                1410
              Ser Arg Ile Ser Asn Tyr Asp Tyr Glu Gln Phe Leu Asn Leu Met
                  1415                1420                1425
              Asn Met Leu Lys Asn Lys Glu Gln Asn Ser Val Ile Ser Leu Ser
                  1430                1435                1440
              Ala Cys Ser Val Asp Phe Ala Ile Ala Leu Arg Ser Arg Met Trp
                  1445                1450                1455
              Arg Lys Leu Ala Lys Gly Arg Leu Ile Tyr Gly Leu Glu Val Pro
                  1460                1465                1470
              Asp Pro Ile Glu Ala Met Ile Gly Phe Leu Ile Leu Gly Ser Glu
                  1475                1480                1485
              Asn Cys Leu Leu Cys Asp Ser Gly Ser Lys Asn Tyr Thr Trp Phe
                  1490                1495                1500
              Phe Ile Pro Lys Asp Val Gln Leu Asp Lys Ile Asp Lys Asp His
                  1505                1510                1515
                                                  Page 35

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Ala Ser Ile Arg Val Pro Tyr Val Gly Ser Thr Thr Glu Glu Arg
                  1520                1525                 1530
              Ser Glu Ile Lys Leu Gly Ser Val Lys Asn Pro Ser Lys Ser Leu
                  1535                1540                1545
              Lys Ser Ala Ile Arg Leu Ala Thr Val Tyr Thr Trp Ala Phe Gly
                  1550                1555                1560
<removed-apn>
              Thr Ser Asp Ala Glu Trp Trp Glu Ala Trp Tyr Leu Ser Asn Gln
                  1565                1570                1575
              Arg Ala Asn Ile Pro Leu Asp Val Leu Lys Thr Ile Thr Pro Ile
                  1580                1585                1590
              Ser Thr Ser Thr Asn Ile Ala His Arg Leu Arg Asp Arg Ser Thr
                  1595                1600                1605
              Gln Val Lys Tyr Ala Ser Thr Ser Leu Asn Arg Val Ser Arg His
                  1610                1615                1620
              Val Thr Ile Ser Asn Asp Asn Met Asn Phe Glu Phe Asp Gly Val
                  1625                1630                1635
              Lys Met Asp Thr Asn Leu Ile Tyr Gln Gln Val Met Leu Leu Gly
                  1640                1645                1650
              Leu Ser Cys Leu Glu Ser Leu Phe Arg Asn Arg Lys Met Thr Asn
                  1655                1660                1665
              Ser Tyr Asn Ile Val Tyr His Leu His Val Gln Glu His Cys Cys
                  1670                1675                1680
              Val Lys Ala Leu Asn Asp Leu Pro Tyr Thr Pro Ser Thr His Pro
                  1685                1690                1695
              Val Pro Asn Tyr Thr Glu Val Arg Asp Asn Arg Leu Ile Tyr Asp
                  1700                1705                1710
                                                  Page 36

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Pro Gln Pro Ile Leu Glu Phe Asp Glu Leu Arg Leu Ala Ile Gln
                  1715                1720                 1725
              Gln Thr Lys Lys Val Asp Leu Glu Phe Ser Leu Trp Asp Thr Lys
                  1730                1735                1740
              Glu Leu His Glu Asn Leu Ala Gln Ser Leu Ala Ile Thr Val Thr
                  1745                1750                1755
<removed-apn>
              Asp Ile Met Thr Lys Ser Asp Lys Asp His Ile Lys Asp Gln Arg
                  1760                1765                1770
              Ser Ile Asp Val Asp Asp Asn Ile Lys Thr Leu Ile Thr Glu Phe
                  1775                1780                1785
              Leu Leu Val Asp Pro Glu Met Phe Ala Val Asn Leu Gly Leu His
                  1790                1795                1800
              Ile Ser Ile Lys Trp Ser Phe Asp Ile His Phe Lys Arg Pro Arg
                  1805                1810                1815
              Gly Arg Tyr Ser Met Ile Glu Tyr Leu Thr Asp Leu Leu Asp Asn
                  1820                1825                1830
              Thr Ser Ser His Val Tyr Arg Ile Leu Thr Asn Val Leu Ser His
                  1835                1840                1845
              Pro Arg Val Met Arg Lys Phe Thr Asn Ala Gly Leu Leu Val Pro
                  1850                1855                1860
              Lys Tyr Gly Pro Tyr Leu Thr Ser Gln Asp Phe Lys Lys Met Ala
                  1865                1870                1875
              Val Asp Phe Ile Ile Thr Ala Tyr Thr Thr Phe Leu Thr Asn Trp
                  1880                1885                1890
              Cys Asn Asn Asn Lys Phe Ser Ile Leu Ile Pro Glu Gln Asp Pro
                  1895                1900                1905
                                                  Page 37

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Asp Ile Leu Glu Leu Arg Lys Asp Ile Thr His Ala Arg His Leu
                  1910                1915                 1920
              Cys Met Ile Ser Asp Leu Tyr Cys Tyr Ser Phe Lys Gln Pro Trp
                  1925                1930                1935
              Ile Lys Glu Leu Thr Pro Gln Glu Lys Ile Cys Val Met Glu Asp
                  1940                1945                1950
<removed-apn>
              Phe Ile Ala Asn Cys Val Ala Asn Asp Gln Thr Ser Ala Gly Trp
                  1955                1960                1965
              Asn Ile Thr Pro Leu Arg Val Tyr Asn Leu Pro Ala Ser Thr Thr
                  1970                1975                1980
              Tyr Ile Arg Arg Gly Ile Ile Lys Gln Leu Arg Ile Arg Gln Ser
                  1985                1990                1995
              Asn Glu Pro Ile Asp Leu Glu Asp Ile Arg Ile Gly Gln Asn Pro
                  2000                2005                2010
              Asp Phe Val Asn Lys Pro Ile Glu Phe Cys Ser Ser Glu Phe Gly
                  2015                2020                2025
              Ile Thr Ile Tyr Asn Leu Glu Glu Ile Leu Gln Ser Asn Val His
                  2030                2035                2040
              Leu Ser Val Asn Met Asn Ile Asp Ser Ser Thr Ser Asn Asn Thr
                  2045                2050                2055
              Glu Asn His Leu Phe Arg Arg Val Gly Leu Asn Ser Thr Ser Ser
                  2060                2065                2070
              Tyr Lys Ala Leu Ser Leu Thr Pro Val Ile Lys Arg Tyr His Gln
                  2075                2080                2085
              Gln Asn Thr Asn Arg Leu Phe Ile Gly Glu Gly Ser Gly Ser Met
                  2090                2095                2100
                                                  Page 38

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Met Tyr Leu Tyr Gln Lys Thr Leu Gly Glu Thr Ile Cys Phe Phe
                  2105                2110                 2115
              Asn Ser Gly Val Gln Tyr Asn Glu Asp Leu Gly Gln Arg Glu Gln
                  2120                2125                2130
              Ser Leu Tyr Pro Ser Glu Tyr Ser Ile Cys Glu Gln Gly Val Lys
                  2135                2140                2145
<removed-apn>
              Lys Glu Asn Pro Leu Thr Gly His Val Ile Pro Leu Phe Asn Gly
                  2150                2155                2160
              Arg Pro Glu Thr Thr Trp Val Gly Asn Asp Asp Ser Phe Lys Tyr
                  2165                2170                2175
              Ile Leu Glu His Thr Ile Asn Arg Asp Ile Gly Leu Val His Ser
                  2180                2185                2190
              Asp Met Glu Thr Gly Ile Gly Lys Asp Asn Tyr Thr Ile Leu Asn
                  2195                2200                2205
              Glu His Ala His Leu Ile Ala Leu Ser Leu Thr Val Met Ile Asp
                  2210                2215                2220
              Asp Gly Ile Leu Val Ser Lys Val Ala Tyr Ala Pro Gly Phe Cys
                  2225                2230                2235
              Ile Ser Ser Leu Leu Asn Met Tyr Arg Thr Phe Phe Ser Leu Val
                  2240                2245                2250
              Leu Cys Ala Phe Pro Pro Tyr Ser Asn Phe Glu Ser Thr Glu Phe
                  2255                2260                2265
              Tyr Leu Ile Cys Leu Gln Lys Ser Ile Pro Gly Pro Ile Thr Pro
                  2270                2275                2280
              Ala Arg Ala Ile Gln Gln Thr Thr Lys Gln Ser Arg Glu Glu Asp
                  2285                2290                2295
                                                  Page 39

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Asn Ser Ile Thr Asn Asn Ile Leu Lys Ile Lys Asn Leu Val Gln
                  2300                2305                 2310
              Lys Glu Phe Ile Lys Thr Val Lys Lys Lys Tyr Glu Ile His Pro
                  2315                2320                2325
              Ser Phe Asn Cys Pro Ile Asn Phe Thr Lys Asp Asp Lys Tyr Leu
                  2330                2335                2340
<removed-apn>
              Met Ser Val Gly Phe Gln Ala Asn Gly Pro Asp Met Ile Arg Lys
                  2345                2350                2355
              Glu Thr Gly Tyr Asp Ile Gly Ser Asn Val Glu Asn Leu Arg Asp
                  2360                2365                2370
              Val Leu Ile Lys Leu Phe Ala Asp Ala Val Thr Phe Tyr Asp Asp
                  2375                2380                2385
              Val Thr Asn Lys Lys Asn Phe Leu Asn Pro Tyr Pro Val Tyr Thr
                  2390                2395                2400
              Arg Thr Gln Tyr Lys Ile Leu Met Asp Lys Ile Cys Lys Lys Val
                  2405                2410                2415
              Thr Leu Tyr Thr Leu Ile Ile Ser Cys Lys Gly Ser Asn Gln Tyr
                  2420                2425                2430
              Cys Trp Glu Ile Lys Ser Gln Ile Arg Lys His Cys Leu Ile Leu
                  2435                2440                2445
              Asp Leu Lys Ser Lys Val Phe Thr Lys Leu Ile Pro Lys Gly Leu
                  2450                2455                2460
              Arg Glu Arg Gly Asp Ser Lys Gly Met Lys Ser Ile Trp Phe Thr
                  2465                2470                2475
              Lys Leu Thr Ser Gln Glu Val Lys Arg Trp Trp Lys Met Ile Ser
                  2480                2485                2490
                                                  Page 40

                             (74871835)_(1)_044508-5045-WO-SequenceListing.TXT
<removed-date>
              Tyr Ile Val Ile Ile Ser Asn Pro
                  2495                2500
<removed-apn>
                                                  Page 41

